<SEC-DOCUMENT>0001193125-24-004363.txt : 20240108
<SEC-HEADER>0001193125-24-004363.hdr.sgml : 20240108
<ACCEPTANCE-DATETIME>20240108160530
ACCESSION NUMBER:		0001193125-24-004363
CONFORMED SUBMISSION TYPE:	S-3/A
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20240108
DATE AS OF CHANGE:		20240108

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Scilex Holding Co
		CENTRAL INDEX KEY:			0001820190
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-3/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-276245
		FILM NUMBER:		24520070

	BUSINESS ADDRESS:	
		STREET 1:		960 SAN ANTONIO ROAD
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94303
		BUSINESS PHONE:		(650) 516-4310

	MAIL ADDRESS:	
		STREET 1:		960 SAN ANTONIO ROAD
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94303

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Scilex Holding Company/DE
		DATE OF NAME CHANGE:	20221117

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Vickers Vantage Corp. I
		DATE OF NAME CHANGE:	20200804
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3/A
<SEQUENCE>1
<FILENAME>d559675ds3a.htm
<DESCRIPTION>S-3/A
<TEXT>
<HTML><HEAD>
<TITLE>S-3/A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>As filed with the Securities and Exchange Commission on January&nbsp;8, 2024 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="right"><B>Registration No.&nbsp;333-276245 </B></P>  <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES
AND EXCHANGE COMMISSION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10.5pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, DC&nbsp;20549 </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Amendment No.&nbsp;1 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:15pt; font-family:Times New Roman" ALIGN="center"><B>to
</B></P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">FORM&nbsp;S-3</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10.5pt; font-family:Times New Roman" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10.5pt; font-family:Times New Roman" ALIGN="center"><B><I>THE
SECURITIES ACT OF&nbsp;1933 </I></B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:22pt; font-family:Times New Roman" ALIGN="center"><B>Scilex Holding Company </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2836</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">92-1062542</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(Primary Standard Industrial</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Classification Code Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Scilex Holding Company </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>960 San Antonio Road </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Palo
Alto, CA 94303 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(Address, including zip code, and telephone number, including area code, of registrant&#146;s principal executive
offices) </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Jaisim Shah </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Chief
Executive Officer&nbsp;&amp; President </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>960 San Antonio Road </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Palo Alto, CA 94303 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(650) <FONT
STYLE="white-space:nowrap">516-4310</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(Name, address, including zip code, and telephone number, including area code, of agent
for service) </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B><I>Copies to: </I></B></P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Jeffrey
T. Hartlin, Esq. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Elizabeth A. Razzano, Esq. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Paul Hastings LLP </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>1117 S.
California Avenue </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Palo Alto, CA&nbsp;94304 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(650) <FONT STYLE="white-space:nowrap">320-1800</FONT> </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman"><B>Approximate
date of commencement of proposed sale to the public</B>: From time to time after the effective date of this registration statement </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">If the
only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule&nbsp;415 under the
Securities Act of&nbsp;1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box.&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">If this Form is filed to register additional securities for an offering pursuant to Rule&nbsp;462(b) under the Securities Act, please check the
following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule&nbsp;462(c) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">If
this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule&nbsp;462(e) under the Securities Act, check the following
box.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D.
filed to register additional securities or additional classes of securities pursuant to Rule&nbsp;413(b) under the Securities Act, check the following box.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
<FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, a smaller reporting company or an emerging growth company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting
company&#148; and &#147;emerging growth company&#148; in <FONT STYLE="white-space:nowrap">Rule&nbsp;12b-2</FONT> of the Exchange Act. </P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">Large&nbsp;accelerated&nbsp;filer</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">Accelerated filer</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><FONT STYLE="white-space:nowrap">Non-accelerated</FONT> filer</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&#9746;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">Smaller&nbsp;reporting&nbsp;company</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">Emerging growth company</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman"><B>The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the
registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of&nbsp;1933 or until the registration statement shall
become effective on such date as the Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXPLANATORY NOTE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This registration statement contains: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A base prospectus, which covers the offering, issuance and sale by us of up to $500,000,000 in the aggregate of
the securities identified herein from time to time in one or more offerings; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A sales agreement prospectus covering the offering, issuance and sale by us of up to a maximum aggregate offering
price of $170,000,000 of our common stock, par value $0.0001 per share (&#147;Common Stock&#148;), that may be issued and sold under a Sales Agreement with B. Riley Securities Inc., Cantor Fitzgerald&nbsp;&amp; Co., and H.C. Wainwright&nbsp;&amp;
Co., LLC (the &#147;Sales Agreement&#148;). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The base prospectus immediately follows this explanatory note. The specific terms of any
securities to be offered pursuant to the base prospectus will be specified in a prospectus supplement to the base prospectus. The sales agreement prospectus immediately follows the base prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The $170,000,000 of our Common Stock that may be offered, issued and sold under the sales agreement prospectus is included in the $500,000,000 of securities
that may be offered, issued and sold by us under the base prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon termination of the Sales Agreement, any portion of the $170,000,000 included
in the sales agreement prospectus that is not sold pursuant to the Sales Agreement will be available for sale in other offerings pursuant to the base prospectus and a corresponding prospectus supplement, and if no shares are sold under the Sales
Agreement, the full $170,000,000 securities may be sold in other offerings pursuant to the base prospectus and a corresponding prospectus supplement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><FONT COLOR="#ff4338"><B>The information in this preliminary prospectus is not complete and may be changed. We
may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these
securities in any state where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ff4338"><B>SUBJECT TO COMPLETION, DATED JANUARY&nbsp;8, 2024 </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>SCILEX HOLDING COMPANY
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>$500,000,000 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Preferred
Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Debt Securities </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Warrants </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Rights </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Units </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may offer
and sell, from time to time in one or more offerings, up to $500,000,000 in the aggregate of any combination of the securities identified above from time to time in one or more offerings, either individually or in combination with other securities.
We may also offer common stock or preferred stock upon conversion of debt securities, common stock upon conversion of preferred stock, or common stock, preferred stock or debt securities upon the exercise of warrants, rights or units. This
prospectus provides you with a general description of the securities that we may offer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each time we offer and sell securities, we will
provide a supplement to this prospectus that contains specific information about the offering and the amounts, prices and terms of the securities. We may also authorize one or more free writing prospectuses to be provided to you in connection with
these offerings. The prospectus, prospectus supplement and any related free writing prospectuses may also add, update or change information contained in this prospectus with respect to that offering. You should carefully read this prospectus and the
applicable prospectus supplement and any related free writing prospectus, as well as any documents incorporated by reference, before you invest in any of our securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may offer and sell the securities described in this prospectus and any prospectus supplement to or through one or more underwriters,
dealers and agents, or directly to purchasers, or through a combination of these methods. If any underwriters, dealers or agents are involved in the sale of any of the securities, their names and any applicable purchase price, fee, commission or
discount arrangement between or among them will be set forth, or will be calculable from the information set forth, in the applicable prospectus supplement. See the sections of this prospectus titled &#147;<I>About this Prospectus</I>&#148; and
&#147;<I>Plan of Distribution</I>&#148; for more information. No securities may be sold without delivery of this prospectus and the applicable prospectus supplement describing the method and terms of the offering of such securities. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:12pt; font-family:Times New Roman"><B><I>Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the
heading &#147;<A HREF="#rom559675_3">Risk Factors</A>&#148; beginning on page&nbsp;6 of this prospectus, any applicable prospectus supplement and in any applicable free writing prospectuses, and under similar headings in the documents that are
incorporated by reference into this prospectus. </I></B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock, par value $0.0001 per share (&#147;Common Stock&#148;), is
currently listed on the Nasdaq Capital Market under the symbol &#147;SCLX&#148;. On January&nbsp;5, 2024, the last reported sales price for our Common Stock was $2.04&nbsp;per share. The applicable prospectus supplement will contain information,
where applicable, as to any other listing on the Nasdaq Capital Market or any securities market or other exchange of the securities, if any, covered by the applicable prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities, or
passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date
of this prospectus is</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B>, 2024</B>. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom559675_1">About This Prospectus</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom559675_2">Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom559675_3">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom559675_4">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom559675_5">Cautionary Note Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom559675_6">Description of Capital Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom559675_7">Description of Debt Securities</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom559675_8">Description of Warrants</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom559675_9">Description of Rights</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom559675_10">Description of Units</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom559675_11">Legal Ownership of Securities</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom559675_12">Plan of Distribution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom559675_13">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom559675_14">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom559675_15">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom559675_16">Important Information Incorporated by Reference</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom559675_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever we refer to &#147;Scilex,&#148; &#147;we,&#148; &#147;our&#148; or &#147;us&#148; in this prospectus, we mean Scilex Holding Company,
unless the context suggests otherwise. When we refer to &#147;you&#148; or &#147;yours,&#148; we mean the holders of the applicable series of securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a &#147;shelf&#148; registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> that we filed
with the Securities and Exchange Commission (the &#147;SEC&#148;), using a &#147;shelf&#148; registration process. Under this shelf registration process, we may sell any combination of the securities described in this prospectus in one or more
offerings, up to a total dollar amount of $500,000,000. This prospectus provides you with a general description of the securities we may offer. Each time we offer to sell securities under this prospectus, we will provide a prospectus supplement that
will contain specific information about the terms of that offering. We may also authorize one or more free writing prospectuses to be provided to you that may contain material information relating to these offerings. The prospectus supplement and
any related free writing prospectus that we may authorize may also add, update or change information contained in this prospectus. To the extent that any statement that we make in a prospectus supplement is inconsistent with statements made in this
prospectus, the statements made in this prospectus will be deemed modified or superseded by those made in a prospectus supplement. You should read both this prospectus, any prospectus supplement and any free writing prospectus prepared by or on
behalf of us, together with the additional information described under the heading &#147;<I>Where You Can Find More Information</I>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should rely only on the information contained in this prospectus, in an accompanying prospectus supplement or incorporated by reference
herein or therein and any related free writing prospectus that we may authorize to be provided to you. We have not authorized anyone to provide you with information or make any representation that is different. If anyone provides you with different
or inconsistent information, you should not rely on it. This prospectus, any accompanying prospectus supplement and any related free writing prospectus do not constitute an offer to sell or a solicitation of an offer to buy any securities other than
the registered securities to which they relate, and this prospectus and any accompanying prospectus supplement do not constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction where, or to any person to whom,
it is unlawful to make such an offer or solicitation. You should not assume that the information contained in this prospectus, any accompanying prospectus supplement and any related free writing prospectus is correct on any date after the respective
dates of the prospectus, such prospectus supplement or supplements and free writing prospectus, as applicable, even though this prospectus, such prospectus supplement or supplements and free writing prospectus are delivered or securities are sold
pursuant thereto, as applicable, at a later date. Since the respective dates of the prospectus contained in this registration statement, any accompanying prospectus supplement and any free writing prospectus, our business, financial condition,
results of operations and prospects may have changed since those dates. This prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete
information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration
statement of which this prospectus is a part, and you may obtain copies of those documents as described below under the heading &#147;<I>Where You Can Find More Information</I>.&#148; We may only sell securities pursuant to this prospectus if this
prospectus is accompanied by a prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We further note that the representations, warranties and covenants made by us in
any agreement that is filed as an exhibit to any document that is incorporated by reference into this prospectus were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among
the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations,
warranties and covenants should not be relied on as accurately representing the current state of our affairs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom559675_2"></A>SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights selected information contained elsewhere in this prospectus or incorporated by reference in this prospectus, and
does not contain all of the information that you need to consider in making your investment decision. You should carefully read the entire prospectus, any applicable prospectus supplement and any related free writing prospectus, including the risks
of investing in our securities discussed under the heading &#147;Risk Factors&#148; contained in this prospectus, any applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that
are incorporated by reference into this prospectus. You should also carefully read the information incorporated by reference into this prospectus, including our financial statements, and the exhibits to the registration statement of which this
prospectus forms a part. Unless otherwise mentioned or unless the context requires otherwise, all references in this prospectus to &#147;Scilex&#148;, &#147;the Company&#148;, &#147;we&#148;, &#147;us&#148;, &#147;our&#148; or similar references
mean Scilex Holding Company. </I></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Scilex Holding Company </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an innovative
revenue-generating company focused on acquiring, developing and commercializing <FONT STYLE="white-space:nowrap">non-opioid</FONT> pain management products for the treatment of acute and chronic pain. We target indications with high unmet needs and
large market opportunities with <FONT STYLE="white-space:nowrap">non-opioid</FONT> therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. We launched our first commercial
product in October&nbsp;2018 and are developing our late-stage pipeline, which includes a candidate with completed pivotal Phase 3 study, a candidate with completed Phase 2 study, and a candidate with completed multiple Phase 1 studies and expected
to enter Phase&nbsp;2 studies in&nbsp;2024. Our commercial product, ZTlido<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (lidocaine topical system) 1.8% is a prescription lidocaine topical product approved by the U.S.&nbsp;Food and Drug
Administration (the &#147;FDA&#148;) for the relief of neuropathic pain associated with post-herpetic neuralgia (&#147;PHN&#148;), which is a form of post-shingles nerve pain. ZTlido possesses novel delivery and adhesion technology designed to
address many of the limitations of current prescription lidocaine patches by providing significantly improved adhesion and continuous pain relief throughout <FONT STYLE="white-space:nowrap">the&nbsp;12-hour</FONT> administration period. We believe
our marketed product, ZTlido, has multiple advantages over currently available prescription and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> (&#147;OTC&#148;)&nbsp;lidocaine patches, of which
over&nbsp;147&nbsp;million and&nbsp;136&nbsp;million of such patches were sold in the United States in&nbsp;2021 and&nbsp;2020, respectively, according to Symphony Healthcare. We license the rights to ZTlido from and rely exclusively on Oishi
Koseido Co., Ltd. (&#147;Oishi&#148;) and Itochu Chemical Frontier Corporation (&#147;Itochu,&#148;) pursuant to the Product Development Agreement, dated as of May&nbsp;11, 2011, by and among Scilex Pharmaceuticals, Inc., our wholly-owned subsidiary
(&#147;Scilex Pharma&#148;), as successor to Stason Pharmaceuticals, Inc., Oishi and Itochu, and the Commercial Supply Agreement, dated as of February&nbsp;16, 2017, by and among Scilex Pharma, Oishi and Itochu. We have acquired two FDA approved <FONT
STYLE="white-space:nowrap">non-opioid</FONT> pain products, GLOPERBA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> and ELYXYB<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, for the treatment of gout in adults and oral
solution for the acute treatment of migraine, with or without aura, in adults. We launched ELYXYB in the U.S.&nbsp;in April&nbsp;2023 and are planning to commercialize GLOPERBA in&nbsp;2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our three product candidates are <FONT STYLE="white-space:nowrap">(i)&nbsp;SP-102</FONT> (10 mg, dexamethasone sodium phosphate viscous gel)
(&#147;SEMDEXA<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>&#148;), a Phase&nbsp;3, novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica; <FONT
STYLE="white-space:nowrap">(ii)&nbsp;SP-103</FONT> (lidocaine topical system) 5.4%, <FONT STYLE="white-space:nowrap">(&#147;SP-103&#148;),</FONT> a Phase&nbsp;2, next-generation, triple-strength formulation of ZTlido, for the treatment of chronic
neck pain; and <FONT STYLE="white-space:nowrap">(iii)&nbsp;SP-104</FONT> (4.5 mg, <FONT STYLE="white-space:nowrap">low-dose</FONT> naltrexone hydrochloride delayed-release capsules) <FONT STYLE="white-space:nowrap">(&#147;SP-104&#148;),</FONT> a
novel <FONT STYLE="white-space:nowrap">low-dose</FONT> delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia, for which Phase&nbsp;1 trials were completed in the second quarter of&nbsp;2022 and a Phase&nbsp;2
clinical trial is expected to commence in&nbsp;2024. If these product candidates are approved by the FDA, we believe each of them could become the preferred treatment option for their respective indications in the United States. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;14, 2022, we entered into a License and Commercialization Agreement (the
&#147;Romeg Agreement&#148;) with RxOmeg Therapeutics, LLC (a/k/a Romeg Therapeutics, Inc.) (&#147;Romeg&#148;). Pursuant to the Romeg Agreement, among other things, Romeg granted us (1)&nbsp;the right to manufacture, promote, market, distribute and
sell pharmaceutical products comprising liquid formulations of colchicine for the prophylactic treatment of gout in adult humans in the United States and (2)&nbsp;an exclusive, transferable license to use the trademark &#147;GLOPERBA&#148;. We
believe Gloperba is the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. Gout is a painful arthritic disorder affecting an estimated&nbsp;9.2&nbsp;million people
in the United States. Gout pain can be excruciating and is a form of inflammatory arthritis that develops in some people who have high levels of uric acid in their blood. It can cause sudden severe episodes of pain and can be disabling with
tenderness, warmth and swelling. <FONT STYLE="white-space:nowrap">Non-steroidal</FONT> anti-inflammatory drugs, colchicine and corticosteroids are used a majority of time as the first line to treat acute gout. The U.S.&nbsp;is observed to have a
high prevalence of gout, owing to lifestyle issues such as high alcohol intake, obesity, and smoking. We are planning to commercialize GLOPERBA in&nbsp;2024 and believe we are well-positioned to market and distribute the product. We have a direct
distribution network to national and regional wholesalers and pharmacies throughout the U.S.&nbsp;On February&nbsp;12, 2023, we acquired from BioDelivery Sciences International, Inc. and Collegium Pharmaceutical, Inc. the rights to certain patents,
trademarks, regulatory approvals, data, contracts, and other rights related to ELYXYB (celecoxib oral solution) and the commercialization thereof in the United States and Canada. ELYXYB is a potential first-line treatment and the only <FONT
STYLE="white-space:nowrap">FDA-approved,</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ready-to-use</FONT></FONT> oral solution for the acute treatment of migraine, with or without aura, in adults. We launched ELYXYB in
the U.S.&nbsp;in April&nbsp;2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are focused on identifying treatment options for pain management with established mechanisms that
have deficiencies in safety, efficacy or patient experience. We believe this approach allows us to potentially leverage the regulatory approval pathway available under Section&nbsp;505(b)(2) of the Federal Food, Drug, and Cosmetic Act for each of
these pipeline product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We acquired <FONT STYLE="white-space:nowrap">SP-102</FONT> from Semnur Pharmaceuticals, Inc. in
March&nbsp;2019 and are developing <FONT STYLE="white-space:nowrap">SP-102</FONT> to be an injectable viscous gel formulation of a widely used corticosteroid designed to address the serious risks posed by
<FONT STYLE="white-space:nowrap">off-label</FONT> epidural steroid injections (&#147;ESI&#148;), which are administered over&nbsp;12&nbsp;million times annually in the United States. SEMDEXA has been granted fast track designation by the FDA and, if
approved, could become the only <FONT STYLE="white-space:nowrap">FDA-approved</FONT> ESI for the treatment of sciatica. According to a report by Decision Resources Group, it was estimated that over&nbsp;4.8&nbsp;million patients would suffer from
sciatica in the United States in&nbsp;2022. <FONT STYLE="white-space:nowrap">SP-103</FONT> has also been granted fast track designation by the FDA and, if approved, could become the first <FONT STYLE="white-space:nowrap">FDA-approved</FONT>
lidocaine topical product for the treatment of chronic neck pain. We are developing <FONT STYLE="white-space:nowrap">SP-104</FONT> as a novel delayed-release formulation of <FONT STYLE="white-space:nowrap">low-dose</FONT> naltrexone hydrochloride
for the treatment of fibromyalgia, which remains a largely unmet medical need given the low response rates of commercially available therapies. Naltrexone is routinely used <FONT STYLE="white-space:nowrap">off-label</FONT> to treat fibromyalgia.
There are no <FONT STYLE="white-space:nowrap">low-dose</FONT> formulations commercially available in the United States. Our patented formulation is designed to overcome undesirable effects of immediate release naltrexone, such as hyperalgesia,
dysphoria, nausea, anxiety and insomnia. We believe our currently approved product and future product candidates, if approved, could address what we believe are the significant unmet needs of the targeted populations. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Marketed Product and Pipeline </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following chart illustrates our current commercial products and novel product candidates. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g559675g07a07.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a complete description of our business, financial condition, results of operations and other important
information, we refer you to our filings with the SEC that are incorporated by reference in this prospectus, including our <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1820190/000095017023006493/sclx-20221231.htm">Annual
 Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December<U></U>&nbsp;
31, 2022</A> and our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarters ended <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001820190/000095017023021743/sclx-20230331.htm">March
<U></U>&nbsp;31, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001820190/000095017023041842/sclx-20230630.htm">June<U></U>&nbsp;
30, 2023</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1820190/000095017023063810/sclx-20230930.htm">September<U></U>&nbsp;30, 2023</A>, each as amended, supplemented or superseded from time to time by
other reports we file with the SEC in the future, which are incorporated by reference into this prospectus. For instructions on how to find copies of these documents, see &#147;<I>Where You Can Find More Information</I>&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See the section titled &#147;<I>Risk Factors</I>&#148; in this prospectus for a discussion of some of the risks related to the execution of
our business strategy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Business Combination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;10, 2022, Vickers Vantage Corp. I, our predecessor company (&#147;Vickers&#148;), consummated the previously announced
business combination (the &#147;Business Combination&#148;) pursuant to the terms of that certain Agreement and Plan of Merger, dated as of March&nbsp;17, 2022, by and among us, Vantage Merger Sub Inc., a Delaware corporation that was a wholly owned
subsidiary of Vickers prior to the Closing (&#147;Merger Sub&#148;), and the <FONT STYLE="white-space:nowrap">pre-Business</FONT> Combination Scilex Holding Company (&#147;Legacy Scilex&#148;), as it may be amended or restated from time to time (the
&#147;Merger Agreement&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Merger Agreement, (i)&nbsp;prior to the closing of the Business Combination (the
&#147;Closing&#148;), Vickers changed its jurisdiction of incorporation by deregistering as a Cayman Islands exempted company and continuing and domesticating as a corporation incorporated under the laws of the State of Delaware (the
&#147;Domestication&#148;) and (ii)&nbsp;at the Closing, and following the Domestication, Merger Sub merged with and into Legacy Scilex (the &#147;Merger&#148;), with Legacy Scilex as the surviving company in the Merger, and, after giving effect to
such Merger, Legacy Scilex became a wholly owned subsidiary of Vickers. The Merger was approved by Vickers&#146;s shareholders at a meeting held on November&nbsp;9, 2022. In connection with the Business Combination, Vickers changed its name to
&#147;Scilex Holding Company.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated under the name &#147;Vickers Vantage Corp. I&#148; on February&nbsp;21, 2020 as a Cayman Islands exempted company for the
purpose of effecting a merger, share exchange, asset acquisition, share purchase, </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reorganization or similar business combination with one or more businesses or entities. On November&nbsp;9, 2022, we changed our jurisdiction of incorporation by deregistering as a Cayman Islands
exempted company and continuing and domesticating as a corporation incorporated under the laws of the State of Delaware. On November&nbsp;9, 2022, we changed our name to &#147;Scilex Holding Company&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal executive offices are located at&nbsp;960 San Antonio Road, Palo Alto, California&nbsp;94303, and our telephone number is (650) <FONT
STYLE="white-space:nowrap">516-4310.</FONT> Our website address is <I>www.scilexholding.com</I>. Any information contained on, or that can be accessed through, our website is not incorporated by reference into, nor is it in any way part of this
prospectus and should not be relied upon in connection with making any decision with respect to an investment in our securities. We are required to file annual, quarterly and current reports, proxy statements and other information with the SEC. You
may obtain any of the documents filed by us with the SEC at no cost from the SEC&#146;s website at <I>http://www.sec.gov</I>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an
Emerging Growth Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company,&#148; as defined in Section&nbsp;2(a) of the Securities Act
of&nbsp;1933, as amended (the &#147;Securities Act&#148;), as modified by the Jumpstart Our Business Startups Act of 2012 (the &#147;JOBS Act&#148;). As an emerging growth company, we are eligible to take advantage of certain exemptions from various
reporting requirements that are applicable to other public companies that are not emerging growth companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the
Sarbanes-Oxley Act of 2002, as amended (the &#147;Sarbanes-Oxley Act&#148;), reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a <FONT
STYLE="white-space:nowrap">non-binding</FONT> advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, Section&nbsp;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial
accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Securities Exchange Act of 1934, as amended (the
&#147;Exchange Act&#148;)) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <FONT
STYLE="white-space:nowrap">non-emerging</FONT> growth companies but any such election to opt out is irrevocable. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, will be
subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. As a result, changes in rules of U.S. generally accepted accounting principles or their interpretation, the adoption of new
guidance or the application of existing guidance to changes in our business could significantly affect our business, financial condition and results of operations. In addition, we are in the process of evaluating the benefits of relying on the other
exemptions and reduced reporting requirements provided by the JOBS Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will remain an emerging growth company until the earlier of:
(i)&nbsp;the last day of the fiscal year (a)&nbsp;following the fifth anniversary of the closing of the initial public offering of our company, (b)&nbsp;in which we have total annual gross revenue of at least $1.235&nbsp;billion, or (c)&nbsp;in
which we are deemed to be a large accelerated filer, which means the market value of our common equity that is held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> equals or exceeds $700&nbsp;million as of the last business day of our most
recently completed second fiscal quarter; and (ii)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities during the prior three-year period. References herein to
&#147;emerging growth company&#148; have the meaning associated with it in the JOBS Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, the information in this prospectus
and that we provide to our investors in the future may be different than what you might receive from other public reporting companies. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom559675_3"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Investing in our securities involves a high degree of risk. Before you make a decision to buy our securities, in addition to the risks and
uncertainties discussed above under &#147;Cautionary Note Regarding Forward-Looking Statements&#148;, you should carefully consider the risks and uncertainties described under the section titled &#147;Risk Factors&#148; contained in our most recent
Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> together with all of the other information appearing in or incorporated by reference into this prospectus, as updated by our subsequent filings with the SEC, as well as the risk
factors and other information contained in any applicable prospectus supplement and any applicable free writing prospectus before deciding to invest in our securities. If any of these risks actually occurs, it may materially harm our business,
financial condition, liquidity and results of operations. As a result, the market price of our securities could decline, and you could lose all or part of your investment. Additionally, the risks and uncertainties described in this prospectus, any
prospectus supplement, any post-effective amendment or in any filing or document incorporated by reference herein or therein are not the only risks and uncertainties that we face. Additional risks and uncertainties not presently known to us or that
we currently believe to be immaterial may become material and adversely affect our business. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom559675_4"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise provided in the applicable prospectus supplement or in any free writing prospectuses we have authorized for use in
connection with a specific offering, we currently intend to use the net proceeds from the sale of the securities offered by this prospectus, if any, for working capital and general corporate purposes, which may include capital expenditures,
commercialization expenditures, research and development expenditures, regulatory affairs expenditures, clinical trial expenditures, acquisitions of new technologies and investments, business combinations and the repayment, refinancing, redemption
or repurchase of indebtedness or capital stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The intended application of proceeds from the sale of any particular offering of
securities using this prospectus will be described in the accompanying prospectus supplement relating to such offering. The precise amount and timing of the application of these proceeds will depend upon a number of factors, such as the costs and
timing of commercial and development activities, including, for example, conducting preclinical studies and clinical trials, our funding requirements and the availability and costs of other funds. Pending application of the net proceeds as described
above, we intend to temporarily invest the proceeds in interest-bearing instruments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may bear all other costs, fees and expenses
incurred in effecting the registration of the shares covered by this prospectus, including, without limitation, all registration and filing fees, Nasdaq Capital Market listing fees, and fees and expenses of our counsel and our accountants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom559675_5"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus, any accompanying prospectus supplement and the documents incorporated by reference into this prospectus may contain
forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act, and Section&nbsp;21E of the Exchange Act, about us and our subsidiaries. These forward-looking statements are intended to be covered by the safe harbor for
forward-looking statements provided by the Private Securities Litigation Reform&nbsp;Act of&nbsp;1995. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or
achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These forward-looking statements rely on a number of assumptions concerning future events and
include statements relating to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain the listing of our Common Stock on the Nasdaq Capital Market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our public securities&#146; liquidity and trading; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to raise financing in the future; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our use of proceeds in connection with any offering; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our future use of equity or debt financings to execute our business strategy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to use cash on hand to meet current and future financial obligations, including funding our
operations, debt service requirements and capital expenditures; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the outcome of any legal proceedings that may be instituted against us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract and retain qualified directors, officers, employees and key personnel;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to compete effectively in a highly competitive market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the competition from larger biotechnology companies that have greater resources, technology, relationships and/or
expertise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to protect and enhance our corporate reputation and brand; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact from future regulatory, judicial and legislative changes in our industry; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain and maintain regulatory approval of any of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to research, discover and develop additional product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to grow and manage growth profitably; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain and maintain intellectual property protection and not infringe on the rights of others;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to execute our business plans and strategy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of global economic and political developments, including the conflicts in Ukraine and Israel;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of <FONT STYLE="white-space:nowrap">COVID-19</FONT> and other similar disruptions in the future; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other factors detailed under the section of this prospectus titled &#147;<I>Risk Factors</I>.&#148;
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any forward-looking statements should be considered in light of these factors. Such statements can be identified by the
fact that they do not relate strictly to historical or current facts. Any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward looking
statements. Forward-looking statements are typically identified by words such as &#147;plan,&#148; &#147;believe,&#148; &#147;expect,&#148; &#147;anticipate,&#148; &#147;contemplate,&#148; &#147;intend,&#148; &#147;outlook,&#148;
&#147;estimate,&#148; &#147;forecast,&#148; &#147;project,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;may,&#148; &#147;might,&#148; &#147;possible,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;should,&#148; &#147;will,&#148;
&#147;would&#148; and other similar words and expressions (including the negative of any of the foregoing), but the absence of these </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
words does not mean that a statement is not forward-looking. These forward-looking statements are based on information available as of the date of this prospectus and our management&#146;s
current expectations, forecasts and assumptions, and involve a number of judgments, known and unknown risks and uncertainties and other factors, many of which are outside the control of the Company and our directors, officers and affiliates. There
can be no assurance that future developments will be those that have been anticipated. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. You are cautioned not to put undue reliance
on any forward-looking statements. Except as otherwise required by law, we do not assume any obligation to update any forward-looking statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this prospectus, or any accompanying prospectus supplement and the documents incorporated by reference completely and with the
understanding that our actual future results may be materially different from what we currently expect. Our business and operations are and will be subject to a variety of risks, uncertainties and other factors. Consequently, actual results and
experience may materially differ from those contained in any forward-looking statements. Such risks, uncertainties and other factors that could cause actual results and experience to differ from those projected include, but are not limited to, the
risk factors set forth in Part I &#151;Item&nbsp;1A, &#147;Risk Factors&#148;, in our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1820190/000095017023006493/sclx-20221231.htm">Form<U></U><FONT
STYLE="white-space:nowrap">&nbsp;10-K</FONT> for the year ended December<U></U>&nbsp;31, 2022</A> and Part II&#151;Item&nbsp;1A, &#147;Risk Factors&#148;, in our Quarterly Reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT> for the
quarters ended <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1820190/000095017023021743/sclx-20230331.htm">March<U></U>&nbsp;
31, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1820190/000095017023041842/sclx-20230630.htm">June<U></U>&nbsp;
30, 2023</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1820190/000095017023063810/sclx-20230930.htm">September<U></U>&nbsp;30, 2023</A> and in other filings with the SEC, which may be amended,
supplemented or superseded from time to time by other reports we file with the SEC in the future, that are incorporated by reference in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should assume that the information appearing in this prospectus, any accompanying prospectus supplement, any related free writing
prospectus and any document incorporated herein by reference is accurate as of its date only. Because the risk factors referred to above could cause actual results or outcomes to differ materially from those expressed in any forward-looking
statements made by us or on our behalf, you should not place undue reliance on any forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made. New factors emerge from time to time, and it is not
possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those
contained in any forward-looking statements. Some of these risks and uncertainties may in the future be amplified by <FONT STYLE="white-space:nowrap">COVID-19</FONT> (or other similar disruptions), and there may be additional risks that we consider
immaterial or which are unknown. It is not possible to predict or identify all such risks. All written or oral forward-looking statements attributable to us or any person acting on our behalf made after the date of this prospectus are expressly
qualified in their entirety by the risk factors and cautionary statements contained in and incorporated by reference into this prospectus. Unless legally required, we do not undertake any obligation to release publicly any revisions to such
forward-looking statements to reflect events or circumstances after the date of this prospectus or to reflect the occurrence of unanticipated events. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom559675_6"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General Matters </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Restated Certificate
of Incorporation of the Company (the &#147;Certificate of Incorporation&#148;) authorizes the issuance of (i) 740,000,000 shares of Common Stock and (ii) 45,000,000 shares of preferred stock, $0.0001 par value per share (the &#147;Preferred
Stock&#148;), of which&nbsp;29,057,097 shares have been designated as Series A Preferred Stock. As of November&nbsp;30, 2023, there were&nbsp;157,905,655 shares of Common Stock and&nbsp;29,057,097 shares of Series A Preferred Stock issued and
outstanding. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Certificate of Incorporation provides the following with respect to the rights, powers, preferences and privileges of our Common Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividend
Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of our Common Stock are entitled to receive ratably those dividends, if any, that may be declared from time to
time by our board of directors (the &#147;Board&#148;) upon the shares of our capital stock, which dividends may be paid either in cash, in property or in shares of our capital stock, subject to preferences that may be applicable to preferred stock,
if any, then outstanding. Subject to applicable law and the Certificate of Incorporation, our Board will have full power to determine whether any dividends shall be declared and paid to stockholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each holder of our
Common Stock will be entitled to one vote for each share of our Common Stock held of record by such holder on all matters on which stockholders generally are entitled to vote, except for any amendment to the Certificate of Incorporation that relates
solely to the terms of one or more outstanding classes or series of our Preferred Stock if the holders of such affected classes or series are entitled, either separately or together with the holders of one or more other such classes or series, to
vote thereon pursuant to the Certificate of Incorporation or the Delaware General Corporation Law, as amended (the &#147;DGCL&#148;). Any action or matter presented to the stockholders at a duly called or convened meeting, at which a quorum is
present, will be decided by the affirmative vote of the holders of a majority of the votes cast affirmatively or negatively (excluding abstentions) at the meeting by the holders entitled to vote thereon, except that our directors will be elected by
a plurality of the votes cast. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Right to Receive Liquidation Distributions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a liquidation, dissolution or winding up of the Company, the holders of our Common Stock will be entitled to share ratably in
all assets remaining after payment of liabilities, subject to prior distribution rights of our Preferred Stock, if any, then outstanding. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>No
Preemptive or Similar Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Common Stock have no preemptive or conversion rights or other subscription rights. There are no
redemption or sinking fund provisions applicable to our Common Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fully Paid and <FONT STYLE="white-space:nowrap">Non-Assessable</FONT>
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The outstanding Vickers Ordinary Shares and the shares of our Common Stock issued in the Business Combination are fully paid and <FONT
STYLE="white-space:nowrap">non-assessable.</FONT> The &#147;Vickers Ordinary Shares&#148; consist of (i)&nbsp;the ordinary shares, par value $0.0001 per share, of Vickers prior to the Domestication and (ii)&nbsp;the Common Stock following the
Domestication. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation authorizes our Board, subject to limitations prescribed by Delaware law, to issue up to&nbsp;45,000,000 shares
of preferred stock in one or more series, to determine and fix from time to time the number of shares to be included in each such series and to fix the designations, powers, rights and preferences of the shares of each such series, and the
qualifications, limitations and restrictions thereof, including voting rights (if any), dividend rights, dissolution rights, conversion rights, exchange rights and redemption rights, in each case without further vote or action by our stockholders.
The number of authorized shares of our Common Stock and our Preferred Stock may be increased or decreased (but not below the number of the shares thereof then outstanding) by the affirmative vote of the holders of a majority in voting power of our
outstanding stock entitled to vote thereon. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board may authorize the issuance of preferred stock with voting or conversion rights that
could adversely affect the voting power or other rights of the holders of our Common Stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other
things, have the effect of delaying, deferring or preventing a change in control and may adversely affect the market price of our Common Stock and the voting and other rights of the holders of our Common Stock. Other than the Series A Preferred
Stock issued to Sorrento Therapeutics, Inc. (&#147;Sorrento&#148;) in connection with the closing of the Business Combination, there are no other Preferred Stock outstanding and we have no current plans to issue any other shares of preferred stock.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Number and Designation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We filed the Certificate of Designations of the Company, designating&nbsp;29,057,097 shares of our preferred stock as &#147;Series A Preferred
Stock&#148; (&#147;Certificate of Designations&#148;). As of the date of this prospectus, 29,057,097&nbsp;shares of the Series A Preferred Stock are held by SCLX Stock Acquisition JV LLC, our indirect wholly-owned subsidiary, which shares were
repurchased from Sorrento pursuant to the terms of the Stock Purchase Agreement, dated September&nbsp;21, 2023, entered into between us and Sorrento (the &#147;Sorrento SPA&#148;) and represent all of the shares of Series A Preferred Stock that were
previously owned by Sorrento. The shares of Series A Preferred Stock have all of the rights, preferences and privileges set forth in the Certificate of Designations as more fully described below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Rank </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Series A Preferred Stock
shall rank (i)&nbsp;senior to all of our Common Stock, and to all other classes or series of our capital stock, except for any such other class or series, the terms of which expressly provide that it ranks on parity with the Series A Preferred Stock
as to dividend rights and rights on liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company (&#147;Junior Securities&#148;); and (ii)&nbsp;on parity with each class or series of our capital stock, created
specifically ranking by its terms on parity with the Series A Preferred Stock as to dividend rights and rights on liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company (&#147;Parity Securities&#148;). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividend Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of the
Series A Preferred Stock shall not be entitled to dividends unless we pay dividends to holders of the Common Stock and shall be entitled to receive, when, as and if declared by our Board, such dividends (whether in cash or other property) as are
paid to holders of our Common Stock to the same extent as if such holders of Series A Preferred Stock had been deemed to convert their shares of Series A Preferred Stock into Common Stock and had held such shares of Common Stock on the record date
for such dividends and distributions. Such payments will be made concurrently with the dividend or distribution to the holders of the Common Stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation Preference </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the
event of a change of control, liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company, whether voluntary or involuntary, before any payment or distribution of our property or assets (whether capital or surplus)
shall be made to or set apart for the holders of Junior Securities, the holders of Series A Preferred Stock shall be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
entitled to receive an amount per share of Series A Preferred Stock equal to the greater of (i)&nbsp;the sum of $10.00 (which amount shall be appropriately adjusted in the event of any stock
split, stock combination or other similar recapitalization of the Series A Preferred Stock) and all accrued and unpaid dividends and (ii)&nbsp;the amount such share of Series A Preferred Stock would be entitled to receive pursuant to the change of
control, liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company assuming that such share had been converted into shares of Common Stock in a Deemed Conversion (as defined below). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Conversion and Redemption Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of Series A Preferred Stock will not be convertible into Common Stock or any of our other securities and will not be redeemable by
the Company; provided, however, a number of the rights, preferences and privileges of the Series A Preferred Stock set forth in the Certificate of Designations will be determined based on an <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">as-converted-to-Common</FONT></FONT></FONT> Stock basis or otherwise assume that the shares of Series A Preferred Stock are converted into shares of Common Stock. Accordingly, the number of
shares of Common Stock that each share of Series A Preferred Stock is deemed to be (or otherwise being treated as) converted into for the purpose of affecting the various rights, preferences and privileges of the Series A Preferred Stock set forth
in the Certificate of Designation (a &#147;Deemed Conversion&#148;), whether in connection with a change of control or otherwise, shall be equal to the result obtained by dividing (i)&nbsp;stated value by (ii) $10.00 (subject to anti-dilution
adjustments). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting and Other Preferred Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise required by law or as set forth in the Certificate of Designations, the holders of shares of Series A Preferred Stock will
be entitled to vote, together with the holders of shares of Common Stock and not separately as a class, on all matters upon which holders of shares of Common Stock have the right to vote. The holders of shares of Series A Preferred Stock will be
entitled to one vote for each share of Common Stock that such share of Series A Preferred Stock would otherwise be convertible into pursuant to a Deemed Conversion on the record date for the determination of the stockholders entitled to vote. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As long as any shares of Series A Preferred Stock are outstanding, we shall not, without the affirmative vote of the holders of at least a
majority of the outstanding shares of Series A Preferred Stock (a)&nbsp;change the Series A Preferred Stock (whether by merger, consolidation, reclassification or otherwise) into cash, securities or other property except in accordance with the terms
of the Certificate of Designations; (b)&nbsp;create, authorize or issue any Parity Security or other equity security the terms of which provide that it ranks senior to the Series A Preferred Stock with respect to dividend rights or rights upon
liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company, or increase the authorized amount of any such other class or series; or (c)&nbsp;amend the Certificate of Incorporation or the Certificate of Designations
in any manner that adversely affects the holders of Series A Preferred Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Registration Rights Agreement entered into in connection with the closing of the Business Combination, certain of our
stockholders are able to demand that we register their registrable securities under certain circumstances and each also have piggyback registration rights for these securities. In addition, we are required to file and maintain an effective
registration statement under the Securities Act covering the resale of all such registrable securities. We have filed a registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> (File
<FONT STYLE="white-space:nowrap">No.&nbsp;333-268603)</FONT> which was initially declared effective by the SEC on December&nbsp;27, 2022, in order to satisfy these obligations. The registration of these securities will enable the public sale of such
securities. The presence of these additional shares of Common Stock trading in the public market may have an adverse effect on the market price of our securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Matters in our Governing Documents and Under Delaware Law </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain provisions of Delaware law, along with the Certificate of Incorporation and the Bylaws of Company (the &#147;Bylaws&#148;), all of
which are summarized below, may have the effect of delaying, deferring or discouraging another person from acquiring control of the Company. These provisions are expected to discourage coercive takeover practices and inadequate takeover bids. These
provisions are also designed, in part, to encourage persons seeking to acquire control of the Company to first negotiate with our Board. However, these provisions could have the effect of delaying, discouraging or preventing attempts to acquire the
Company, which could deprive our stockholders of opportunities to sell their shares of our Common Stock at prices higher than prevailing market prices. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Authorized but Unissued Capital Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The authorized but unissued shares of our Common Stock and our Preferred Stock are available for future issuance without stockholder approval,
subject to any limitations imposed by the rules and listing standards of The Nasdaq Stock Market LLC. These additional shares may be used for a variety of corporate finance transactions, acquisitions and employee benefit plans. The existence of
authorized but unissued and unreserved Common Stock and Preferred Stock could make more difficult or discourage an attempt to obtain control of the Company by means of a proxy contest, tender offer, merger or otherwise. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Impact of the Equity Repurchase Transaction on Provisions Related to a Sorrento Trigger Event </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain provisions of our Certificate of Incorporation related to the number of authorized directors, filling vacancies on the Board, removal
of directors, stockholder actions by written consent, calling of special meetings of our stockholders, our election to not be governed by Section&nbsp;203 of the DGCL and amendments to our Certificate of Incorporation and our Bylaws lapse upon or
are triggered at the time Sorrento Therapeutics, Inc. (&#147;Sorrento&#148;, together with its affiliates, subsidiaries, successors and assigns (other than us and our subsidiaries)) first ceases to beneficially own more than&nbsp;50% in voting power
of the then-outstanding shares of our capital stock entitled to vote generally in the election of directors (the &#147;Sorrento Trigger Event&#148;). Upon the closing of the equity repurchase transaction pursuant to the Sorrento SPA, a Sorrento
Trigger Event occurred. The disclosures below related to the foregoing provisions are based on the occurrence of such event. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Classified Board
of Directors </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation provides that our Board are divided into three classes, with the classes as nearly
equal in number as practical and each class serving three-year staggered terms. The directors in each class serve for a three-year term (except that the term of our current Class&nbsp;II directors shall expire at the second annual meeting of
stockholders following the closing of the Business Combination), with one class being elected each year by the stockholders. This system of electing and removing directors may tend to discourage a third party from making a tender offer or otherwise
attempting to obtain control of the Company, because it generally makes it more difficult for stockholders to replace a majority of the directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation also provides that the total number of directors shall be determined from time to time exclusively by our
Board. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Removal of Directors; Vacancies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation provides that, except as otherwise required by law or the Certificate of Incorporation, directors may be
removed only for cause and only by the affirmative vote of the holders of at least&nbsp;66 2/3% in voting power of all the then-outstanding shares of our capital stock entitled to vote thereon, voting together as a single class, in each case subject
to the rights of holders of any series of Preferred Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Certificate of Incorporation provides that, except as otherwise provided
therein or by law, any vacancy resulting from the death, resignation, removal or disqualification of a director or other cause, or any newly created directorship in our Board, shall be filled only by a majority of the directors then in office,
although less than a quorum, and shall not be filled by our stockholders, in each case subject to the rights of the holders of any series of Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These provisions may have the effect of deferring, delaying, or discouraging hostile takeovers, changes in control of the Company or changes
in our management. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Delaware Anti-Takeover Law </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation provides that we are governed by Section&nbsp;203 of the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;203 of the DGCL prohibits persons deemed to be &#147;interested stockholders&#148; from engaging in a &#147;business
combination&#148; with a publicly held Delaware corporation for three years following the date such persons become interested stockholders, unless the business combination is, or the transaction in which the person became an interested stockholder
was, approved in a prescribed manner or another prescribed exception applies. Generally, an &#147;interested stockholder&#148; is a person who, together with affiliates and associates, owns, or within three years prior to the determination of
interested stockholder status did own, 15% or more of a corporation&#146;s voting stock. Generally, a &#147;business combination&#148; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested
stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions that are not approved in advance by our Board, including discouraging attempts that might result in a premium over the market price for the
shares of Common Stock held by stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation provides that the restrictions on business combination of
Section&nbsp;203 of the DGCL will not apply to Sorrento or its current or future Affiliates (as defined in the Certificate of Incorporation) regardless of the percentage of ownership of the total voting power of all the then-outstanding shares of
our capital stock entitled to vote generally in the election of directors beneficially owned by them. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>No Cumulative Voting </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Delaware law, the right to vote cumulatively does not exist unless the certificate of incorporation specifically authorizes cumulative
voting. The Certificate of Incorporation does not authorize cumulative voting. Therefore, stockholders holding a majority of the shares of our capital stock entitled to vote generally in the election of directors will be able to elect all of our
directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Special Stockholder Meetings </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation provides that special meetings of stockholders may only be called by order of the Chairperson of our Board,
our Board or the Chief Executive Officer, subject to the rights of the holders of any series of Preferred Stock with respect to such series of preferred stock. The Bylaws prohibits the conduct of any business at a special meeting other than as
specified in the notice for such meeting. These provisions may have the effect of deferring, delaying, or discouraging hostile takeovers or changes in control or management. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Director Nominations and Stockholder Proposals </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Bylaws establishes advance notice procedures with respect to stockholder proposals and the nomination of candidates for election as
directors, other than nominations made by or at the direction of our Board or a committee of our Board. In order for any matter to be &#147;properly brought&#148; before a meeting, a stockholder will have to comply with advance notice requirements
and provide us with certain information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, to be timely, a stockholder&#146;s notice must be delivered to our secretary at
our principal executive offices not earlier than the close of business on the&nbsp;120th day nor later than the close of business on the&nbsp;90th day prior to the first anniversary of the preceding year&#146;s annual meeting (in the case of the
first annual meeting of stockholders held after January&nbsp;1, 2023, the date of the preceding year&#146;s annual meeting of the stockholders shall be deemed to be June&nbsp;30, 2022); provided, however, that, if the date of the annual meeting is
advanced more than&nbsp;30&nbsp;days prior to or delayed by more than&nbsp;60&nbsp;days after the anniversary of the preceding year&#146;s annual meeting, or if no annual meeting was held in the preceding year, notice by the stockholder to be timely
must be so delivered not earlier than the close of business on the&nbsp;120th day prior to such annual meeting and not later than the close of business on the later of the&nbsp;90th day prior to such annual meeting and the&nbsp;10th day following
the day on which public announcement of the date of such meeting is first made by us. The Bylaws also specifies requirements as to the form and content of a stockholder&#146;s notice. The Bylaws allows any previously scheduled stockholders meeting
to be postponed, adjourned or canceled by resolution of our Board; provided, however, that with respect to any special meeting of stockholders scheduled at the request of Sorrento, our Board is not allowed to postpone, reschedule or cancel without
the prior written consent of Sorrento. In addition, the Bylaws allows the chair of a meeting of the stockholders to adopt rules and regulations for the conduct of that meeting that may have the effect of precluding the conduct of certain business at
that meeting if the rules and regulations are not followed. These provisions may also defer, delay, or discourage a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#146;s own slate of directors or otherwise
attempting to influence or obtain control. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stockholder Action by Written Consent </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Section&nbsp;228 of the DGCL and the terms of the Certificate of Incorporation, any action required or permitted to be taken by our
stockholders must be effected by a duly called annual or special meeting of such stockholders, subject to the rights of the holders of any series of Preferred Stock with respect to such series of preferred stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amendment of Certificate of Incorporation or Bylaws </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The DGCL provides generally that the affirmative vote of a majority of the shares entitled to vote on any matter is required to amend a
corporation&#146;s certificate of incorporation or bylaws, unless a corporation&#146;s certificate of incorporation or bylaws, as the case may be, requires a greater percentage. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation provides that the affirmative vote of the holders of at least&nbsp;66 2/3% of the voting power of the
then-outstanding shares of our capital stock entitled to vote thereon, voting together as a single class, will be required to alter, amend or repeal the following provisions of the Certificate of Incorporation: Article&nbsp;V (Board of Directors),
Article&nbsp;VI (Consent of Stockholders in Lieu of Meeting; Special Meetings of Stockholders), Article&nbsp;VII (Limitation of Liability), Article&nbsp;VIII (Corporate Opportunities and Competition), Article&nbsp;IX (Exclusive Forum),
Article&nbsp;X (Section&nbsp;203 of the DGCL) and Article&nbsp;XI (Amendment of Certificate of Incorporation and Bylaws), and no other provision may be adopted, amended or repealed that would have the effect of modifying or permitting the
circumvention of the provisions set forth in any of such Articles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation and the Bylaws provide that, our
Board is authorized to make, alter and repeal the Bylaws, without the consent or vote of the stockholders, by an approval of a majority of the total authorized number of directors. The affirmative vote of the holders of at least&nbsp;66 2/3% of the
voting power of the then-outstanding shares of our capital stock entitled to vote thereon, voting together as a single class, will be required to alter, amend or repeal the Bylaws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The provisions of the DGCL, the Certificate of Incorporation and the Bylaws could have the effect of discouraging others from attempting
hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our Common Stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing
changes in the composition of our Board and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Exclusive Forum </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate
of Incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter
jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) and any appellate court therefrom shall, to the
fullest extent permitted by law, be the sole and exclusive forum for (i)&nbsp;any derivative action or proceeding brought on behalf of the Company, (ii)&nbsp;any action asserting a claim of breach of a fiduciary duty owed by any of our current or
former directors, officers, employees or stockholders to us or our stockholders, (iii)&nbsp;any action asserting a claim against us or any of our current or former directors, officers, employees or stockholders arising pursuant to any provision of
the DGCL or of the Certificate of Incorporation or the Bylaws, (iv)&nbsp;any claim or cause of action seeking to interpret, apply, enforce or determine the validity of the Certificate of Incorporation or the Bylaws, (v)&nbsp;any action or proceeding
asserting a claim against us or any of our current or former directors, officers, employees or stockholders as to which the DGCL confers jurisdiction to the Court of Chancery of the State of Delaware, or (vi)&nbsp;any action asserting an
&#147;internal corporate claim,&#148; as that term is defined in Section&nbsp;115 of the DGCL. The foregoing exclusive forum provisions will not apply to claims arising under the Exchange Act or any other claim for which the federal courts have
exclusive jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Certificate of Incorporation provides that, unless we consent in writing to the selection of an
alternative forum, to the fullest extent permitted by law, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we believe these provisions benefit us by providing increased consistency in the application of applicable law in the types of
lawsuits to which they apply, the provisions may have the effect of discouraging lawsuits against our directors and officers. The enforceability of similar choice of forum provisions in other companies&#146; certificates of incorporation has been
challenged in legal proceedings and there is uncertainty as to whether a court would enforce such provisions. In addition, investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. It is possible
that, in connection with any applicable action brought against us, a court could find the choice of forum provisions contained in the Certificate of Incorporation to be inapplicable or unenforceable in such action. We may incur additional costs
associated with resolving such action in other jurisdictions, which could harm our business, operating results and financial condition. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be
deemed to have notice of and consented to the forum provisions in the Certificate of Incorporation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Limitation of Liability and Indemnification of
Directors and Officers </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation and the Bylaws contain provisions that limit the liability of our
directors for monetary damages to the fullest extent permitted by the DGCL. Consequently, our directors will not be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duties as directors, except liability
for the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any breach of their duty of loyalty to us or our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unlawful payments of dividends or unlawful stock repurchases or redemptions in violation of the DGCL; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction from which the director derived an improper personal benefit. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation also provides that if the DGCL is amended to permit further
elimination or limitation of the personal liability of directors, then the liability of our directors will be eliminated or limited to the fullest extent permitted by the DGCL, as so amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Bylaws provide that we shall indemnify any person who is or was a director or officer of the Company or who is or was serving at our
request as a director, officer or trustee of another corporation, limited liability company, partnership, joint venture, employee benefit plan, trust, nonprofit entity or other enterprise (a &#147;Covered Person&#148;) and who is or was a party to,
is threatened to be made a party to, or is otherwise involved (including as a witness) in any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative, or investigative based on such person&#146;s actions
in his or her official capacity as a director or officer of the Company or as a director, officer or trustee of another corporation, limited liability company, partnership, joint venture, employee benefit plan, trust, nonprofit entity or other
enterprise (to the extent serving in such position at our request), in each case against all liability and loss suffered (including, without limitation, any judgments, fines, excise taxes or penalties arising under the Employee Retirement Income
Security Act of&nbsp;1974 and amounts paid in settlement consented to in writing by us) and expenses (including attorneys&#146; fees), actually and reasonably incurred by such person in connection therewith, subject to certain conditions. In
addition, the Bylaws provide that we may, to the fullest extent permitted by law, (i)&nbsp;advance costs, fees or expenses (including attorneys&#146; fees) incurred by a Covered Person defending or participating in any proceeding in advance of the
final disposition of such proceeding, subject to certain exceptions, and (ii)&nbsp;purchase and maintain insurance, at our expense, to protect us and any person who is or was a director, officer, employee or agent of the Company or is or was a
director, officer, employee or agent of the Company serving at our request as a director, officer, employee or agent of another corporation, limited liability company, partnership, joint venture, trust, employee benefit plan or other enterprise
against any liability, expense or loss, whether or not we would have the power or obligation to indemnify such person against such liability, expense or loss under the DGCL or the provisions of the Bylaws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into indemnification agreements with each of our directors, executive officers and certain other employees as determined by
our Board. These agreements, among other things, require us to indemnify our directors and executive officers against liabilities that may arise by reason of their status or service. These indemnification agreements also require us to advance all
expenses actually and reasonably incurred by the directors and executive officers in connection with any proceeding. Our Board believes that these agreements are necessary to attract and retain qualified individuals to serve as directors and
executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The above description of the indemnification provisions of the Certificate of Incorporation, the Bylaws and the
indemnification agreements is not complete and is qualified in its entirety by reference to these documents, each of which is filed as an exhibit to the registration statement of which this prospectus is a part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors may, through their relationships with their employers, be
insured or indemnified against certain liabilities incurred in their capacity as members of our Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The limitation of liability and
indemnification provisions in the Certificate of Incorporation and the Bylaws may discourage stockholders from bringing a lawsuit against our directors and officers for breach of their fiduciary duty. They may also reduce the likelihood of
derivative litigation against our directors and officers, even though an action, if successful, might benefit us and our stockholders. In addition, a stockholder&#146;s investment may be adversely affected to the extent we pay the costs of
settlement and damage awards against directors and officers pursuant to these indemnification provisions. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors or executive officers, we have been
informed that in the opinion of the SEC, such indemnification is against public policy and is therefore unenforceable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conflicts of Interest </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Delaware law permits corporations to adopt provisions renouncing any interest or expectancy in certain opportunities that are presented to the
corporation or its officers, directors or stockholders. The Certificate of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Incorporation provides that, to the fullest extent permitted by law, no Identified Person (as defined therein) will have any duty to refrain from (i)&nbsp;engaging in a corporate opportunity in
the same or similar business activities or lines of business in which we or our affiliates are engaged or that are deemed to be competing with us or any of our affiliates or (ii)&nbsp;otherwise investing in or providing services to any person that
is engaged in the same or similar business activities as we or our affiliates or competes with us or our affiliates. In addition, to the fullest extent permitted by law, no Identified Person will have any obligation to offer to us or our
subsidiaries or affiliates the right to participate in any corporate opportunity in the same or similar business activities or lines of business in which we or our affiliates are engaged or that are deemed to be competing with us or any of our
affiliates. Subject to the preceding sentences and to the fullest extent permitted by applicable law, neither we nor any of our subsidiaries shall have any rights in any business interests, activities or ventures of any Identified Person, and we
waive and renounce any interest or expectancy therein, except with respect to opportunities offered solely and expressly to our officers in their capacity as such. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rights of Appraisal and Payment </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under
the DGCL, with certain exceptions, our stockholders will have appraisal rights in connection with a merger or consolidation of the Company. Pursuant to Section&nbsp;262 of the DGCL, stockholders who properly demand and perfect appraisal rights in
connection with such merger or consolidation will have the right to receive payment of the fair value of their shares as determined by the Delaware Court of Chancery. However, appraisal rights are not available in all circumstances. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stockholders&#146; Derivative Actions </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the DGCL, any of our stockholders may bring an action in the Company&#146;s name to procure a judgment in its favor, also known as a
derivative action, provided that the stockholder bringing the action is a holder of our capital stock at the time of the transaction to which the action relates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SPAC Warrants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the effective time of
the Domestication, each warrant to purchase Vickers Ordinary Shares that was issued and outstanding immediately prior to the effective time of the Domestication and not terminated pursuant to its terms was converted into a warrant to purchase shares
of our Common Stock on the same terms and conditions as are in effect with respect to such warrant immediately prior to the effective time of the Domestication. As of November&nbsp;30, 2023, there are 10,958,309 outstanding SPAC Warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;SPAC Warrants&#148; consist of (i)&nbsp;the redeemable warrants that were included in the Units (each of which consisted of one Vickers
Ordinary Share <FONT STYLE="white-space:nowrap">and&nbsp;one-half&nbsp;of</FONT> one redeemable warrant) that entitle the holder of each whole warrant to purchase one Vickers Ordinary Share at a price of $11.50 per share (the &#147;Public
Warrants&#148;), and (ii)&nbsp;the 6,840,000 warrants sold in a private placement to Vickers Venture Fund VI Pte Ltd and Vickers Venture Fund VI (Plan) Pte Ltd consummated on January&nbsp;11, 2021 (of which 2,736,000 were subsequently forfeited and
3,104,000 were transferred to Sorrento, in each case in connection with the Business Combination) (the &#147;Private Placement Warrants&#148;). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Public Warrants </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Public
Warrant entitles the registered holder thereof to purchase one share of our Common Stock at a price of $11.50 per share, subject to adjustment as described in this prospectus. We may, in our sole discretion, lower the warrant exercise price at any
time prior to the expiration date for a period of not less than 20 business days and any such reduction will be applied consistently to all of the warrants, provided that we will provide at least 20 days&#146; prior written notice to registered
holders of the warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, no Public Warrants will be exercisable for cash unless we have an effective and
current registration statement covering the issuance of the Common Stock issuable upon exercise of the warrants and a current prospectus relating to such Common Stock. Notwithstanding the foregoing, if a registration statement covering the issuance
of the Common Stock issuable upon exercise of the Public Warrants is not effective within 90 days from the consummation of the Business Combination, warrantholders may, from the 91st day after the consummation of the Business Combination until such
time as there is an effective registration statement and during any period when we shall have failed to maintain an effective registration statement, exercise warrants on a cashless basis pursuant to an available exemption from registration under
the Securities Act. If an exemption from registration is not available, holders will not be able to exercise their warrants on a cashless basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The warrants will expire five years from the consummation of the Business Combination (i.e., November&nbsp;10, 2027) at 5:00 p.m., New York
City time or earlier upon redemption or liquidation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may call the warrants for redemption (excluding the Private Placement Warrants),
in whole and not in part, at a price of $0.01 per warrant: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at any time while the warrants are exercisable, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon not less than 30 days&#146; prior written notice of redemption to each warrantholder, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if, and only if, the closing price of the Common Stock equals or exceeds $18.00 per share (as adjusted for <FONT
STYLE="white-space:nowrap">share&nbsp;sub-divisions,&nbsp;share</FONT> dividends, reorganizations and recapitalizations), for any 20 trading days within a 30 trading day period commencing after the warrants become exercisable and ending on the third
trading day prior to the date on which notice of redemption is given, and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if, and only if, there is an effective registration statement covering the Common Stock issuable upon exercise of
the Public Warrants, and a current prospectus relating thereto, available throughout <FONT STYLE="white-space:nowrap">the&nbsp;30-day&nbsp;redemption.</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not exercise such redemption right if the issuance of the Common Stock upon exercise of the warrants is not exempt from registration or
qualification under applicable state blue sky laws or we are unable to effect such registration or qualification. The right to exercise will be forfeited unless the warrants are exercised prior to the date specified in the notice of redemption. On
and after the redemption date, a record holder of a warrant will have no further rights except to receive the redemption price for such holder&#146;s warrant upon surrender of such warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The redemption criteria for our warrants have been established at a price which is intended to provide warrantholders a reasonable premium to
the initial exercise price and provide a sufficient differential between the then-prevailing per share price of our Common Stock and the warrant exercise price so that if the per share price of our Common Stock declines as a result of our redemption
call, the redemption will not cause the per share price of our Common Stock to drop below the exercise price of the warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we call
the warrants for redemption as described above, our management will have the option to require all holders of warrants to exercise their warrants on a &#147;cashless basis.&#148; In such event, each holder would pay the exercise price by
surrendering the warrants for that number of shares of Common Stock equal to the quotient obtained by dividing (x)&nbsp;the product of the number of shares of Common Stock underlying the warrants, multiplied by the difference between the exercise
price of the warrants and the fair market value by (y)&nbsp;the fair market value. The &#147;fair market value&#148; for this purpose shall mean the average reported closing price of the shares of our Common Stock for the 10 trading days ending on
the third trading day prior to the date on which the notice of redemption is sent to the holders of warrants. For example, if a holder held 150 warrants to purchase 150 shares of our Common Stock and the fair market value on the trading date prior
to exercise was $15.00, that holder would receive 35 shares of our Common Stock without the payment of any additional cash consideration. Whether we will exercise our option to require all holders to exercise their warrants on a &#147;cashless
basis&#148; will depend on a variety of factors including the price of our Common Stock at the time the warrants are called for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
redemption, our cash needs at such time and concerns regarding dilutive share issuances. Requiring a cashless exercise in this manner will reduce the number of shares of our Common Stock to be
issued and thereby lessen the dilutive effect of a warrant redemption. We believe this feature is an attractive option to use if we do not need the cash from the exercise of the Public Warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The warrants are issued in registered form under a warrant agreement (the &#147;Warrant Agreement&#148;) between Continental Stock
Transfer&nbsp;&amp; Trust Company, as warrant agent, and us. The Warrant Agreement provides that the terms of the warrants may be amended without the consent of any holder to cure any ambiguity or correct any defective provision, but requires the
approval, by written consent or vote, of the registered holders of a majority of the then-outstanding warrants (including the Private Placement Warrants) in order to make any change that adversely affects the interests of the registered holders.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exercise price and number of shares of Common Stock issuable on exercise of the warrants may be adjusted in certain circumstances
including in the event of (i)&nbsp;a stock dividend or split up, (ii)&nbsp;a consolidation, combination, reverse stock split or reclassification of the Common Stock, (iii)&nbsp;extraordinary dividend or (iv)&nbsp;reclassification or reorganization
of the outstanding Common Stock or an merger or consolidation of us with or into another corporation. However, the warrants will not be adjusted for issuances of shares of Common Stock at a price below the par value per share issuable upon exercise
of the warrants. Whenever the number of shares of Common Stock purchasable upon the exercise of the warrants is adjusted, the warrant exercise price will be adjusted by multiplying such warrant exercise price immediately prior to such adjustment by
a fraction (x)&nbsp;the numerator of which will be the number of shares of Common Stock purchasable upon the exercise of the warrants immediately prior to such adjustment, and (y)&nbsp;the denominator of which will be the number of shares of Common
Stock so purchasable immediately thereafter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The warrants may be exercised upon surrender of the warrant certificate on or prior to the
expiration date at the offices of the warrant agent, with the exercise form on the reverse side of the warrant certificate completed and executed as indicated, accompanied by full payment of the exercise price (or on a cashless basis, if
applicable), by certified check or bank draft payable to the order of the warrant agent or wire transfer, for the number of warrants being exercised. The warrantholders do not have the rights or privileges of holders of shares of Common Stock and
any voting rights until they exercise their warrants and receive shares of Common Stock. After the issuance of shares of Common Stock upon exercise of the warrants, each holder will be entitled to one vote for each share of Common Stock held of
record on all matters to be voted on by stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as described above, no Public Warrants will be exercisable for cash and we
will not be obligated to issue shares of Common Stock upon exercise of a warrant unless the shares of Common Stock issuable upon such warrant exercise have been registered, qualified or deemed to be exempt under the securities laws of the state of
residence of the registered holder of the warrants. Under the terms of the Warrant Agreement, we have agreed to use our best efforts to meet these conditions and to maintain a current prospectus relating to the Common Stock issuable upon exercise of
the warrants until the expiration of the warrants. However, we cannot assure you that we will be able to do so and, if we do not maintain a current prospectus relating to the Common Stock issuable upon exercise of the warrants, holders will be
unable to exercise their warrants and we will not be required to settle any such warrant exercise. If the prospectus relating to the Common Stock issuable upon the exercise of the warrants is not current or if the Common Stock is not qualified or
exempt from qualification in the jurisdictions in which the holders of the warrants reside, we will not be required to net cash settle or cash settle the warrant exercise, the warrants may have no value, the market for the warrants may be limited
and the warrants may expire worthless. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Warrantholders may elect to be subject to a restriction on the exercise of their warrants such
that an electing warrantholder would not be able to exercise their warrants to the extent that, after giving effect to such exercise, such holder (together with such holder&#146;s affiliates) would beneficially own in excess of 9.8% of the Common
Stock outstanding immediately after giving effect to such exercise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No fractional shares will be issued upon exercise of the warrants. If, upon exercise of the
warrants, a holder would be entitled to receive a fractional interest in a share, we will, upon exercise, round up to the nearest whole number of shares of Common Stock to be issued to the warrantholder. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Private Placement Warrants </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Private Placement Warrants are identical to the Public Warrants except that such Private Placement Warrants are exercisable for cash (even if a registration statement covering the issuance of the Common Stock issuable upon exercise of such warrants
is not effective) or on a cashless basis, at the holder&#146;s option, and will not be redeemable by us, in each case so long as they are still held by the initial purchasers or their affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing summary of the terms and conditions of the SPAC Warrants does not purport to be complete and is qualified in its entirety by
reference to the copy of the specimen warrant certificate and the Warrant Agreement that are filed as exhibits to the registration statement of which this prospectus forms a part. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Penny Warrants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the
closing of the transactions contemplated by the Securities Purchase Agreement, dated September&nbsp;21, 2023, between us and Oramed Pharmaceuticals Inc. (&#147;Oramed&#148; and such Securities Purchase Agreement, the &#147;Scilex-Oramed SPA&#148;),
we issued warrants to purchase Common Stock, having an exercise price of $0.01 per share, subject to adjustment as provided therein (such warrants, the &#147;Penny Warrants&#148;), to Oramed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The warrant to purchase up to an aggregate of 4,500,000 shares of our Common Stock, with an exercise price of $0.01 per share, which we issued
to Oramed pursuant to the Scilex-Oramed SPA (the &#147;Closing Penny Warrant&#148;), will be exercisable upon the earliest of (i)&nbsp;March&nbsp;14, 2025, (ii) the date on which the senior secured promissory note due 18 months from the date of
issuance in the principal amount of $101, 875,000 issued by us to Oramed pursuant to the Scilex-Oramed SPA (the &#147;Oramed Note&#148;) has been repaid in full and (iii)&nbsp;the Management Sale Trigger Date (as defined therein), if any, and will
expire on the date that is the fifth anniversary of the issuance date. For purposes of the Penny Warrants, the Management Sale Trigger Date is generally the first date on which either Dr.&nbsp;Henry Ji, our Executive Chairperson, or Mr.&nbsp;Jaisim
Shah, our Chief Executive Officer and President and a member of the Board, engages in certain sales or other similar transfers of shares of Common Stock or other of our or any of our subsidiaries&#146; securities, subject to certain exceptions as
are customary for <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements executed by directors and officers in connection with financings or similar transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Scilex-Oramed SPA, we issued to Oramed four warrants (each a &#147;Subsequent Penny Warrant&#148;) to purchase up to an
aggregate of 8,500,000 shares of our Common Stock, each with an exercise price of $0.01 per share, each for 2,125,000 shares of Common Stock, one of which shall vest and become exercisable on the date that is the later of (i)&nbsp;each of
March&nbsp;19, 2024, June&nbsp;17, 2024, September&nbsp;15, 2024 or December&nbsp;14, 2024 (the &#147;Subsequent Penny Warrant Vesting Date&#148;) and (ii)&nbsp;the earliest of (A)&nbsp;March&nbsp;14, 2025, (B) the date on which the Oramed Note has
been repaid in full and (C)&nbsp;the Management Sale Trigger Date (as defined therein), if any. Each Subsequent Penny Warrant will expire on the date that is the fifth anniversary of the issuance date; provided that, if the Oramed Note is repaid in
full prior to the Subsequent Penny Warrant Vesting Date applicable to such Subsequent Penny Warrant, such Subsequent Penny Warrant will expire on the date the Oramed Note is repaid in full. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exercise price of the Closing Penny Warrant issued to Oramed pursuant to the Scilex-Oramed SPA is $0.01 per share, subject to adjustment
as provided therein. The exercise price and number of shares of Common Stock issuable upon the exercise of the Penny Warrants will be subject to adjustment in the event of any stock dividend, stock split, recapitalization, reorganization or similar
transaction, as described in the Penny Warrants; provided that there shall not be any adjustment to the exercise price of the Penny Warrants in the event we combine (by combination, reverse stock split or otherwise) our Common Stock into a smaller
number of shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Oramed may exercise the Penny Warrants by means of a &#147;cashless exercise.&#148; The Closing Penny Warrant and the Subsequent Penny Warrants utilize the same form of warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Penny Warrants may not be exercised if Oramed, together with its affiliates, would beneficially own in excess of 9.9% of the number of
shares of Common Stock outstanding immediately after giving effect to such exercise (the &#147;Oramed Beneficial Ownership Limitation&#148;); provided, however, that upon 61 days&#146; prior notice to us, Oramed may increase or decrease the Oramed
Beneficial Ownership Limitation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing summary of the terms and conditions of the Penny Warrants does not purport to be complete
and is qualified in its entirety by reference to the copy of the form of Penny Warrants that is filed as an exhibit to the registration statement of which this prospectus forms a part. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
transfer agent and registrar for our Common Stock is Continental Stock Transfer&nbsp;&amp; Trust Company. The transfer agent&#146;s address is&nbsp;1 State Street, 30<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Floor, New York, New York
10004. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares of our Common
Stock and Public Warrants are listed on the Nasdaq Capital Market under the symbols &#147;SCLX&#148; and &#147;SCLXW&#148;, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom559675_7"></A>DESCRIPTION OF DEBT SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue debt securities from time to time, in one or more series, as either senior or subordinated debt or as senior or subordinated
convertible debt. While the terms we have summarized below will apply generally to any debt securities that we may offer under this prospectus, we will describe the particular terms of any debt securities that we may offer in more detail in the
applicable prospectus supplement. The terms of any debt securities offered under a prospectus supplement may differ from the terms described below. Unless the context requires otherwise, whenever we refer to the indenture, we also are referring to
any supplemental indentures that specify the terms of a particular series of debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will issue the debt securities under the
indenture that we will enter into with the trustee named in the indenture. The indenture will be qualified under the Trust Indenture Act of&nbsp;1939, as amended (the &#147;Trust Indenture Act&#148;). We have filed the form of indenture as an
exhibit to the registration statement of which this prospectus is a part, and supplemental indentures and forms of debt securities containing the terms of the debt securities being offered will be filed as exhibits to the registration statement of
which this prospectus is a part or will be incorporated by reference from reports that we file with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summary of
material provisions of the debt securities and the indenture is subject to, and qualified in its entirety by reference to, all of the provisions of the indenture applicable to a particular series of debt securities. We urge you to read the
applicable prospectus supplements and any related free writing prospectuses we authorize for use in connection with a specific offering of debt securities, as well as the complete indenture that contains the terms of the debt securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General Matters </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture does not
limit the amount of debt securities that we may issue. It provides that we may issue debt securities up to the principal amount that we may authorize and in any currency or currency unit that we may designate. Except for the limitations on
consolidation, merger and sale of all or substantially all of our assets contained in the indenture, the terms of the indenture do not contain any covenants or other provisions designed to give holders of any debt securities protection against
changes in our operations or financial condition or transactions involving us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue the debt securities issued under the
indenture as &#147;discount securities&#148;, which means they may be sold at a discount below their stated principal amount. These debt securities, as well as other debt securities that are not issued at a discount, may be issued with
&#147;original issue discount&#148; (&#147;OID&#148;), for U.S.&nbsp;federal income tax purposes because of interest payment and other characteristics or terms of the debt securities. Material U.S.&nbsp;federal income tax considerations applicable
to debt securities issued with OID will be described in more detail in the applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will describe in the
applicable prospectus supplement the terms of the series of debt securities being offered, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title of the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the price or prices (expressed as a percentage of the principal amount) at which we will issue the debt
securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any limit on the aggregate principal amount of the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date or dates on which we will pay the principal on the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the form of the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate or rates (which may be fixed or variable) per annum or the method used to determine the rate or rates
(including any commodity, commodity index, stock exchange index or financial index) at </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
which the debt securities will bear interest, the date or dates from which interest will accrue, the date or dates on which interest will commence and be payable and any regular record date for
the interest payable on any interest payment date; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the place or places where principal of and interest on the debt securities will be payable;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the applicability of any guarantees; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms and conditions upon which we may redeem the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether and under what circumstances, if any, we will pay additional amounts on any debt securities held by a
person who is not a United States person for tax purposes, and whether we can redeem the debt securities if we have to pay such additional amounts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any obligation we have to redeem or purchase the debt securities pursuant to any sinking fund or analogous
provisions or at the option of a holder of debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dates on which and the price or prices at which we will repurchase debt securities at the option of the
holders of debt securities and other detailed terms and provisions of these repurchase obligations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the denominations in which the debt securities will be issued, if other than denominations of $1,000 and any
integral multiple thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities will be issued in the form of certificated debt securities or global debt securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the debt securities of the series will be issued in whole or in part in the form of a global debt security,
the terms and conditions, if any, upon which such global debt security may be exchanged in whole or in part for other individual debt securities in definitive registered form, the depositary (as defined in the applicable prospectus supplement) for
such global security and the form of any legend or legends to be borne by any such global security in addition to or in lieu of the legend referred to in the indenture; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the principal amount due at maturity, and whether the debt securities will be issued with original issue
discount; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the portion of principal amount of the debt securities payable upon declaration of acceleration of the maturity
date, if other than the principal amount; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency of denomination of the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation of the currency, currencies or currency units in which payment of principal of and interest on
the debt securities will be made; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if payments of principal of or interest on the debt securities will be made in one or more currencies or currency
units other than that or those in which the debt securities are denominated, the manner in which the exchange rate with respect to these payments will be determined; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the manner in which the amounts of payment of principal of or interest on the debt securities will be determined,
if these amounts may be determined by reference to an index based on a currency or currencies other than that in which the debt securities are denominated or designated to be payable or by reference to a commodity, commodity index, stock exchange
index or financial index; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions relating to any security provided for the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of the subordination of any series of the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on transfer, sale or other assignment of the debt securities, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the principal amount payable at the stated maturity of debt securities of the series will not be determinable
as of any one or more dates prior to such stated maturity, the amount that will be deemed to be such principal amount as of any such date for any purpose, including the principal amount thereof which will be due and payable upon any maturity other
than the stated maturity or which will be </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
deemed to be outstanding as of any such date (or, in any such case, the manner in which such deemed principal amount is to be determined), and if necessary, the manner of determining the
equivalent thereof in U.S.&nbsp;dollars; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the right, if any, to extend the interest payment periods or defer the payment of interest and maximum length of
any such deferral period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">with regard to the debt securities that do not bear interest, the dates for certain required reports to the
trustee; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions granting special rights to holders when a specified event occurs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any addition to or change in the provisions relating to or dealing with defeasance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any addition to or change in the events of default described in this prospectus or in the indenture with respect
to the debt securities and any change in the acceleration provisions described in this prospectus or in the indenture with respect to the debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any addition to or change in the covenants described in this prospectus or in the indenture with respect to the
debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other terms of the debt securities, which may supplement, modify or delete any provision of the indenture as
it applies to that series; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any depositaries, interest rate calculation agents, exchange rate calculation agents or other agents with respect
to the debt securities. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conversion or Exchange Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will set forth in the applicable prospectus supplement the terms on which a series of debt securities may be convertible into or
exchangeable for our Common Stock or our other securities. We will include provisions as to settlement upon conversion or exchange and whether conversion or exchange is mandatory, at the option of the holder or at our option. We may include
provisions pursuant to which the number of shares of our Common Stock or our other securities that the holders of the series of debt securities receive would be subject to adjustment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Protection in the Event of a Change of Control </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we state otherwise in the applicable prospectus supplement, the debt securities will not contain any provisions that may afford holders
of the debt securities protection in the event we have a change in control or in the event of a highly leveraged transaction (whether or not such transaction results in a change in control) that could adversely affect holders of debt securities.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Covenants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will set forth in the
applicable prospectus supplement any restrictive covenants applicable to any issue of debt securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Subordination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Debt securities of a series may be subordinated, which we refer to as subordinated debt securities, to senior indebtedness (as defined in the
applicable prospectus supplement) to the extent set forth in the prospectus supplement relating thereto. To the extent we conduct operations through subsidiaries, the holders of debt securities (whether or not subordinated debt securities) will be
structurally subordinated to the creditors of our subsidiaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consolidation, Merger or Sale </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not consolidate with or merge with or into, or convey, transfer or lease all or substantially all of our properties and assets to, any
person, which we refer to as a successor person, unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we are the surviving corporation or the successor person (if other than Scilex) is a corporation organized and
validly existing under the laws of any U.S.&nbsp;domestic jurisdiction and expressly assumes our obligations on the debt securities and under the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">immediately after giving effect to the transaction, no event of default, and no event which, after notice or
lapse of time, or both, would become an event of default, shall have occurred and be continuing under the indenture; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain other conditions are met. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the above, any of our subsidiaries may consolidate with, merge into or transfer all or part of its properties to us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Events of Default under the Indenture </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the following are events of
default under the indenture with respect to any series of debt securities that we may issue: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">default in the payment of any interest upon any debt security of that series when it becomes due and payable, and
continuance of that default for a period of&nbsp;30&nbsp;days (unless the entire amount of the payment is deposited by us with the trustee or with a paying agent prior to the expiration of <FONT STYLE="white-space:nowrap">the&nbsp;30-day</FONT>
period); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">default in the payment of principal of any debt security of that series when due and payable;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">default in the performance or breach of any other covenant or warranty by us in the indenture or any debt
security (other than a covenant or warranty that has been included in the indenture solely for the benefit of a series of debt securities other than that series), which default continues uncured for a period of&nbsp;60&nbsp;days after we receive
written notice from the trustee or we and the trustee receive written notice from the holders of not less than&nbsp;25% in principal amount of the outstanding debt securities of that series as provided in the indenture; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain events of bankruptcy, insolvency or reorganization of our company; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other event of default provided with respect to debt securities of that series that is described in the
applicable prospectus supplement accompanying this prospectus. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No event of default with respect to a particular series
of debt securities (except as to certain events of bankruptcy, insolvency or reorganization) necessarily constitutes an event of default with respect to any other series of debt securities. The occurrence of certain events of default or an
acceleration under the indenture may constitute an event of default under certain of our other indebtedness outstanding from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an event of default with respect to debt securities of any series outstanding at the time occurs and is continuing, then the trustee or the
holders of not less than&nbsp;25% in principal amount of the outstanding debt securities of that series may, by a notice in writing to us (and to the trustee if given by the holders), declare to be due and payable immediately the principal (or, if
the debt securities of that series are discount securities, that portion of the principal amount as may be specified in the terms of that series) of, and accrued and unpaid interest, if any, on all debt securities of that series. In the case of an
event of default resulting from certain events of bankruptcy, insolvency or reorganization, the principal (or such specified amount) of and accrued and unpaid interest, if any, on all outstanding debt securities will become and be immediately due
and payable without any declaration or other act on the part of the trustee or any holder of outstanding debt securities. At any time after a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
declaration of acceleration with respect to debt securities of any series has been made, but before a judgment or decree for payment of the money due has been obtained by the trustee, the holders
of a majority in principal amount of the outstanding debt securities of that series may rescind and annul the acceleration if all events of default, other than the <FONT STYLE="white-space:nowrap">non-payment</FONT> of accelerated principal and
interest, if any, with respect to debt securities of that series, have been cured or waived as provided in the indenture. We refer you to the prospectus supplement relating to any series of debt securities that are discount securities for the
particular provisions relating to acceleration of a portion of the principal amount of such discount securities upon the occurrence of an event of default. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture provides that the trustee will be under no obligation to exercise any of its rights or powers under the indenture, unless the
trustee receives indemnity satisfactory to it against any loss, liability or expense. Subject to certain rights of the trustee, the holders of a majority in principal amount of the outstanding debt securities of any series will have the right to
direct the time, method and place of conducting any proceeding for any remedy available to the trustee or exercising any trust or power conferred on the trustee with respect to the debt securities of that series. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No holder of any debt security of any series will have any right to institute any proceeding, judicial or otherwise, with respect to the
indenture or for the appointment of a receiver or trustee, or for any remedy under the indenture, unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that holder has previously given to the trustee written notice of a continuing event of default with respect to
debt securities of that series; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the holders of not less than&nbsp;25% in principal amount of the outstanding debt securities of that series have
made written request, and offered reasonable indemnity, to the trustee to institute the proceeding as trustee, and the trustee has not received from the holders of not less than&nbsp;25% in principal amount of the outstanding debt securities of that
series a direction inconsistent with that request and has failed to institute the proceeding within&nbsp;60&nbsp;days. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, the holder of any debt security will have an absolute and unconditional right to receive payment of the
principal of and any interest on that debt security on or after the due dates expressed in that debt security and to institute suit for the enforcement of payment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture requires us, within&nbsp;120&nbsp;days after the end of our fiscal year, to furnish to the trustee a statement as to compliance
with the indenture. The indenture provides that the trustee may withhold notice to the holders of debt securities of any series of any default or event of default (except in payment on any debt securities of that series) with respect to debt
securities of that series if it in good faith determines that withholding notice is in the interest of the holders of those debt securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Modification of Indenture; Waiver </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may
modify and amend the indenture with the consent of the holders of at least a majority in principal amount of the outstanding debt securities of each series affected by the modifications or amendments. We may not make any modification or amendment
without the consent of the holders of each affected debt security then outstanding if that amendment will: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the amount of debt securities whose holders must consent to an amendment, supplement or waiver;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the rate of, or extend the time for, payment of interest (including default interest) on any debt
security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the principal of, or change the fixed maturity of, any debt security or reduce the amount of, or postpone
the date fixed for, the payment of any sinking fund or analogous obligation with respect to any series of debt securities; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the principal amount of discount securities payable upon acceleration of maturity; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">waive a default in the payment of the principal of, or interest on, any debt security (except a rescission of
acceleration of the debt securities of any series by the holders of at least a majority in aggregate principal amount of the then outstanding debt securities of that series and a waiver of the payment default that resulted from such acceleration);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make the principal of, or interest on, any debt security payable in currency other than that stated in the debt
security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make any change to certain provisions of the indenture relating to, among other things, the right of holders of
debt securities to receive payment of the principal of and interest on those debt securities and to institute a suit for the enforcement of any such payment and to waivers or amendments; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">waive a redemption payment with respect to any debt security. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except for certain specified provisions, the holders of at least a majority in principal amount of the outstanding debt securities of any
series may on behalf of the holders of all debt securities of that series waive our compliance with provisions of the indenture. The holders of a majority in principal amount of the outstanding debt securities of any series may on behalf of the
holders of all the debt securities of such series waive any past default under the indenture with respect to that series and its consequences, except a default in the payment of the principal of or any interest on, any debt security of that series;
<I>provided</I>, <I>however</I>, that the holders of a majority in principal amount of the outstanding debt securities of any series may rescind an acceleration and its consequences, including any related payment default that resulted from the
acceleration. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Defeasance of Debt Securities and Certain Covenants in Certain Circumstances </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Legal Defeasance.</I> The indenture provides that, unless otherwise provided by the terms of the applicable series of debt securities, we
may be discharged from any and all obligations in respect of the debt securities of any series (except for certain obligations to register the transfer or exchange of debt securities of such series, to replace stolen, lost or mutilated debt
securities of such series, and to maintain paying agencies and certain provisions relating to the treatment of funds held by paying agents). We will be so discharged upon the deposit with the trustee, in trust, of money and/or U.S.&nbsp;government
obligations or, in the case of debt securities denominated in a single currency other than U.S.&nbsp;dollars, foreign government obligations, that, through the payment of interest and principal in accordance with their terms, will provide money in
an amount sufficient in the opinion of a nationally recognized firm of independent certified public accountants to pay and discharge each installment of principal and interest on and any mandatory sinking fund payments in respect of the debt
securities of that series on the stated maturity of those payments in accordance with the terms of the indenture and those debt securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discharge may occur only if, among other things, we have delivered to the trustee an opinion of counsel stating that we have received
from, or there has been published by, the United States Internal Revenue Service a ruling or, since the date of execution of the indenture, there has been a change in the applicable U.S.&nbsp;federal income tax law, in either case to the effect
that, and such opinion shall confirm based thereon that, the holders of the debt securities of that series will not recognize income, gain or loss for U.S.&nbsp;federal income tax purposes as a result of the deposit, defeasance and discharge and
will be subject to U.S.&nbsp;federal income tax on the same amounts and in the same manner and at the same times as would have been the case if the deposit, defeasance and discharge had not occurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Defeasance of Certain Covenants.</I> The indenture provides that, unless otherwise provided by the terms of the applicable series of debt
securities, upon compliance with certain conditions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may omit to comply with the covenant described under the heading &#147;&#151;Consolidation, Merger or
Sale&#148; and certain other covenants set forth in the indenture, as well as any additional covenants that may be set forth in the applicable prospectus supplement; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any omission to comply with those covenants will not constitute a default or an event of default with respect to
the debt securities of that series, or covenant defeasance. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The conditions include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">depositing with the trustee money and/or U.S.&nbsp;government obligations or, in the case of debt securities
denominated in a single currency other than U.S.&nbsp;dollars, foreign government obligations, that, through the payment of interest and principal in accordance with their terms, will provide money in an amount sufficient in the opinion of a
nationally recognized firm of independent certified public accountants to pay and discharge each installment of principal of and interest on and any mandatory sinking fund payments in respect of the debt securities of that series on the stated
maturity of those payments in accordance with the terms of the indenture and those debt securities; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delivering to the trustee an opinion of counsel to the effect that the holders of the debt securities of that
series will not recognize income, gain or loss for United States federal income tax purposes as a result of the deposit and related covenant defeasance and will be subject to United States federal income tax on the same amounts and in the same
manner and at the same times as would have been the case if the deposit and related covenant defeasance had not occurred. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Covenant Defeasance and Events of Default.</I> In the event we exercise our option to effect covenant defeasance with respect to any series
of debt securities and the debt securities of that series are declared due and payable because of the occurrence of any event of default, the amount of money and/or U.S.&nbsp;government obligations or foreign government obligations on deposit with
the trustee will be sufficient to pay amounts due on the debt securities of that series at the time of their stated maturity but may not be sufficient to pay amounts due on the debt securities of that series at the time of the acceleration resulting
from the event of default. In such a case, we would remain liable for those payments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Foreign Government Obligations</I>&#148;
means, with respect to debt securities of any series that are denominated in a currency other than U.S.&nbsp;dollars: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">direct obligations of the government that issued or caused to be issued such currency for the payment of which
obligations its full faith and credit is pledged which are not callable or redeemable at the option of the issuer thereof; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obligations of a person controlled or supervised by, or acting as an agency or instrumentality of, that
government, the timely payment of which is unconditionally guaranteed as a full faith and credit obligation by that government, which are not callable or redeemable at the option of the issuer thereof. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Form, Exchange and Transfer </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each debt
security will be represented by either one or more global securities registered in the name of The Depository Trust Company, as depositary, or a nominee (we will refer to any debt security represented by a global debt security as a book-entry debt
security), or a certificate issued in definitive registered form&nbsp;(we will refer to any debt security represented by a certificated security as a certificated debt security) as set forth in the applicable prospectus supplement. Except as set
forth under the heading &#147;-Global Debt Securities and Book-Entry System&#148; below, book-entry debt securities will not be issuable in certificated form. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Certificated Debt Securities.</I> The holder may transfer or exchange certificated debt securities at any office we maintain for this
purpose in accordance with the terms of the indenture. No service charge will be made for any transfer or exchange of certificated debt securities, but we may require payment of a sum sufficient to cover any tax or other governmental charge payable
in connection with a transfer or exchange. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holder may effect the transfer of certificated debt securities and the right to receive
the principal of and interest on, certificated debt securities only by surrendering the certificate representing those certificated debt </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
securities and either reissuance by us or the trustee of the certificate to the new holder or the issuance by us or the trustee of a new certificate to the new holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Global Debt Securities and Book-Entry System.</I> Each global debt security representing book-entry debt securities will be deposited with,
or on behalf of, the depositary, and registered in the name of the depositary or a nominee of the depositary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will require the
depositary to agree to follow the following procedures with respect to book-entry debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ownership of beneficial interests in
book-entry debt securities will be limited to persons who have accounts with the depositary for the related global debt security, which we refer to as participants, or persons who may hold interests through participants. Upon the issuance of a
global debt security, the depositary will credit, on its book-entry registration and transfer system, the participants&#146; accounts with the respective principal amounts of the book-entry debt securities represented by such global debt security
beneficially owned by such participants. The accounts to be credited will be designated by any dealers, underwriters or agents participating in the distribution of the book-entry debt securities. Ownership of book-entry debt securities will be shown
on, and the transfer of such ownership interests will be effected only through, records maintained by the depositary for the related global debt security (with respect to interests of participants) and on the records of participants (with respect to
interests of persons holding through participants). The laws of some states may require that certain purchasers of securities take physical delivery of such securities in definitive form. These laws may impair the ability to own, transfer or pledge
beneficial interests in book-entry debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">So long as the depositary for a global debt security, or its nominee, is the
registered owner of that global debt security, the depositary or its nominee, as the case may be, will be considered the sole owner or holder of the book-entry debt securities represented by such global debt security for all purposes under the
indenture. Except as described below, beneficial owners of book-entry debt securities will not be entitled to have securities registered in their names, will not receive or be entitled to receive physical delivery of a certificate in definitive form
representing securities and will not be considered the owners or holders of those securities under the indenture. Accordingly, each person beneficially owning book-entry debt securities must rely on the procedures of the depositary for the related
global debt security and, if such person is not a participant, on the procedures of the participant through which such person owns its interest, to exercise any rights of a holder under the indenture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We understand, however, that under existing industry practice, the depositary will authorize the persons on whose behalf it holds a global
debt security to exercise certain rights of holders of debt securities, and the indenture provides that we, the trustee and our respective agents will treat as the holder of a debt security the persons specified in a written statement of the
depositary with respect to that global debt security for purposes of obtaining any consents or directions required to be given by holders of the debt securities pursuant to the indenture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will make payments of principal of, and premium and interest on, book-entry debt securities to the depositary or its nominee, as the case
may be, as the registered holder of the related global debt security. Scilex, the trustee and any other agent of ours or agent of the trustee will not have any responsibility or liability for any aspect of the records relating to or payments made on
account of beneficial ownership interests in a global debt security or for maintaining, supervising or reviewing any records relating to beneficial ownership interests. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that the depositary, upon receipt of any payment of principal of, and premium or interest on, a global debt security, will
immediately credit participants&#146; accounts with payments in amounts proportionate to the respective amounts of book-entry debt securities held by each participant as shown on the records of such depositary. We also expect that payments by
participants to owners of beneficial interests in book-entry debt securities held through those participants will be governed by standing customer instructions and customary practices, as is now the case with the securities held for the accounts of
customers in bearer form or registered in &#147;street name,&#148; and will be the responsibility of those participants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will issue certificated debt securities in exchange for each global debt security if the
depositary is at any time unwilling or unable to continue as depositary or ceases to be a clearing agency registered under the Exchange Act and a successor depositary registered as a clearing agency under the Exchange Act is not appointed by us
within&nbsp;90&nbsp;days. In addition, we may at any time and in our sole discretion determine not to have the book-entry debt securities of any series represented by one or more global debt securities and, in that event, will issue certificated
debt securities in exchange for the global debt securities of that series. Global debt securities will also be exchangeable by the holders for certificated debt securities if an event of default with respect to the book-entry debt securities
represented by those global debt securities has occurred and is continuing. Any certificated debt securities issued in exchange for a global debt security will be registered in such name or names as the depositary shall instruct the trustee. We
expect that such instructions will be based upon directions received by the depositary from participants with respect to ownership of book-entry debt securities relating to such global debt security. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have obtained the foregoing information concerning the depositary and the depositary&#146;s book-entry system from sources we believe to be
reliable, but we take no responsibility for the accuracy of this information. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information Concerning the Trustee </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trustee, other than during the occurrence and continuance of an event of default under an indenture, undertakes to perform only those
duties as are specifically set forth in the applicable indenture. Upon an event of default under an indenture, the trustee must use the same degree of care as a prudent person would exercise or use in the conduct of his or her own affairs. Subject
to this provision, the trustee is under no obligation to exercise any of the powers given to it by the indenture at the request of any holder of debt securities unless it is offered reasonable security and indemnity against the costs, expenses and
liabilities that it might incur. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture and provisions of the Trust Indenture Act that are incorporated by reference therein
contain limitations on the rights of the trustee, should it become one of our creditors, to obtain payment of claims in certain cases or to realize on certain property received by it in respect of any such claim as security or otherwise. The trustee
is permitted to engage in other transactions with us or any of our affiliates; <I>provided</I>, <I>however</I>, that if it acquires any conflicting interest (as defined in the indentures or in the Trust Indenture Act), it must eliminate such
conflict or resign. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Payment and Paying Agents </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we otherwise indicate in the applicable prospectus supplement, we will make payment of the interest on any debt securities on any
interest payment date to the person in whose name the debt securities, or one or more predecessor securities, are registered at the close of business on the regular record date for the interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will pay principal of and any premium and interest on the debt securities of a particular series at the office of the paying agents
designated by us, except that, unless we otherwise indicate in the applicable prospectus supplement, we will make interest payments by check that we will mail to the holder or by wire transfer to certain holders. Unless we otherwise indicate in the
applicable prospectus supplement, we will designate the corporate trust office of the trustee as our sole paying agent for payments with respect to debt securities of each series. We will name in the applicable prospectus supplement any other paying
agents that we initially designate for the debt securities of a particular series. We will maintain a paying agent in each place of payment for the debt securities of a particular series. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All money we pay to a paying agent or the trustee for the payment of the principal of, or any premium or interest on, any debt securities that
remains unclaimed at the end of two years after such principal, premium or interest has become due and payable will be repaid to us, and the holder of the debt security thereafter may look only to us for payment thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture and the debt securities will be governed by and construed in accordance with the laws of the State of New York, except to the
extent that the Trust Indenture Act is applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom559675_8"></A>DESCRIPTION OF WARRANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description, together with the additional information we may include in the applicable prospectus supplements and free writing
prospectuses we have authorized for use in connection with a specific offering, summarizes the material terms and provisions of the warrants that we may offer under this prospectus, which may consist of warrants to purchase Common Stock, preferred
stock or debt securities and may be issued in one or more series. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Warrants may be issued independently or together with Common Stock,
preferred stock or debt securities offered by any prospectus supplement, and may be attached to or separate from those securities. While the terms we have summarized below will apply generally to any warrants that we may offer under this prospectus,
we will describe the particular terms of any series of warrants that we may offer in more detail in the applicable prospectus supplement and any applicable free writing prospectus we authorize for use in connection with the specific offering. The
terms of any warrants offered under a prospectus supplement may differ from the terms described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will file as exhibits to the
registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of warrant agreement, if any, including a form of warrant certificate, that describes the terms of the
particular series of warrants we are offering. The following summaries of material provisions of the warrants and the warrant agreements are subject to, and qualified in their entirety by reference to, all the provisions of the warrant agreement and
warrant certificate applicable to the particular series of warrants that we may offer under this prospectus. We urge you to read the applicable prospectus supplements related to the particular series of warrants that we may offer under this
prospectus, as well as any related free writing prospectuses we have authorized for use in connection with a specific offering, and the complete warrant agreements and warrant certificates that contain the terms of the warrants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General Matters </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will describe in the
applicable prospectus supplement the terms relating to a series of warrants being offered, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title of such securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the offering price or prices and aggregate number of warrants offered; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency or currencies for which the warrants may be purchased; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the designation and terms of the securities with which the warrants are issued and the number of
warrants issued with each such security or each principal amount of such security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the date on and after which the warrants and the related securities will be separately
transferable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the minimum or maximum amount of such warrants which may be exercised at any one time;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of warrants to purchase debt securities, the principal amount of debt securities purchasable upon
exercise of one warrant and the price at which, and currency in which, this principal amount of debt securities may be purchased upon such exercise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of warrants to purchase Common Stock or preferred stock, the number of shares of Common Stock or
preferred stock, as the case may be, purchasable upon the exercise of one warrant and the price at which, and the currency in which, these shares may be purchased upon such exercise; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreements and
the warrants; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of any rights to redeem or call the warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of any rights to force the exercise of the warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise
of the warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dates on which the right to exercise the warrants will commence and expire; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the manner in which the warrant agreements and warrants may be modified; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a discussion of any material or special U.S.&nbsp;federal income tax consequences of holding or exercising the
warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of the securities issuable upon exercise of the warrants; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other specific terms, preferences, rights or limitations of or restrictions on the warrants.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before exercising their warrants, holders of warrants will not have any of the rights of holders of the securities
purchasable upon such exercise, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of warrants to purchase debt securities, the right to receive payments of principal of, or premium,
if any, or interest on, the debt securities purchasable upon exercise or to enforce covenants in the applicable indenture; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of warrants to purchase Common Stock or preferred stock, the right to receive dividends, if any, or,
payments upon our liquidation, dissolution or winding up or to exercise voting rights, if any. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exercise of Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each warrant will entitle the holder to purchase the securities that we specify in the applicable prospectus supplement at the exercise price
that we describe in the applicable prospectus supplement. Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise the warrants at any time up to the specified time on the expiration date that we set
forth in the applicable prospectus supplement. After the close of business on the expiration date, unexercised warrants will become void. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise the warrants by delivering the
warrant certificate representing the warrants to be exercised together with specified information, and paying the required amount to the warrant agent in immediately available funds, as provided in the applicable prospectus supplement. We will set
forth on the reverse side of the warrant certificate and in the applicable prospectus supplement the information that the holder of the warrant will be required to deliver to the warrant agent in connection with the exercise of the warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon receipt of the required payment and the warrant certificate properly completed and duly executed at the corporate trust office of the
warrant agent or any other office indicated in the applicable prospectus supplement, we will issue and deliver the securities purchasable upon such exercise. If fewer than all of the warrants represented by the warrant certificate are exercised,
then we will issue a new warrant certificate for the remaining amount of warrants. If we so indicate in the applicable prospectus supplement, holders of the warrants may surrender securities as all or part of the exercise price for warrants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we provide
otherwise in the applicable prospectus supplement, the warrants and warrant agreements, and any claim, controversy or dispute arising under or related to the warrants or warrant agreements, will be governed by and construed in accordance with the
laws of the State of New York. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Enforceability of Rights By Holders of Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each warrant agent will act solely as our agent under the applicable warrant agreement and will not assume any obligation or relationship of
agency or trust with any holder of any warrant. A single bank or trust company may act as warrant agent for more than one issue of warrants. A warrant agent will have no duty or responsibility in case of any default by us under the applicable
warrant agreement or warrant, including any duty or responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder of a warrant may, without the consent of the related warrant agent or the holder of any
other warrant, enforce by appropriate legal action its right to exercise, and receive the securities purchasable upon exercise of, its warrants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Warrant Agreement Will Not Be Qualified Under Trust Indenture Act </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No warrant agreement will be qualified as an indenture, and no warrant agent will be required to qualify as a trustee, under the Trust
Indenture Act. Therefore, holders of warrants issued under a warrant agreement will not have the protection of the Trust Indenture Act with respect to their warrants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Calculation Agent </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calculations relating
to warrants may be made by a calculation agent, an institution that we appoint as our agent for this purpose. The prospectus supplement for a particular warrant will name the institution that we have appointed to act as the calculation agent for
that warrant as of the original issue date for that warrant. We may appoint a different institution to serve as calculation agent from time to time after the original issue date without the consent or notification of the holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The calculation agent&#146;s determination of any amount of money payable or securities deliverable with respect to a warrant will be final
and binding in the absence of manifest error. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom559675_9"></A>DESCRIPTION OF RIGHTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue rights to purchase
Common Stock, preferred stock, units or the other securities described in this prospectus. This prospectus and any accompanying prospectus supplement will contain the material terms and conditions for each right. The accompanying prospectus
supplement may add, update or change the terms and conditions of the rights as described in this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will describe in the
applicable prospectus supplement the terms and conditions of the issue of rights being offered, the rights agreement relating to the rights and the rights certificates representing the rights, including, as applicable: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title of the rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date of determining the stockholders entitled to the rights distribution; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title, aggregate number of shares of Common Stock, preferred stock or other securities purchasable upon
exercise of the rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the exercise price; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currencies in which the rights are being offered; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the aggregate number of rights issued; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date, if any, on and after which the rights will be separately transferable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date on which the right to exercise the rights will commence and the date on which the right will expire; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other terms of the rights, including terms, procedures and limitations relating to the distribution, exchange
and exercise of the rights. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exercise of Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each right will entitle the holder of rights to purchase for cash the principal amount of shares of Common Stock, preferred stock, units or
other securities at the exercise price provided in the applicable prospectus supplement. Rights may be exercised at any time up to the close of business on the expiration date for the rights provided in the applicable prospectus supplement. After
the close of business on the expiration date, all unexercised rights will be void. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders may exercise rights as described in the
applicable prospectus supplement. Upon receipt of payment and the rights certificate properly completed and duly executed at the corporate trust office of the rights agent or any other office indicated in the prospectus supplement, we will, as soon
as practicable, forward the shares of Common Stock or preferred stock purchasable upon exercise of the rights. If less than all of the rights issued in any rights offering are exercised, we may offer any unsubscribed securities directly to persons
other than stockholders, to or through agents, underwriters, brokers or dealers or through a combination of such methods, including pursuant to standby underwriting arrangements, as described in the applicable prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom559675_10"></A>DESCRIPTION OF UNITS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue units consisting of any combination of the other types of securities offered under this prospectus in one or more series. We may
evidence each series of units by unit certificates that we will issue under a separate agreement. We may enter into unit agreements with a unit agent. Each unit agent will be a bank or trust company that we select. We will indicate the name and
address of the unit agent in the applicable prospectus supplement relating to a particular series of units. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description,
together with the additional information included in the applicable prospectus supplement, summarizes the general features of the units that we may offer under this prospectus. You should read any prospectus supplement and any free writing
prospectus we authorize for use in connection with a specific offering of units, as well as the complete unit agreements that contain the terms of the units. Specific unit agreements will contain additional important terms and provisions and we will
file as an exhibit to the registration statement of which this prospectus is a part, or will incorporate by reference from another report that we file with the SEC, the form of each unit agreement relating to units offered under this prospectus.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we offer any units, certain terms of that series of units will be described in the applicable prospectus supplement, including,
without limitation, the following, as applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identification and description of the separate constituent securities comprising the units;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the price or prices at which the units will be issued; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date, if any, on and after which the constituent securities comprising the units will be separately
transferable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a discussion of certain U.S.&nbsp;federal income tax considerations applicable to the units; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other terms of the units and their constituent securities. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom559675_11"></A>LEGAL OWNERSHIP OF SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We can issue securities in registered form or in the form of one or more global securities. We describe global securities in greater detail
below. We refer to those persons who have securities registered in their own names on the books that we or any applicable trustee or depositary maintain for this purpose as the &#147;holders&#148; of those securities. These persons are the legal
holders of the securities. We refer to those persons who, indirectly through others, own beneficial interests in securities that are not registered in their own names, as &#147;indirect holders&#148; of those securities. As we discuss below,
indirect holders are not legal holders, and investors in securities issued in book-entry form or in street name will be indirect holders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Book-Entry
Holders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue securities in book-entry form only, as we will specify in the applicable prospectus supplement. This means
securities may be represented by one or more global securities registered in the name of a financial institution that holds them as depositary on behalf of other financial institutions that participate in the depositary&#146;s book-entry system.
These participating institutions, which are referred to as participants, in turn, hold beneficial interests in the securities on behalf of themselves or their customers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only the person in whose name a security is registered is recognized as the holder of that security. Global securities will be registered in
the name of the depositary or its participants. Consequently, for global securities, we will recognize only the depositary as the holder of the securities, and we will make all payments on the securities to the depositary. The depositary passes
along the payments it receives to its participants, which in turn pass the payments along to their customers who are the beneficial owners. The depositary and its participants do so under agreements they have made with one another or with their
customers; they are not obligated to do so under the terms of the securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, investors in a global security will not own
securities directly. Instead, they will own beneficial interests in a global security, through a bank, broker or other financial institution that participates in the depositary&#146;s book-entry system or holds an interest through a participant. As
long as the securities are issued in global form, investors will be indirect holders, and not legal holders, of the securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Street Name Holders
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may terminate a global security in certain situations, as described under &#147;&#151;Special Situations When a Global Security
Will Be Terminated&#148;, or issue securities that are not issued in global form. In these cases, investors may choose to hold their securities in their own names or in &#147;street name&#148;. Securities held by an investor in street name would be
registered in the name of a bank, broker or other financial institution that the investor chooses, and the investor would hold only a beneficial interest in those securities through an account he or she maintains at that institution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For securities held in street name, we or any applicable trustee or depositary will recognize only the intermediary banks, brokers and other
financial institutions in whose names the securities are registered as the holders of those securities, and we or any such trustee or depositary will make all payments on those securities to them. These institutions pass along the payments they
receive to their customers who are the beneficial owners, but only because they agree to do so in their customer agreements or because they are legally required to do so. Investors who hold securities in street name will be indirect holders, not
holders, of those securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Holders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our obligations, as well as the obligations of any applicable trustee or third party employed by us or a trustee, run only to the legal holders
of the securities. We do not have obligations to investors who hold beneficial interests in global securities, in street name or by any other indirect means. This will be the case </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
whether an investor chooses to be an indirect holder of a security or has no choice because we are issuing the securities only in global form. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, once we make a payment or give a notice to the legal holder, we have no further responsibility for the payment or notice even if
that legal holder is required, under agreements with its participants or customers or by law, to pass the payment or notice along to the indirect holders but does not do so. Similarly, we may want to obtain the approval of the holders to amend an
indenture, to relieve us of the consequences of a default or of our obligation to comply with a particular provision of an indenture, or for other purposes. In such an event, we would seek approval only from the legal holders, and not the indirect
holders, of the securities. Whether and how the legal holders contact the indirect holders is up to the legal holders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special Considerations for
Indirect Holders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you hold securities through a bank, broker or other financial institution, either in book-entry form because the
securities are represented by one or more global securities or in street name, you should check with your own institution to find out: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">how it handles securities payments and notices; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether it imposes fees or charges; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">how it would handle a request for the holder&#146;s consent, if ever required; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether and how you can instruct it to send you securities registered in your own name so you can be a holder, if
that is permitted in the future; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">how it would exercise rights under the securities if there were a default or other event triggering the need for
holders to act to protect their interests; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the securities are in book-entry form, how the depositary&#146;s rules and procedures will affect these
matters. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Global Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A global security is a security that represents one or any other number of individual securities held by a depositary. Generally, all
securities represented by the same global securities will have the same terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each security issued in book-entry form will be
represented by a global security that we issue to, deposit with and register in the name of a financial institution or its nominee that we select. The financial institution that we select for this purpose is called the depositary. Unless we specify
otherwise in the applicable prospectus supplement, The Depository Trust Company, New York, New York, known as DTC, will be the depositary for all securities issued in book-entry form. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A global security may not be transferred to or registered in the name of anyone other than the depositary, its nominee or a successor
depositary, unless special termination situations arise. We describe those situations below under &#147;&#151;Special Situations When a Global Security Will Be Terminated&#148;. As a result of these arrangements, the depositary, or its nominee, will
be the sole registered owner and legal holder of all securities represented by a global security, and investors will be permitted to own only beneficial interests in a global security. Beneficial interests must be held by means of an account with a
broker, bank or other financial institution that in turn has an account with the depositary or with another institution that does. Thus, an investor whose security is represented by a global security will not be a legal holder of the security, but
only an indirect holder of a beneficial interest in the global security. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the prospectus supplement for a particular security indicates
that the security will be issued as a global security, then the security will be represented by a global security at all times unless and until the global security </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
is terminated. If termination occurs, we may issue the securities through another book-entry clearing system or decide that the securities may no longer be held through any book-entry clearing
system. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special Considerations for Global Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As an indirect holder, an investor&#146;s rights relating to a global security will be governed by the account rules of the investor&#146;s
financial institution and of the depositary, as well as general laws relating to securities transfers. We do not recognize an indirect holder as a holder of securities and instead deal only with the depositary that holds the global security. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If securities are issued only as global securities, an investor should be aware of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an investor cannot cause the securities to be registered in his or her name, and cannot obtain <FONT
STYLE="white-space:nowrap">non-global</FONT> certificates for his or her interest in the securities, except in the special situations described below; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an investor will be an indirect holder and must look to his or her own bank or broker for payments on the
securities and protection of his or her legal rights relating to the securities, as described above; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an investor may not be able to sell interests in the securities to some insurance companies and to other
institutions that are required by law to own their securities in <FONT STYLE="white-space:nowrap">non-book-entry</FONT> form; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an investor may not be able to pledge his or her interest in the global security in circumstances where
certificates representing the securities must be delivered to the lender or other beneficiary of the pledge in order for the pledge to be effective; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the depositary&#146;s policies, which may change from time to time, will govern payments, transfers, exchanges
and other matters relating to an investor&#146;s interest in the global security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we and any applicable trustee have no responsibility for any aspect of the depositary&#146;s actions or for its
records of ownership interests in the global security, nor will we or any applicable trustee supervise the depositary in any way; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the depositary may, and we understand that DTC will, require that those who purchase and sell interests in the
global security within its book-entry system use immediately available funds, and your broker or bank may require you to do the same; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">financial institutions that participate in the depositary&#146;s book-entry system, and through which an investor
holds its interest in the global security, may also have their own policies affecting payments, notices and other matters relating to the securities. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There may be more than one financial intermediary in the chain of ownership for an investor. We do not monitor and are not responsible for the
actions of any of those intermediaries. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special Situations When a Global Security Will Be Terminated </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In a few special situations described below, a global security will terminate and interests in it will be exchanged for physical certificates
representing those interests. After that exchange, the choice of whether to hold securities directly or in street name will be up to the investor. Investors must consult their own banks or brokers to find out how to have their interests in
securities transferred to their own names, so that they will be direct holders. The rights of holders and street name investors are described above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A global security will terminate when the following special situations occur: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the depositary notifies us that it is unwilling, unable or no longer qualified to continue as depositary for
that global security and we do not appoint another institution to act as depositary within&nbsp;90&nbsp;days; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we notify any applicable trustee that we wish to terminate that global security; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if an event of default has occurred with regard to securities represented by that global security and has not
been cured or waived. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The applicable prospectus supplement may also list additional situations for terminating a
global security that would apply only to the particular series of securities covered by the prospectus supplement. When a global security terminates, the depositary, and neither we nor any applicable trustee, is responsible for deciding the names of
the institutions that will be the initial direct holders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom559675_12"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell the securities from time to time pursuant to underwritten public offerings, direct sales to the public, &#147;at the market&#148;
offerings, negotiated transactions, block trades or a combination of these methods. We may sell the securities to or through underwriters or dealers, through agents, or directly to one or more purchasers. We may distribute securities from time to
time in one or more transactions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at a fixed price or prices, which may be changed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at market prices prevailing at the time of sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at prices related to such prevailing market prices; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at negotiated prices. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A prospectus supplement or supplements (and any related free writing prospectus that we may have authorized for use in connection with a
specific offering) will describe the terms of the offering of the securities, including, to the extent applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the name or names of the underwriters, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the purchase price of the securities or other consideration therefor, and the proceeds, if any, we will receive
from the sale; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any over-allotment options under which underwriters may purchase additional securities from us;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any agency fees or underwriting discounts and other items constituting agents&#146; or underwriters&#146;
compensation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any public offering price; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any discounts or concessions allowed or <FONT STYLE="white-space:nowrap">re-allowed</FONT> or paid to dealers;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any securities exchange or market on which the securities may be listed. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only underwriters named in the prospectus supplement will be underwriters of the securities offered by the prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If underwriters are used in the sale, they will acquire the securities for their own account and may resell the securities from time to time
in one or more transactions at a fixed public offering price or at varying prices determined at the time of sale. The obligations of the underwriters to purchase the securities will be subject to the conditions set forth in the applicable
underwriting agreement. We may offer the securities to the public through underwriting syndicates represented by managing underwriters or by underwriters without a syndicate. Subject to certain conditions, the underwriters will be obligated to
purchase all of the securities offered by the prospectus supplement, other than securities covered by any over-allotment option. Any public offering price and any discounts or concessions allowed or <FONT STYLE="white-space:nowrap">re-allowed</FONT>
or paid to dealers may change from time to time. We may use underwriters with whom we have a material relationship. We will describe in the prospectus supplement, naming the underwriter, the nature of any such relationship. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell securities directly or through agents we designate from time to time. We will name any agent involved in the offering and sale of
securities and we will describe any commissions we will pay the agent in the prospectus supplement. Unless the prospectus supplement states otherwise, our agent will act on a best-efforts basis for the period of its appointment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may authorize agents or underwriters to solicit offers by certain types of institutional investors to purchase securities from us at the
public offering price set forth in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. We will describe the conditions to these contracts and the commissions we must
pay for solicitation of these contracts in the prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may provide agents and underwriters with indemnification against civil liabilities,
including liabilities under the Securities Act, or contribution with respect to payments that the agents or underwriters may make with respect to these liabilities. Agents and underwriters may engage in transactions with, or perform services for, us
in the ordinary course of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All securities we may offer, other than Common Stock, will be new issues of securities with no
established trading market. Any underwriters may make a market in these securities, but will not be obligated to do so and may discontinue any market making at any time without notice. We cannot guarantee the liquidity of the trading markets for any
securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any underwriter may engage in over-allotment, stabilizing transactions, short-covering transactions and penalty bids in
accordance with Regulation&nbsp;M under the Exchange Act. Over-allotment involves sales in excess of the offering size, which create a short position. Stabilizing transactions permit bids to purchase the underlying security so long as the
stabilizing bids do not exceed a specified maximum price. Syndicate-covering or other short-covering transactions involve purchases of the securities, either through exercise of the over-allotment option or in the open market after the distribution
is completed, to cover short positions. Penalty bids permit the underwriters to reclaim a selling concession from a dealer when the securities originally sold by the dealer are purchased in a stabilizing or covering transaction to cover short
positions. Those activities may cause the price of the securities to be higher than it would otherwise be. If commenced, the underwriters may discontinue any of the activities at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any underwriters that are qualified market makers on the Nasdaq Capital Market may engage in passive market making transactions in the Common
Stock on the Nasdaq Capital Market in accordance with Regulation&nbsp;M under the Exchange Act, during the business day prior to the pricing of the offering, before the commencement of offers or sales of the Common Stock. Passive market makers must
comply with applicable volume and price limitations and must be identified as passive market makers. In general, a passive market maker must display its bid at a price not in excess of the highest independent bid for such security; if all
independent bids are lowered below the passive market maker&#146;s bid, however, the passive market maker&#146;s bid must then be lowered when certain purchase limits are exceeded. Passive market making may stabilize the market price of the
securities at a level above that which might otherwise prevail in the open market and, if commenced, may be discontinued at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
compliance with guidelines of the Financial Industry Regulatory Authority (FINRA), the maximum consideration or discount to be received by any FINRA member or independent broker dealer may not exceed&nbsp;8% of the aggregate amount of the securities
offered pursuant to this prospectus and the applicable prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom559675_13"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated in the applicable prospectus supplement, the validity of the securities offered by this prospectus, and any
supplement thereto, will be passed upon for us by Paul Hastings LLP, Palo Alto, California. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom559675_14"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of Scilex Holding Company appearing in Scilex Holding Company&#146;s Annual Report <FONT
STYLE="white-space:nowrap">(Form&nbsp;10-K)</FONT> for the year ended December&nbsp;31, 2022, have been audited by Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, as set forth in their report thereon (which contains an
explanatory paragraph describing conditions that raise substantial doubt about the Company&#146;s ability to continue as a going concern as described in Note 2 to the consolidated financial statements) included therein, and incorporated herein by
reference. Such financial statements are, and audited financial statements to be included in subsequently filed documents will be, incorporated herein in reliance upon the report of Ernst&nbsp;&amp; Young LLP pertaining to such financial statements
(to the extent covered by consents filed with the SEC) given on the authority of such firm as experts in accounting and auditing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom559675_15">
</A>WHERE YOU CAN FIND MORE INFORMATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a reporting company and file annual, quarterly and current reports, proxy statements
and other information with the SEC. We have filed with the SEC a registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> under the Securities Act with respect to the securities being offered under this prospectus. This
prospectus does not contain all of the information set forth in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities being offered under this prospectus, we refer
you to the registration statement and the exhibits and schedules filed as a part of the registration statement. The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that
file electronically with the SEC, including Scilex Holding Company. The SEC&#146;s Internet site can be found at <I>http://www.sec.gov</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also maintain a website at <I>www.scilexholding.com</I>. Through our website, we make available, free of charge, annual, quarterly and
current reports, proxy statements and other information as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. The information contained on, or that may be accessed through, our website is not part of,
and is not incorporated into, this prospectus and should not be relied upon in connection with making any decision with respect to an investment in our securities, and the inclusion of our website address in this prospectus is an inactive textual
reference only. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom559675_16"></A>IMPORTANT INFORMATION INCORPORATED BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; information into this prospectus, which means that we can disclose important
information to you by referring you to another document filed separately with the SEC. The documents incorporated by reference into this prospectus contain important information that you should read about us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following documents are incorporated by reference into this prospectus: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001820190/000095017023006493/sclx-20221231.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the fiscal year ended December&nbsp;31, 2022, filed with the SEC on March&nbsp;7, 2023; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001820190/000095017023021743/sclx-20230331.htm">March
<U></U>&nbsp;31, 2023</A>, filed with the SEC on May&nbsp;12, 2023, the quarter ended <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001820190/000095017023041842/sclx-20230630.htm">June<U></U>&nbsp;30,
2023</A>, filed with the SEC on August&nbsp;11, 2023, and the quarter ended <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1820190/000095017023063810/sclx-20230930.htm">September<U></U>&nbsp;30, 2023</A>, filed
with the SEC on November&nbsp;14, 2023; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (other than any portions thereof
furnished under Item 2.02 or Item&nbsp;
7.01 of Form <FONT STYLE="white-space:nowrap">8-K</FONT> and any exhibits accompanying such reports that relate to such items) filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001820190/000119312523004041/d371589d8k.htm">January
<U></U>&nbsp;9, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001820190/000119312523009256/d426852d8k.htm">January<U></U>&nbsp;
17, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001820190/000119312523024777/d462081d8k.htm">February<U></U>&nbsp;
6, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001820190/000119312523030002/d802493d8k.htm">February<U></U>&nbsp;
9, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001820190/000119312523035934/d447754d8k.htm">February<U></U>&nbsp;
13, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001820190/000119312523075731/d280460d8k.htm">March<U></U>&nbsp;
21, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001820190/000119312523097796/d429390d8k.htm">April<U></U>&nbsp;
11, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001820190/000119312523108354/d498999d8k.htm">April<U></U>&nbsp;
20, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001820190/000119312523116108/d466902d8k.htm">April<U></U>&nbsp;
26, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001820190/000119312523137199/d327950d8k.htm">May<U></U>&nbsp;
5, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001820190/000119312523176273/d443585d8k.htm">June<U></U>&nbsp;
27, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001820190/000119312523183184/d507324d8k.htm">July<U></U>&nbsp;
7, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001820190/000119312523226362/d533212d8k.htm">August<U></U>&nbsp;
31, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001820190/000119312523231529/d485283d8k.htm">September<U></U>&nbsp;
8, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001820190/000119312523234357/d527905d8k.htm">September 13. 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001820190/000119312523239551/d554572d8k.htm">September
<U></U>&nbsp;21, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001820190/000119312523240648/d440182d8k.htm">September<U></U>&nbsp;
22, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001820190/000119312523242508/d537034d8k.htm">September<U></U>&nbsp;
26, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001820190/000119312523243665/d559663d8ka.htm">September<U></U>&nbsp;
27, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001820190/000119312523245653/d526196d8k.htm">September<U></U>&nbsp;
28, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001820190/000119312523254137/d439599d8k.htm">October<U></U>&nbsp;
11, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001820190/000119312523268931/d545216d8k.htm">November<U></U>&nbsp;
2, 2023</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1820190/000119312523302132/d564196d8k.htm">December&nbsp;22, 2023</A>; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The description of our Common Stock set forth in our Registration Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000121390021000590/ea132712-8a12b_vickers1.htm">Form
 <FONT STYLE="white-space:nowrap">8-A</FONT></A> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-39852),</FONT> filed with the SEC on January&nbsp;6, 2021, including any amendments or reports filed for the purpose of updating such description,
including <A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000095017023006493/sclx-ex4_2.htm">Exhibit 4.2</A> to our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2022 filed
with the SEC on March&nbsp;7, 2023. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also incorporate by reference any future filings (other than current reports
furnished under Item&nbsp;2.02 or Item&nbsp;7.01 of <FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> and exhibits filed on such form that are related to such items unless such <FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> expressly
provides to the contrary) made with the SEC pursuant to Sections&nbsp;13(a), 13(c), 14 or&nbsp;15(d) of the Exchange Act, including those made after the date of the initial filing of the registration statement of which this prospectus forms a part,
until we file a post-effective amendment that indicates the termination of the offering of the securities made by this prospectus and such future filings will become a part of this prospectus from the respective dates that such documents are filed
with the SEC. Any statement contained herein or in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes hereof or of the related prospectus supplement to the extent that a
statement contained herein or in any other subsequently filed document which is also incorporated or deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be
deemed, except as so modified or superseded, to constitute a part of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Documents incorporated by reference are available
from us, without charge. You may obtain documents incorporated by reference in this prospectus by requesting them in writing or by telephone at the following address: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Scilex Holding Company </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attn:
Investor Relations </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">960 San Antonio Road </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Palo Alto, CA 94303 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">investorrelations@scilexholdings.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Phone: (650) <FONT STYLE="white-space:nowrap">516-4310</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><FONT COLOR="#ff4338"><B>The information in this preliminary prospectus is not complete and may be changed. We
may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these
securities in any state where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ff4338"><B>SUBJECT TO COMPLETION, DATED JANUARY&nbsp;8, 2024 </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>SCILEX HOLDING COMPANY
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Up to $170,000,000 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
December&nbsp;22, 2023, we entered into a Sales Agreement (the &#147;Sales Agreement&#148;), with B. Riley Securities Inc., Cantor Fitzgerald&nbsp;&amp; Co. and H.C. Wainwright&nbsp;&amp; Co., LLC (the &#147;Sales Agents&#148;), relating to shares
of our common stock, par value $0.0001 per share (&#147;Common Stock&#148;), having an aggregate offering price of up to $170,000,000. In accordance with the terms of the Sales Agreement, we may offer and sell shares of our Common Stock pursuant to
this prospectus having an aggregate offering price of up to $170,000,000 from time to time through or to the Sales Agents, acting as sales agents or principals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales of our Common Stock, if any, under this prospectus may be made in sales deemed to be &#147;at the market offerings&#148; as defined in
Rule 415 promulgated under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;). If authorized by us in writing, each Sales Agent may also sell shares of our Common Stock in negotiated transactions at market prices prevailing at
the time of sale or at prices related to such prevailing market prices. No Sales Agent is required to sell any specific number or dollar amount of securities, and each Sales Agent will act as a Sales Agent using commercially reasonable efforts
consistent with its normal trading and sales practices, on mutually agreed terms between such Sales Agent and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The compensation to each Sales Agent for sales of Common Stock sold pursuant to the Sales Agreement will initially be equal to 3.0% of the
gross proceeds of any shares of Common Stock sold under the Sales Agreement, which percentage may be adjusted based on the aggregate amount of securities sold by such Sales Agent pursuant to the Sales Agreement. In connection with the sale of the
Common Stock on our behalf, each Sales Agent will be deemed to be an &#147;underwriter&#148; within the meaning of the Securities Act and the compensation of such sales will be deemed to be underwriting commissions or discounts. We have also agreed
to provide indemnification and contribution to each Sales Agent with respect to certain liabilities, including liabilities under the Securities Act or the Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;). </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:12pt; font-family:Times New Roman"><B><I>Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the
heading &#147;<A HREF="#srom559675_3">Risk Factors</A>&#148; beginning on page&nbsp;S-8 of this prospectus and under similar headings in the documents that are incorporated by reference into this prospectus. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Common Stock is currently listed on the Nasdaq Capital Market under the symbol &#147;SCLX&#148;. On January&nbsp;5, 2024, the last
reported sales price for our Common Stock was $2.04 per share. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state
securities commission has approved or disapproved of these securities, or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:16pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:16pt">
<TD VALIGN="top" NOWRAP><B>B.&nbsp;Riley&nbsp;Securities</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="right"><B>Cantor</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="right"><B>H.C.&nbsp;Wainwright&nbsp;&amp;&nbsp;Co.</B></TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus
is</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B>, 2024</B>. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#srom559675_1">About This Prospectus</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#srom559675_2">Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-2</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#srom559675_3">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-8</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#srom559675_4">Cautionary Note Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-11</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#srom559675_5">Market and Industry Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-13</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#srom559675_6">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-14</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#srom559675_7">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-15</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#srom559675_8">Plan of Distribution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-17</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#srom559675_9">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-19</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#srom559675_10">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-19</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#srom559675_11">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-19</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#srom559675_12">Important Information Incorporated by Reference</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-20</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="srom559675_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever we refer to &#147;Scilex,&#148; &#147;we,&#148; &#147;our&#148; or &#147;us&#148; in this prospectus, we mean Scilex Holding Company,
unless the context suggests otherwise. When we refer to &#147;you&#148; or &#147;yours,&#148; we mean the holders of the applicable series of securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a &#147;shelf&#148; registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> that we filed
with the Securities and Exchange Commission (the &#147;SEC&#148;), using a &#147;shelf&#148; registration process. This prospectus describes the specific terms of this offering of shares of Common Stock and also adds to and updates information
contained in the documents incorporated by reference into this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus relates only to an offering of up to
$170,000,000 of shares of our Common Stock through the Sales Agents. These sales, if any, will be made pursuant to the terms of the Sales Agreement entered into among us and B. Riley Securities Inc., Cantor Fitzgerald&nbsp;&amp; Co. and H.C.
Wainwright&nbsp;&amp; Co., LLC on December&nbsp;22, 2023, a copy of which is filed as an exhibit to the registration statement of which this prospectus is a part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before you invest, you should carefully read this prospectus, all information incorporated by reference herein and the additional information
described under &#147;<I>Where You Can Find More Information</I>&#148; and &#147;<I>Important Information Incorporated by Reference</I>&#148;. These documents contain information you should consider when making your investment decision. To the
extent that any statement that we make in this prospectus is inconsistent with statements made in any documents incorporated by reference, the statements made in this prospectus will be deemed to modify or supersede those made in such documents
incorporated by reference; however, if any statement in one of these documents is inconsistent with a statement in another document having a later date and that is incorporated by reference herein, the statement in the document having the later date
modifies or supersedes the earlier statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should rely only on the information contained or incorporated by reference in this
prospectus, the documents incorporated by reference herein and any free writing prospectus we may provide you. We have not, and no Sales Agent has, authorized anyone to provide you with different information. If anyone provides you with different or
inconsistent information, you should not rely on it. We are not, and no Sales Agent is, making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this
prospectus, the documents incorporated by reference herein and any free writing prospectus we provide you is accurate only as of the date on those respective documents. Our business, financial condition, results of operations and prospects may have
changed since those dates. You should read this prospectus, including the documents incorporated by reference herein, when making your investment decision. You should also read and consider the information in the documents we have referred you to in
the sections of this prospectus entitled &#147;<I>Where You Can Find More Information</I>&#148; and &#147;<I>Important Information Incorporated</I> <I>by Reference</I>.&#148; The distribution of this prospectus and the offering of the Common Stock
in certain jurisdictions may be restricted by law. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the Common Stock and the
distribution of this prospectus outside the United States. This prospectus does not constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by this prospectus by any person
in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We further note that the
representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference into this prospectus were made solely for the benefit of the parties to such agreement, including, in
some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the
date when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="srom559675_2"></A>SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights selected information contained elsewhere in this prospectus or incorporated by reference in this prospectus, and
does not contain all of the information that you need to consider in making your investment decision. You should carefully read the entire prospectus, including the risks of investing in our securities discussed under the heading &#147;Risk
Factors&#148; contained in this prospectus and under similar headings in the other documents that are incorporated by reference into this prospectus. You should also carefully read the information incorporated by reference into this prospectus,
including our financial statements, and the exhibits to the registration statement of which this prospectus forms a part. Unless otherwise mentioned or unless the context requires otherwise, all references in this prospectus to &#147;Scilex&#148;,
&#147;the Company&#148;, &#147;we&#148;, &#147;us&#148;, &#147;our&#148; or similar references mean Scilex Holding Company. </I></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Scilex
Holding Company </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are
an innovative revenue-generating company focused on acquiring, developing and commercializing <FONT STYLE="white-space:nowrap">non-opioid</FONT> pain management products for the treatment of acute and chronic pain. We target indications with high
unmet needs and large market opportunities with <FONT STYLE="white-space:nowrap">non-opioid</FONT> therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. We launched our
first commercial product in October&nbsp;2018 and are developing our late-stage pipeline, which includes a candidate with completed pivotal Phase&nbsp;3 study, a candidate with completed Phase&nbsp;2 study, and a candidate with completed multiple
Phase&nbsp;1 studies and expected to enter Phase&nbsp;2 studies in&nbsp;2024. Our commercial product, ZTlido<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (lidocaine topical system) 1.8% is a prescription lidocaine topical product
approved by the U.S.&nbsp;Food and Drug Administration (the &#147;FDA&#148;) for the relief of neuropathic pain associated with post-herpetic neuralgia (&#147;PHN&#148;), which is a form of post-shingles nerve pain. ZTlido possesses novel delivery
and adhesion technology designed to address many of the limitations of current prescription lidocaine patches by providing significantly improved adhesion and continuous pain relief throughout <FONT STYLE="white-space:nowrap">the&nbsp;12-hour</FONT>
administration period. We believe our marketed product, ZTlido, has multiple advantages over currently available prescription and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT>
(&#147;OTC&#148;)&nbsp;lidocaine patches, of which over&nbsp;147&nbsp;million and&nbsp;136&nbsp;million of such patches were sold in the United States in&nbsp;2021 and&nbsp;2020, respectively, according to Symphony Healthcare. We license the rights
to ZTlido from and rely exclusively on Oishi Koseido Co., Ltd. (&#147;Oishi&#148;) and Itochu Chemical Frontier Corporation (&#147;Itochu,&#148;) pursuant to the Product Development Agreement, dated as of May&nbsp;11, 2011, by and among Scilex
Pharmaceuticals, Inc., our wholly-owned subsidiary (&#147;Scilex Pharma&#148;), as successor to Stason Pharmaceuticals, Inc., Oishi and Itochu, and the Commercial Supply Agreement, dated as of February&nbsp;16, 2017, by and among Scilex Pharma,
Oishi and Itochu. We have acquired two FDA approved <FONT STYLE="white-space:nowrap">non-opioid</FONT> pain products, GLOPERBA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> and
ELYXYB<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, for the treatment of gout in adults and oral solution for the acute treatment of migraine, with or without aura, in adults. We launched ELYXYB in the U.S.&nbsp;in April&nbsp;2023 and
are planning to commercialize GLOPERBA in&nbsp;2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our three product candidates are
<FONT STYLE="white-space:nowrap">(i)&nbsp;SP-102</FONT> (10 mg, dexamethasone sodium phosphate viscous gel) (&#147;SEMDEXA<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>&#148;), a Phase&nbsp;3, novel, viscous gel formulation of a widely used
corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica; <FONT STYLE="white-space:nowrap">(ii)&nbsp;SP-103</FONT> (lidocaine topical system) 5.4%, <FONT STYLE="white-space:nowrap">(&#147;SP-103&#148;),</FONT> a
Phase&nbsp;2, next-generation, triple-strength formulation of ZTlido, for the treatment of chronic neck pain; and <FONT STYLE="white-space:nowrap">(iii)&nbsp;SP-104</FONT> (4.5 mg, <FONT STYLE="white-space:nowrap">low-dose</FONT> naltrexone
hydrochloride delayed-release capsules) <FONT STYLE="white-space:nowrap">(&#147;SP-104&#148;),</FONT> a novel <FONT STYLE="white-space:nowrap">low-dose</FONT> delayed-release naltrexone hydrochloride being developed for the treatment of
fibromyalgia, for which Phase&nbsp;1 trials were completed in the second quarter of&nbsp;2022 and a Phase&nbsp;2 clinical trial is expected to commence in&nbsp;2024. If these product candidates are approved by the FDA, we believe each of them could
become the preferred treatment option for their respective indications in the United States. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;14, 2022, we entered into a License and Commercialization Agreement (the
&#147;Romeg Agreement&#148;) with RxOmeg Therapeutics, LLC (a/k/a Romeg Therapeutics, Inc.) (&#147;Romeg&#148;). Pursuant to the Romeg Agreement, among other things, Romeg granted us (1)&nbsp;the right to manufacture, promote, market, distribute and
sell pharmaceutical products comprising liquid formulations of colchicine for the prophylactic treatment of gout in adult humans in the United States and (2)&nbsp;an exclusive, transferable license to use the trademark &#147;GLOPERBA&#148;. We
believe Gloperba is the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. Gout is a painful arthritic disorder affecting an estimated&nbsp;9.2&nbsp;million people
in the United States. Gout pain can be excruciating and is a form of inflammatory arthritis that develops in some people who have high levels of uric acid in their blood. It can cause sudden severe episodes of pain and can be disabling with
tenderness, warmth and swelling. <FONT STYLE="white-space:nowrap">Non-steroidal</FONT> anti-inflammatory drugs, colchicine and corticosteroids are used a majority of time as the first line to treat acute gout. The U.S.&nbsp;is observed to have a
high prevalence of gout, owing to lifestyle issues such as high alcohol intake, obesity, and smoking. We are planning to commercialize GLOPERBA in&nbsp;2024 and believe we are well-positioned to market and distribute the product. We have a direct
distribution network to national and regional wholesalers and pharmacies throughout the U.S.&nbsp;On February&nbsp;12, 2023, we acquired from BioDelivery Sciences International, Inc. and Collegium Pharmaceutical, Inc. the rights to certain patents,
trademarks, regulatory approvals, data, contracts, and other rights related to ELYXYB (celecoxib oral solution) and the commercialization thereof in the United States and Canada. ELYXYB is a potential first-line treatment and the only <FONT
STYLE="white-space:nowrap">FDA-approved,</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ready-to-use</FONT></FONT> oral solution for the acute treatment of migraine, with or without aura, in adults. We launched ELYXYB in
the U.S.&nbsp;in April&nbsp;2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are focused on identifying treatment options for pain management with established mechanisms that
have deficiencies in safety, efficacy or patient experience. We believe this approach allows us to potentially leverage the regulatory approval pathway available under Section&nbsp;505(b)(2) of the Federal Food, Drug, and Cosmetic Act for each of
these pipeline product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We acquired <FONT STYLE="white-space:nowrap">SP-102</FONT> from Semnur Pharmaceuticals, Inc. in
March&nbsp;2019 and are developing <FONT STYLE="white-space:nowrap">SP-102</FONT> to be an injectable viscous gel formulation of a widely used corticosteroid designed to address the serious risks posed by
<FONT STYLE="white-space:nowrap">off-label</FONT> epidural steroid injections (&#147;ESI&#148;), which are administered over&nbsp;12&nbsp;million times annually in the United States. SEMDEXA has been granted fast track designation by the FDA and, if
approved, could become the only <FONT STYLE="white-space:nowrap">FDA-approved</FONT> ESI for the treatment of sciatica. According to a report by Decision Resources Group, it was estimated that over&nbsp;4.8&nbsp;million patients would suffer from
sciatica in the United States in&nbsp;2022. <FONT STYLE="white-space:nowrap">SP-103</FONT> has also been granted fast track designation by the FDA and, if approved, could become the first <FONT STYLE="white-space:nowrap">FDA-approved</FONT>
lidocaine topical product for the treatment of chronic neck pain. We are developing <FONT STYLE="white-space:nowrap">SP-104</FONT> as a novel delayed-release formulation of <FONT STYLE="white-space:nowrap">low-dose</FONT> naltrexone hydrochloride
for the treatment of fibromyalgia, which remains a largely unmet medical need given the low response rates of commercially available therapies. Naltrexone is routinely used <FONT STYLE="white-space:nowrap">off-label</FONT> to treat fibromyalgia.
There are no <FONT STYLE="white-space:nowrap">low-dose</FONT> formulations commercially available in the United States. Our patented formulation is designed to overcome undesirable effects of immediate release naltrexone, such as hyperalgesia,
dysphoria, nausea, anxiety and insomnia. We believe our currently approved product and future product candidates, if approved, could address what we believe are the significant unmet needs of the targeted populations. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Marketed Product and Pipeline </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following chart illustrates our current commercial products and novel product candidates. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g559675g07a07.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a complete description of our business, financial condition, results of operations and other important
information, we refer you to our filings with the SEC that are incorporated by reference in this prospectus, including our <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1820190/000095017023006493/sclx-20221231.htm">Annual
 Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December<U></U>&nbsp;
31, 2022</A> and our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarters ended <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001820190/000095017023021743/sclx-20230331.htm">March
<U></U>&nbsp;31, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001820190/000095017023041842/sclx-20230630.htm">June<U></U>&nbsp;
30, 2023</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1820190/000095017023063810/sclx-20230930.htm">September<U></U>&nbsp;30, 2023</A>, each as amended, supplemented or superseded from time to time by
other reports we file with the SEC in the future, which are incorporated by reference into this prospectus. For instructions on how to find copies of these documents, see &#147;<I>Where You Can Find More Information</I>&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See the section titled &#147;<I>Risk Factors</I>&#148; in this prospectus for a discussion of some of the risks related to the execution of
our business strategy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Business Combination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;10, 2022, Vickers Vantage Corp. I, our predecessor company (&#147;Vickers&#148;), consummated the previously announced
business combination (the &#147;Business Combination&#148;) pursuant to the terms of that certain Agreement and Plan of Merger, dated as of March&nbsp;17, 2022, by and among us, Vantage Merger Sub Inc., a Delaware corporation that was a wholly owned
subsidiary of Vickers prior to the Closing (&#147;Merger Sub&#148;), and the <FONT STYLE="white-space:nowrap">pre-Business</FONT> Combination Scilex Holding Company (&#147;Legacy Scilex&#148;), as it may be amended or restated from time to time (the
&#147;Merger Agreement&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Merger Agreement, (i)&nbsp;prior to the closing of the Business Combination (the
&#147;Closing&#148;), Vickers changed its jurisdiction of incorporation by deregistering as a Cayman Islands exempted company and continuing and domesticating as a corporation incorporated under the laws of the State of Delaware (the
&#147;Domestication&#148;) and (ii)&nbsp;at the Closing, and following the Domestication, Merger Sub merged with and into Legacy Scilex (the &#147;Merger&#148;), with Legacy Scilex as the surviving company in the Merger, and, after giving effect to
such Merger, Legacy Scilex became a wholly owned subsidiary of Vickers. The Merger was approved by Vickers&#146;s shareholders at a meeting held on November&nbsp;9, 2022. In connection with the Business Combination, Vickers changed its name to
&#147;Scilex Holding Company.&#148; </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated under the name &#147;Vickers Vantage Corp. I&#148; on February&nbsp;21, 2020 as a Cayman Islands exempted company for the
purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. On November&nbsp;9, 2022, we changed our jurisdiction of incorporation by
deregistering as a Cayman Islands exempted company and continuing and domesticating as a corporation incorporated under the laws of the State of Delaware. On November&nbsp;9, 2022, we changed our name to &#147;Scilex Holding Company&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal executive offices are located at&nbsp;960 San Antonio Road, Palo Alto, California&nbsp;94303, and our telephone number is (650) <FONT
STYLE="white-space:nowrap">516-4310.</FONT> Our website address is <I>www.scilexholding.com</I>. Any information contained on, or that can be accessed through, our website is not incorporated by reference into, nor is it in any way part of this
prospectus and should not be relied upon in connection with making any decision with respect to an investment in our securities. We are required to file annual, quarterly and current reports, proxy statements and other information with the SEC. You
may obtain any of the documents filed by us with the SEC at no cost from the SEC&#146;s website at <I>http://www.sec.gov</I>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an
Emerging Growth Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company,&#148; as defined in Section&nbsp;2(a) of the Securities Act
of&nbsp;1933, as amended (the &#147;Securities Act&#148;), as modified by the Jumpstart Our Business Startups Act of 2012 (the &#147;JOBS Act&#148;). As an emerging growth company, we are eligible to take advantage of certain exemptions from various
reporting requirements that are applicable to other public companies that are not emerging growth companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the
Sarbanes-Oxley Act of 2002, as amended (the &#147;Sarbanes-Oxley Act&#148;), reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a non-binding
advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further,
Section&nbsp;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration
statement declared effective or do not have a class of securities registered under the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;)) are required to comply with the new or revised financial accounting standards. The
JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <FONT STYLE="white-space:nowrap">non-emerging</FONT> growth companies but any such election to opt out is
irrevocable. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, will be subject to the same new or revised accounting standards as other public companies that are not
emerging growth companies. As a result, changes in rules of U.S. generally accepted accounting principles or their interpretation, the adoption of new guidance or the application of existing guidance to changes in our business could significantly
affect our business, financial condition and results of operations. In addition, we are in the process of evaluating the benefits of relying on the other exemptions and reduced reporting requirements provided by the JOBS Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will remain an emerging growth company until the earlier of: (i)&nbsp;the last day of the fiscal year (a)&nbsp;following the fifth
anniversary of the closing of the initial public offering of our company, (b)&nbsp;in which we have total annual gross revenue of at least $1.235&nbsp;billion, or (c)&nbsp;in which we are deemed to be a large accelerated filer, which means the
market value of our common equity that is held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> equals or exceeds $700&nbsp;million as of the last business day of our most recently completed second fiscal quarter; and (ii)&nbsp;the date on
which we have issued more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities during the prior three-year period. References herein to &#147;emerging growth company&#148; have the meaning associated with
it in the JOBS Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, the information in this prospectus and that we provide to our investors in the future may be different
than what you might receive from other public reporting companies. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Common Stock offered by us </B></P></TD>
<TD>Shares of our Common Stock having an aggregate offering price of up to $170,000,000 pursuant to the Sales Agreement. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Common Stock to be outstanding immediately after this offering </B></P></TD>
<TD>Up to 288,674,885 shares (as more fully described in the notes following this table), assuming sales of 130,769,230 shares of our Common Stock in this offering at an assumed offering price of $1.30 per share, the last reported sale price of our
Common Stock on the Nasdaq Capital Market on December&nbsp;20, 2023. The actual number of shares of Common Stock issued will vary depending on the sales price under this offering. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Manner of offering </B></P></TD>
<TD>&#147;At the market offering&#148; that may be made from time to time through or to B. Riley Securities Inc., Cantor Fitzgerald&nbsp;&amp; Co. and H.C. Wainwright&nbsp;&amp; Co., LLC,&nbsp;as Sales Agents or principals.&nbsp;See &#147;<I>Plan of
Distribution</I>&#148; on <FONT STYLE="white-space:nowrap">page&nbsp;S-17</FONT> of this prospectus. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Use of Proceeds </B></P></TD>
<TD>We currently intend to use the net proceeds from the sale of our Common Stock offered by this prospectus for working capital and general corporate purposes, which may include capital expenditures, commercialization expenditures, research and
development expenditures, regulatory affairs expenditures, clinical trial expenditures, acquisitions of new technologies and investments, business combinations and the repayment, refinancing, redemption or repurchase of indebtedness or capital
stock. We reserve the right, at the sole discretion of our management, to reallocate the proceeds of this offering in response to developments in our business and other factors. See &#147;<I>Use of Proceeds</I>&#148; on <FONT
STYLE="white-space:nowrap">page&nbsp;S-14</FONT> of this prospectus. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Risk Factors </B></P></TD>
<TD>Investing in our Common Stock involves a high degree of risk.&nbsp;Please read the information contained in and incorporated by reference under the heading &#147;<I>Risk Factors</I>&#148; on <FONT STYLE="white-space:nowrap">page&nbsp;S-8</FONT>
of this prospectus and under similar headings in the other documents that are filed after the date hereof and incorporated by reference into this prospectus. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Market for our Common Stock </B></P></TD>
<TD>Our Common Stock is listed on the Nasdaq Capital Market under the symbol &#147;SCLX&#148;. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of
Common Stock outstanding assumes that an aggregate of 157,905,655 shares are outstanding immediately prior to the completion of this offering, which number is based on an aggregate of 154,185,089 shares outstanding as of September&nbsp;30, 2023 plus
an aggregate of 3,720,566 shares of Common Stock issued after September&nbsp;30, 2023 and on or prior to November&nbsp;30, 2023 (comprised of (i)&nbsp;an aggregate of 3,718,465 shares of Common Stock issued pursuant to advances made under the
Company&#146;s existing standby </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
equity lines of credit and (ii) 2,101 shares of Common Stock issued upon exercise of outstanding stock options), and assumes that following November&nbsp;30, 2023 we have not issued any
additional shares of Common Stock, and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">686,956&nbsp;shares of Common Stock issuable upon the exercise of stock options outstanding under the 2017 Scilex
Pharmaceuticals Inc. Equity Incentive Plan with a weighted average exercise price of $0.80 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">15,601,592 shares of Common Stock issuable upon the exercise of stock options outstanding under the 2019 Stock
Option Plan of Scilex, Inc. with a weighted average exercise price of $1.73 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">10,958,309&nbsp;shares of Common Stock issuable upon the exercise of the public and private warrants, with an
exercise price of $11.50 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">13,000,000&nbsp;shares of Common Stock issuable upon the exercise of the warrants, with an exercise price of
$0.01 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">16,835,250 shares of Common Stock issuable upon the exercise of stock options outstanding under the Scilex
Holding Company 2022 Equity Incentive Plan with a weighted average exercise price of $6.97 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">up to 13,726,274 shares of Common Stock available for future issuance under the Scilex Holding Company 2022
Equity Incentive Plan; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">up to 2,875,759&nbsp;shares of Common Stock available for future issuance under the Scilex Holding Company 2022
Employee Stock Purchase Plan; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">up to 1,400,000&nbsp;shares of Common Stock available for future issuance under the Scilex Holding Company 2023
Inducement Plan. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="srom559675_3"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Investing in our securities involves a high degree of risk. Before you make a decision to buy our securities, in addition to the risks and
uncertainties discussed above under &#147;Cautionary Note Regarding Forward-Looking Statements&#148;, you should carefully consider the risks and uncertainties described under the section titled &#147;Risk Factors&#148; contained in our most recent
Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> together with all of the other information appearing in or incorporated by reference into this prospectus, as updated by our subsequent filings with the SEC, as well as the risk
factors and other information contained in any applicable prospectus supplement and any applicable free writing prospectus before deciding to invest in our securities. If any of these risks actually occurs, it may materially harm our business,
financial condition, liquidity and results of operations. As a result, the market price of our securities could decline, and you could lose all or part of your investment. Additionally, the risks and uncertainties described in this prospectus, any
prospectus supplement, any post-effective amendment or in any filing or document incorporated by reference herein or therein are not the only risks and uncertainties that we face. Additional risks and uncertainties not presently known to us or that
we currently believe to be immaterial may become material and adversely affect our business. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to This Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will have broad discretion in the use of the net proceeds from this offering and may not use them effectively. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently intend to use the net proceeds from this offering for working capital and general corporate purposes, which may include capital
expenditures, commercialization expenditures, research and development expenditures, regulatory affairs expenditures, clinical trial expenditures, acquisitions of new technologies and investments, business combinations and the repayment,
refinancing, redemption or repurchase of indebtedness or capital stock, as further described in the section of this prospectus entitled &#147;<I>Use of Proceeds</I>&#148;. We will have broad discretion in the application of the net proceeds in the
category of other working capital and general corporate purposes and investors will be relying on the judgment of our management regarding the application of the proceeds of this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The precise amount and timing of the application of these proceeds will depend upon a number of factors, such as the timing and progress of
our research and development efforts, our funding requirements and the availability and costs of other funds. As of the date of this prospectus, we cannot specify with certainty all of the particular uses for the net proceeds to us from this
offering. Depending on the outcome of our efforts and other unforeseen events, our plans and priorities may change and we may apply the net proceeds of this offering in different manners than we currently anticipate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The failure by our management to apply these funds effectively could harm our business, financial condition and results of operations. Pending
their use, we may invest the net proceeds from this offering in short-term, interest-bearing instruments. These investments may not yield a favorable return to our stockholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>You may experience immediate and substantial dilution. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because the prices per share at which shares of our Common Stock are sold in this offering may be substantially higher than the net tangible
book value per share of our Common Stock, you may suffer immediate and substantial dilution in the net tangible book value of the Common Stock you purchase in this offering. The shares sold in this offering, if any, will be sold from time to time at
various prices. If we sell shares in this offering at a price that is higher than the net tangible book value per share of our Common Stock, investors in this offering will experience dilution. The exercise of outstanding stock options and warrants,
and the vesting of outstanding restricted stock units, may result in further dilution of your investment. See the section of this prospectus entitled &#147;<I>Dilution</I>&#148; for a more detailed illustration of the dilution you would incur if you
participate in this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The shares of Common Stock will be sold in &#147;at the market&#148; offerings, and investors who buy
shares at different times will likely pay different prices. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investors who purchase shares in this offering at different times will
likely pay different prices, and so may experience different outcomes in their investment results. We will have discretion, subject to market demand, to vary the timing, prices, and number of shares sold in this offering. In addition, subject to the
final determination by our board of directors or any restrictions we may place in any applicable placement notice, there is no minimum or maximum sales price for shares to be sold in this offering. Investors may experience a decline in the value of
their shares as a result of share sales made at prices lower than the prices they paid. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The actual number of shares we will issue under the Sales
Agreement with the Sales Agents, at any one time or in total, is uncertain. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to certain limitations in the Sales Agreement
with the Sales Agents and compliance with applicable law, we have the discretion to deliver placement notices to each Sales Agent at any time throughout the term of the Sales Agreement. The number of shares that are sold by each Sales Agent after
delivering a placement notice will fluctuate based on the market price of the Common Stock during the sales period and limits we set with such Sales Agent. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>You may experience future dilution as a result of future equity offerings. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to raise additional capital, we may in the future offer additional shares of our Common Stock or other securities convertible into or
exchangeable for our Common Stock at prices that may not be the same as the price per share in this offering. We may sell shares or other securities in any other offering at a price per share that is less than the price per share paid by investors
in this offering, and investors purchasing shares or other securities in the future could have rights superior to existing stockholders. The price per share at which we sell additional shares of our Common Stock, or securities convertible or
exchangeable into Common Stock, in future transactions may be higher or lower than the price per share paid by investors in this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have
not paid cash dividends in the past and we do not expect to pay cash dividends in the foreseeable future. Any return on investment may be limited to the capital appreciation, if any, of our Common Stock. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not paid cash dividends on our Common Stock and we do not anticipate paying cash dividends on our Common Stock in the foreseeable
future. Should we decide in the future to do so, as a holding company, our ability to pay dividends on our capital stock and meet other obligations depends upon the receipt of dividends or other payments from our operating subsidiaries. In addition,
our ability to pay dividends may be limited by covenants in future outstanding indebtedness that we or our subsidiaries may incur. Since we do not intend to pay dividends, a stockholder&#146;s ability to receive a return on such stockholder&#146;s
investment will depend on any future appreciation in the market value of our Common Stock. There is no guarantee that our Common Stock will appreciate or even maintain the price at which our stockholders have purchased it. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The market price of our Common Stock may fluctuate significantly, and investors in our Common Stock may lose all or a part of their investment.
</I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The market prices for securities of biotechnology and pharmaceutical companies have historically been highly volatile, and the
market has from time to time experienced significant price and volume fluctuations that are unrelated to the operating performance of particular companies. For example, from November&nbsp;11, 2022 (the first trading day following the closing of the
Business Combination) to January&nbsp;5, 2024, our closing stock price ranged from $0.95 to $14.80. The market price of our Common Stock may fluctuate significantly in response to numerous factors, some of which are beyond our control. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sales of a significant number of shares of Common Stock in the public markets, or the perception that
such sales could occur, could depress the market price of our Common Stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales of a substantial number of shares in the public
markets, or the perception that such sales could occur, could depress the market price of our Common Stock and impair our ability to raise capital through the sale of additional equity securities. We have agreed, without the prior written consent of
the Sales Agents, and subject to certain exceptions set forth in the Sales Agreement, not to sell or otherwise dispose of any Common Stock or securities convertible into or exchangeable for shares of Common Stock, warrants or any rights to purchase
or acquire Common Stock during the period beginning on the fifth trading day immediately prior to the delivery of any placement notice delivered by us to any Sales Agent and ending on the fifth trading day immediately following the final settlement
date with respect to the shares sold pursuant to such notice. We have further agreed, subject to certain exceptions set forth in the Sales Agreement, not to sell or otherwise dispose of any Common Stock or securities convertible into or exchangeable
for shares of Common Stock, warrants or any rights to purchase or acquire Common Stock in any other &#147;at the market offering&#148; or continuous equity transaction prior to the sixtieth day immediately following the termination of the Sales
Agreement with the Sales Agents. Therefore, it is possible that we could issue and sell additional shares of our Common Stock in the public markets. We cannot predict the effect that future sales of our Common Stock would have on the market price of
our Common Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="srom559675_4"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus and the documents incorporated by reference into this prospectus may contain forward-looking statements within the meaning of
Section&nbsp;27A of the Securities Act, and Section&nbsp;21E of the Exchange Act, about us and our subsidiaries. These forward-looking statements are intended to be covered by the safe harbor for forward-looking statements provided by the Private
Securities Litigation Reform&nbsp;Act of&nbsp;1995. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future
results, performance or achievements expressed or implied by the forward-looking statements. These forward-looking statements rely on a number of assumptions concerning future events and include statements relating to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain the listing of our Common Stock on the Nasdaq Capital Market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our public securities&#146; liquidity and trading; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to raise financing in the future; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our use of proceeds in connection with this offering; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our future use of equity or debt financings to execute our business strategy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to use cash on hand to meet current and future financial obligations, including funding our
operations, debt service requirements and capital expenditures; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the outcome of any legal proceedings that may be instituted against us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract and retain qualified directors, officers, employees and key personnel;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to compete effectively in a highly competitive market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the competition from larger biotechnology companies that have greater resources, technology, relationships and/or
expertise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to protect and enhance our corporate reputation and brand; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact from future regulatory, judicial and legislative changes in our industry; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain and maintain regulatory approval of any of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to research, discover and develop additional product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to grow and manage growth profitably; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain and maintain intellectual property protection and not infringe on the rights of others;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to execute our business plans and strategy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of global economic and political developments, including the conflicts in Ukraine and Israel;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of <FONT STYLE="white-space:nowrap">COVID-19</FONT> and other similar disruptions in the future; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other factors detailed under the section of this prospectus titled &#147;<I>Risk Factors</I>.&#148;
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any forward-looking statements should be considered in light of these factors. Such statements can be identified by the
fact that they do not relate strictly to historical or current facts. Any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward looking
statements. Forward-looking statements are typically identified by words such as &#147;plan,&#148; &#147;believe,&#148; &#147;expect,&#148; &#147;anticipate,&#148; &#147;contemplate,&#148; &#147;intend,&#148; &#147;outlook,&#148;
&#147;estimate,&#148; &#147;forecast,&#148; &#147;project,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;may,&#148; &#147;might,&#148; &#147;possible,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;should,&#148; &#147;will,&#148;
&#147;would&#148; and other similar words and expressions (including the negative of any of the foregoing), but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
information available as of the date of this prospectus and our management&#146;s current expectations, forecasts and assumptions, and involve a number of judgments, known and unknown risks and
uncertainties and other factors, many of which are outside the control of the Company and our directors, officers and affiliates. There can be no assurance that future developments will be those that have been anticipated. Accordingly,
forward-looking statements should not be relied upon as representing our views as of any subsequent date. You are cautioned not to put undue reliance on any forward-looking statements. Except as otherwise required by law, we do not assume any
obligation to update any forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this prospectus and the documents incorporated by reference
completely and with the understanding that our actual future results may be materially different from what we currently expect. Our business and operations are and will be subject to a variety of risks, uncertainties and other factors. Consequently,
actual results and experience may materially differ from those contained in any forward-looking statements. Such risks, uncertainties and other factors that could cause actual results and experience to differ from those projected include, but are
not limited to, the risk factors set forth in Part I &#151;Item&nbsp;
1A, &#147;Risk Factors&#148;, in our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1820190/000095017023006493/sclx-20221231.htm">Form<U></U><FONT STYLE="white-space:nowrap">&nbsp;
10-K</FONT> for the year ended December<U></U>&nbsp;31, 2022</A> and Part II&#151;Item&nbsp;1A, &#147;Risk Factors&#148;, in our Quarterly Reports on <FONT STYLE="white-space:nowrap">Form&nbsp;
10-Q</FONT> for the quarters ended <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1820190/000095017023021743/sclx-20230331.htm">March<U></U>&nbsp;
31, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1820190/000095017023041842/sclx-20230630.htm">June<U></U>&nbsp;
30, 2023</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1820190/000095017023063810/sclx-20230930.htm">September<U></U>&nbsp;30, 2023</A> and in other filings with the SEC, which may be amended,
supplemented or superseded from time to time by other reports we file with the SEC in the future, that are incorporated by reference in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should assume that the information appearing in this prospectus and any document incorporated herein by reference is accurate as of its
date only. Because the risk factors referred to above could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made by us or on our behalf, you should not place undue reliance on any
forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess
the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Some of these risks and uncertainties may
in the future be amplified by <FONT STYLE="white-space:nowrap">COVID-19</FONT> (or other similar disruptions), and there may be additional risks that we consider immaterial or which are unknown. It is not possible to predict or identify all such
risks. All written or oral forward-looking statements attributable to us or any person acting on our behalf made after the date of this prospectus are expressly qualified in their entirety by the risk factors and cautionary statements contained in
and incorporated by reference into this prospectus. Unless legally required, we do not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date of this prospectus
or to reflect the occurrence of unanticipated events. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="srom559675_5"></A>MARKET AND INDUSTRY DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain information contained in this prospectus relates to or is based on studies, publications, surveys and other data obtained from
third-party sources and our own internal estimates and research. While we believe these third-party sources to be reliable as of the date of this prospectus, we have not independently verified the market and industry data contained in this
prospectus or the underlying assumptions relied on therein. Finally, while we believe our own internal research is reliable, such research has not been verified by any independent source. Notwithstanding the foregoing, we are liable for the
information provided in this prospectus. The industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of factors, including those described in the section of this prospectus titled &#147;<I>Risk
Factors</I>&#148;. These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="srom559675_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently intend to use the net proceeds from the sale of our Common Stock offered by this prospectus for working capital and general
corporate purposes, which may include capital expenditures, commercialization expenditures, research and development expenditures, regulatory affairs expenditures, clinical trial expenditures, acquisitions of new technologies and investments,
business combinations and the repayment, refinancing, redemption or repurchase of indebtedness or capital stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The precise amount and
timing of the application of these proceeds will depend upon a number of factors, such as the costs and timing of commercial and development activities, including, for example, conducting preclinical studies and clinical trials, our funding
requirements and the availability and costs of other funds. Pending application of the net proceeds as described above, we intend to temporarily invest the proceeds in interest-bearing instruments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may bear all other costs, fees and expenses incurred in effecting the registration of the shares covered by this prospectus, including,
without limitation, all registration and filing fees, Nasdaq Capital Market listing fees, and fees and expenses of our counsel and our accountants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="srom559675_7"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you purchase our Common Stock in this offering, your interest will be diluted to the extent of the difference between the public offering
price per share and the net tangible book value per share of our Common Stock after this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2023, we had
net tangible book value of approximately $(213,661,000), or $(1.39) per share. Net&nbsp;tangible book value per share represents the amount of total tangible assets less total liabilities divided by the&nbsp;number of shares of our Common Stock
outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our pro forma net tangible book value as of September&nbsp;30, 2023, before giving effect to this offering, was
approximately $(208,438,000), or $(1.32) per share of our Common Stock. Pro forma net tangible book value, before the issuance and sale of shares of Common Stock in this offering, gives effect to the issuance of an aggregate of 3,720,566 shares of
Common Stock after September&nbsp;30, 2023 and on or prior to November&nbsp;30, 2023 (comprised of (i)&nbsp;an aggregate of 3,718,465 shares of Common Stock issued pursuant to advances made under the Company&#146;s existing standby equity lines of
credit and (ii) 2,101&nbsp;shares of Common Stock issued upon exercise of outstanding stock options), and assumes that following November 30, 2023 we have not issued any additional shares of Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After giving effect to (i)&nbsp;the pro forma adjustments set forth above and (ii)&nbsp;the sale of 130,769,230 shares of Common Stock at an
assumed public offering price of $1.30 per share, the last reported sale price of our Common Stock on the Nasdaq Capital Market on December&nbsp;20, 2023, after deducting commissions at an assumed rate of 3.0% and estimated aggregate offering
expenses payable by us, our pro forma as adjusted net tangible book value as of September&nbsp;30, 2023 would have been approximately $(44,138,000), or approximately $(0.15) per share. This amount represents an immediate increase in pro forma net
tangible book value of approximately $1.17 per share to our existing stockholders and an immediate dilution in net tangible book value of approximately $1.45 per share to new investors purchasing shares of Common Stock in this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors is determined by subtracting pro forma as adjusted net tangible book value per share after this offering
from the offering price per share paid by new investors. The following table illustrates this dilution: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="4"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed public offering price per share </P></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net tangible book value per share as of September&nbsp;30, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1.39</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net tangible book value per share as of September&nbsp;30, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1.32</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in pro forma net tangible book value per share attributable to the issuance of an
aggregate of 3,720,566 shares of our Common Stock after September 30, 2023 and on or prior to November 30, 2023 (as described above)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.07</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="4"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma as adjusted net tangible book value per share, after giving effect to this
offering </P></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="4"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors purchasing shares in this offering </P></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table above assumes for illustrative purposes that an aggregate of 130,769,230 additional shares of our
Common Stock are sold pursuant to the Sales Agreement with the Sales Agents at a price of $1.30 per share, the last reported sale price of our Common Stock on the Nasdaq Capital Market on December&nbsp;20, 2023, for aggregate net proceeds of
approximately $164,300,000, after deducting commissions at an assumed rate of 3.0% and estimated aggregate offering expenses payable by us. The shares pursuant to the Sales Agreement with the Sales Agents are being sold from time to time at various
prices. The pro forma as adjusted information is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
illustrative only and will adjust based on the actual price to the public, the actual number of shares sold and other terms of the offering determined at the time shares of our Common Stock are
sold pursuant to this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An increase of $1.00&nbsp;per share in the price at which the shares are sold from the assumed offering
price of $1.30 per share shown in the table above, assuming all of our Common Stock in the aggregate amount of $170,000,000 pursuant to the Sales Agreement with the Sales Agents is sold at that price, would increase our pro forma as adjusted net
tangible book value per share after the offering to $0.28 per share and would increase the dilution in net tangible book value per share to new investors in this offering to $2.02 per share, after deducting commissions at an assumed rate of 3.0% and
estimated aggregate offering expenses payable by us. A decrease of $1.00&nbsp;per share in the price at which the shares are sold from the assumed offering price of $1.30 per share shown in the table above, assuming all of our Common Stock in the
aggregate amount of $170,000,000 pursuant to the Sales Agreement with the Sales Agents is sold at that price, would decrease our pro forma as adjusted net tangible book value per share after the offering to $(0.59) per share and would decrease the
dilution in pro forma net tangible book value per share to new investors in this offering to $0.89 per share, after deducting commissions at an assumed rate of 3.0% and estimated aggregate offering expenses payable by us. This information is
supplied for illustrative purposes only. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The above discussion and table are based on 154,185,089 shares of our Common Stock issued and
outstanding as of September&nbsp;30, 2023 and excludes the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">686,956 shares of Common Stock issuable upon the exercise of stock options outstanding under the 2017 Scilex
Pharmaceuticals Inc. Equity Incentive Plan with a weighted average exercise price of $0.80 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">15,601,592 shares of Common Stock issuable upon the exercise of stock options outstanding under the 2019 Stock
Option Plan of Scilex, Inc. with a weighted average exercise price of $1.73 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">10,958,309&nbsp;shares of Common Stock issuable upon the exercise of the public and private warrants, with an
exercise price of $11.50 per share </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">13,000,000&nbsp;shares of Common Stock issuable upon the exercise of the warrants, with an exercise price of
$0.01 per share </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">16,835,250 shares of Common Stock issuable upon the exercise of stock options outstanding under the Scilex
Holding Company 2022 Equity Incentive Plan with a weighted average exercise price of $6.97 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">up to 13,726,274 shares of Common Stock available for future issuance under the Scilex Holding Company 2022
Equity Incentive Plan; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">up to 2,875,759 shares of Common Stock available for future issuance under the Scilex Holding Company 2022
Employee Stock Purchase Plan; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">up to 1,400,000 shares of Common Stock available for future issuance under the Scilex Holding Company 2023
Inducement Plan. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that options or warrants outstanding as of September&nbsp;30, 2023 have been or are
exercised, new options or other equity awards are granted under our equity incentive plans, or we issue additional shares in the future, investors purchasing shares in this offering could experience further dilution. In addition, we may choose to
raise additional capital due to market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans. To the extent that additional capital is raised through the sale of equity or
convertible debt securities, the issuance of these securities could result in further dilution to our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="srom559675_8"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We entered into the Sales Agreement with the Sales Agents on December&nbsp;22, 2023, pursuant to which we may issue and sell from time to time
shares of our Common Stock having an aggregate offering price of up to $170,000,000, to or through B. Riley Securities Inc., Cantor Fitzgerald&nbsp;&amp; Co. and H.C. Wainwright&nbsp;&amp; Co., LLC, acting as our Sales Agents. A copy of the Sales
Agreement was filed as Exhibit 1.1 to the Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> of which this prospectus forms a part, and is incorporated by reference into this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The sales of our Common Stock, if any, under this prospectus will be made at market prices by any method deemed to be an &#147;at the market
offering&#148; as defined in Rule 415(a)(4) under the Securities Act, including sales made directly on the Nasdaq Capital Market, on any other existing trading market for our Common Stock or to or through a market maker. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each time that we wish to issue and sell shares of our Common Stock under the Sales Agreement, we will provide a Sales Agent with a placement
notice describing the amount of shares to be sold, the time period during which sales are requested to be made, any limitation on the amount of shares of Common Stock that may be sold in any single day, any minimum price below which sales may not be
made or any minimum price requested for sales in a given time period and any other instructions relevant to such requested sales. Upon receipt of a placement notice, the applicable Sales Agent, acting as our sales agent, will use commercially
reasonable efforts, consistent with its normal trading and sales practices and applicable state and federal laws, rules and regulations and the rules of the Nasdaq Capital Market, to sell shares of our Common Stock under the terms and subject to the
conditions of the placement notice and the Sales Agreement. We or each Sales Agent may suspend the offering of Common Stock pursuant to a placement notice upon notice and subject to other conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Settlement for sales of Common Stock, unless the parties agree otherwise, will occur on the second trading day following the date on which any
sales are made in return for payment of the net proceeds to us. There are no arrangements to place any of the proceeds of this offering in an escrow, trust or similar account. Sales of our Common Stock as contemplated in this prospectus will be
settled through the facilities of The Depository Trust Company or by such other means as we and each Sales Agent may agree upon. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will
pay the Sales Agents commissions for their services in acting as our sales agents in the sale of our Common Stock pursuant to the Sales Agreement. A Sales Agent will be entitled to compensation at a fixed commission rate of 3.0% of the gross
proceeds from the sale of our Common Stock on our behalf pursuant to the Sales Agreement. We have also agreed to reimburse the Sales Agents for their reasonable and documented
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses (including but not limited to the reasonable and documented fees and expenses of their legal counsel) in an amount not to exceed $35,000 in the
aggregate (excluding any periodic due diligence fees for which Sales Agents&#146; counsel will receive up to a maximum of $5,000 per due diligence update session, if any, conducted in connection with our Quarterly Reports on Form <FONT
STYLE="white-space:nowrap">10-Q</FONT> and $10,000 per due diligence update session, if any, conducted in connection with our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> in each case in accordance with the terms of the Sales
Agreement). We estimate such due diligence fees would not exceed $75,000 over the three year term of the Sales Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate
that the total expenses for this offering, excluding compensation payable to the Sales Agents and certain expenses reimbursable to the Sales Agents under the terms of the Sales Agreement, will be approximately $600,000.&nbsp;The remaining sales
proceeds, after deducting any expenses payable by us and any transaction fees imposed by any governmental, regulatory, or self-regulatory organization in connection with the sales, will equal our net proceeds for the sale of such Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because there are no minimum sale requirements as a condition to this offering, the actual total public offering price, commissions and net
proceeds to us, if any, are not determinable at this time. The actual dollar amount and number of shares of Common Stock we sell through this prospectus will be dependent, among other things, on market conditions and our capital raising
requirements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will report at least quarterly the number of shares of Common Stock sold through the
Sales Agents under the Sales Agreement, the net proceeds to us and the compensation paid by us to the Sales Agents in connection with the sales of Common Stock under the Sales Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the sale of the Common Stock on our behalf, each Sales Agent will be deemed to be an &#147;underwriter&#148; within the
meaning of the Securities Act, and the compensation of the Sales Agents will be deemed to be underwriting commissions or discounts. We have agreed to provide indemnification and contribution to the Sales Agents against certain civil liabilities,
including liabilities under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Sales Agents will not engage in any market making activities involving our Common
Stock while the offering is ongoing under this prospectus if such activity would be prohibited under Regulation M or other anti-manipulation rules under the Securities Act.&nbsp;As our sales agents, the Sales Agents will not engage in any
transactions that stabilize our Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The offering pursuant to the Sales Agreement will terminate upon the earlier of
(i)&nbsp;the sale of all shares of Common Stock subject to the Sales Agreement and (ii)&nbsp;termination of the Sales Agreement as permitted therein. We may terminate the Sales Agreement in our sole discretion at any time by giving three business
days&#146; prior notice to the Sales Agents. Each Sales Agent may terminate the Sales Agreement with respect to itself under the circumstances specified in the Sales Agreement and in their sole discretion at any time by giving three business
days&#146; prior notice to us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Sales Agents and/or their affiliates have provided, and may in the future provide, various investment
banking and other financial services for us, for which services they have received and may in the future receive customary fees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This
prospectus in electronic format may be made available on a website maintained by any of the Sales Agents, and the Sales Agents may distribute this prospectus electronically.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="srom559675_9"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the issuance of the Common Stock offered by this prospectus will be passed upon for us by Paul Hastings LLP, Palo Alto,
California. Sheppard, Mullin, Richter&nbsp;&amp; Hampton LLP, New York, New York is counsel for the Sales Agents in connection with this offering. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="srom559675_10"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of Scilex Holding Company appearing in Scilex Holding Company&#146;s Annual Report <FONT
STYLE="white-space:nowrap">(Form&nbsp;10-K)</FONT> for the year ended December&nbsp;31, 2022, have been audited by Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, as set forth in their report thereon (which contains an
explanatory paragraph describing conditions that raise substantial doubt about the Company&#146;s ability to continue as a going concern as described in Note 2 to the consolidated financial statements) included therein, and incorporated herein by
reference. Such financial statements are, and audited financial statements to be included in subsequently filed documents will be, incorporated herein in reliance upon the report of Ernst &amp; Young LLP pertaining to such financial statements (to
the extent covered by consents filed with the SEC) given on the authority of such firm as experts in accounting and auditing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="srom559675_11">
</A>WHERE YOU CAN FIND MORE INFORMATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a reporting company and file annual, quarterly and current reports, proxy statements
and other information with the SEC. We have filed with the SEC a registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> under the Securities Act with respect to the securities being offered under this prospectus. This
prospectus does not contain all of the information set forth in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities being offered under this prospectus, we refer
you to the registration statement and the exhibits and schedules filed as a part of the registration statement. The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that
file electronically with the SEC, including Scilex Holding Company. The SEC&#146;s Internet site can be found at <I>http://www.sec.gov</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also maintain a website at <I>www.scilexholding.com</I>. Through our website, we make available, free of charge, annual, quarterly and
current reports, proxy statements and other information as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. The information contained on, or that may be accessed through, our website is not part of,
and is not incorporated into, this prospectus and should not be relied upon in connection with making any decision with respect to an investment in our securities, and the inclusion of our website address in this prospectus is an inactive textual
reference only. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="srom559675_12"></A>IMPORTANT INFORMATION INCORPORATED BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; information into this prospectus, which means that we can disclose important
information to you by referring you to another document filed separately with the SEC. The documents incorporated by reference into this prospectus contain important information that you should read about us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following documents are incorporated by reference into this prospectus: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001820190/000095017023006493/sclx-20221231.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the fiscal year ended December&nbsp;31, 2022, filed with the SEC on March&nbsp;7, 2023; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001820190/000095017023021743/sclx-20230331.htm">March
<U></U>&nbsp;31, 2023</A>, filed with the SEC on May&nbsp;12, 2023, the quarter ended <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001820190/000095017023041842/sclx-20230630.htm">June<U></U>&nbsp;30,
2023</A>, filed with the SEC on August&nbsp;11, 2023, and the quarter ended <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1820190/000095017023063810/sclx-20230930.htm">September<U></U>&nbsp;30, 2023</A>, filed
with the SEC on November&nbsp;14, 2023; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (other than any portions thereof
furnished under Item 2.02 or Item&nbsp;
7.01 of Form <FONT STYLE="white-space:nowrap">8-K</FONT> and any exhibits accompanying such reports that relate to such items) filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001820190/000119312523004041/d371589d8k.htm">January
<U></U>&nbsp;9, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001820190/000119312523009256/d426852d8k.htm">January<U></U>&nbsp;
17, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001820190/000119312523024777/d462081d8k.htm">February<U></U>&nbsp;
6, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001820190/000119312523030002/d802493d8k.htm">February<U></U>&nbsp;
9, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001820190/000119312523035934/d447754d8k.htm">February<U></U>&nbsp;
13, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001820190/000119312523075731/d280460d8k.htm">March<U></U>&nbsp;
21, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001820190/000119312523097796/d429390d8k.htm">April<U></U>&nbsp;
11, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001820190/000119312523108354/d498999d8k.htm">April<U></U>&nbsp;
20, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001820190/000119312523116108/d466902d8k.htm">April<U></U>&nbsp;
26, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001820190/000119312523137199/d327950d8k.htm">May<U></U>&nbsp;
5, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001820190/000119312523176273/d443585d8k.htm">June<U></U>&nbsp;
27, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001820190/000119312523183184/d507324d8k.htm">July<U></U>&nbsp;
7, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001820190/000119312523226362/d533212d8k.htm">August<U></U>&nbsp;
31, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001820190/000119312523231529/d485283d8k.htm">September<U></U>&nbsp;
8, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001820190/000119312523234357/d527905d8k.htm">September 13. 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001820190/000119312523239551/d554572d8k.htm">September
<U></U>&nbsp;21, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001820190/000119312523240648/d440182d8k.htm">September<U></U>&nbsp;
22, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001820190/000119312523242508/d537034d8k.htm">September<U></U>&nbsp;
26, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001820190/000119312523243665/d559663d8ka.htm">September<U></U>&nbsp;
27, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001820190/000119312523245653/d526196d8k.htm">September<U></U>&nbsp;
28, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001820190/000119312523254137/d439599d8k.htm">October<U></U>&nbsp;
11, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001820190/000119312523268931/d545216d8k.htm">November<U></U>&nbsp;
2, 2023</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1820190/000119312523302132/d564196d8k.htm">December&nbsp;22, 2023</A>; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The description of our Common Stock set forth in our Registration Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000121390021000590/ea132712-8a12b_vickers1.htm">Form
 <FONT STYLE="white-space:nowrap">8-A</FONT></A> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-39852),</FONT> filed with the SEC on January&nbsp;6, 2021, including any amendments or reports filed for the purpose of updating such description,
including <A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000095017023006493/sclx-ex4_2.htm">Exhibit 4.2</A> to our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2022 filed
with the SEC on March&nbsp;7, 2023. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also incorporate by reference any future filings (other than current reports
furnished under Item&nbsp;2.02 or Item&nbsp;7.01 of <FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> and exhibits filed on such form that are related to such items unless such <FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> expressly
provides to the contrary) made with the SEC pursuant to Sections&nbsp;13(a), 13(c), 14 or&nbsp;15(d) of the Exchange Act, including those made after the date of the initial filing of the registration statement of which this prospectus forms a part,
until we file a post-effective amendment that indicates the termination of the offering of the securities made by this prospectus and such future filings will become a part of this prospectus from the respective dates that such documents are filed
with the SEC. Any statement contained herein or in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes hereof to the extent that a statement contained herein or in any
other subsequently filed document which is also incorporated or deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or
superseded, to constitute a part of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Documents incorporated by reference are available from us, without charge. You may
obtain documents incorporated by reference in this prospectus by requesting them in writing or by telephone at the following address: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Scilex Holding Company </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attn:
Investor Relations </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">960 San Antonio Road </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Palo Alto, CA 94303 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">investorrelations@scilexholdings.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Phone: (650) <FONT STYLE="white-space:nowrap">516-4310</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:30pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Up to $170,000,000 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:22pt; font-family:Times New Roman" ALIGN="center"><B>SCILEX HOLDING COMPANY </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>COMMON STOCK </B></P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS
</B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2024 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:16pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:16pt">
<TD VALIGN="top" NOWRAP><B>B.&nbsp;Riley&nbsp;Securities</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><B>Cantor</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><B>H.C.&nbsp;Wainwright&nbsp;&amp;&nbsp;Co.</B></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="srom559675_12"></A>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Item&nbsp;14. Other Expenses of Issuance and Distribution </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the estimated costs and expenses, other than underwriting discounts and commissions, payable by Scilex Holding
Company (the &#147;Registrant&#148;), in connection with the sale of the securities being registered. All the amounts shown are estimates, except for the SEC registration fee and the FINRA filing fee. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</P> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FINRA filing fee (if applicable)</P>
<P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,500</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P>
<P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses</P>
<P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Blue Sky, qualification fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer agent fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trustee fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant agent fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amount of securities and number of offerings are indeterminable and the expenses cannot be estimated at
this time. An estimate of the aggregate expenses in connection with the sale and distribution of securities being offered will be included in the applicable prospectus supplement. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Item&nbsp;15. Indemnification of Directors and Officers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;102 of the General Corporation Law of the State of Delaware (&#147;DGCL&#148;) permits a corporation to eliminate or limit the
personal liability of directors and officers of a corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director or officer, except where the director or officer breached his or her duty of
loyalty to the corporation or its stockholders, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase or redemption in violation of the DGCL or
derived an improper personal benefit, or, with respect to any officer, any action by or in the right of the corporation. The Registrant&#146;s restated certificate of incorporation (the &#147;Certificate of Incorporation&#148;) contains provisions
that limit the liability of the Registrant&#146;s directors and officers for monetary damages to the fullest extent permitted by the DGCL. Consequently, the Registrant&#146;s directors and officers will not be personally liable to the Registrant or
its stockholders for monetary damages for any breach of fiduciary duty as a director or officer, except liability for the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any breach of their duty of loyalty to the Registrant or its stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">with respect to any director, unlawful payments of dividends or unlawful stock repurchases or redemptions in
violation of the DGCL; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction from which the director or officer derived an improper personal benefit; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">with respect to any officer, any action by or in the right of the corporation. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation also provides that if the DGCL is amended to permit further
elimination or limitation of the personal liability of directors or officers, then the liability of the Registrant&#146;s directors and officers will be eliminated or limited to the fullest extent permitted by the DGCL, as so amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;145 of the DGCL provides that a corporation has the power to indemnify a director, officer, employee or agent of the corporation,
or a person serving at the request of the corporation for another corporation, partnership, joint venture, trust or other enterprise in related capacities against expenses (including attorneys&#146; fees), judgments, fines and amounts paid in
settlement actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he or she was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding by
reason of such position, if such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe
his or her conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to judgments, fines and amounts paid in settlement in connection with such action, suit
or proceeding or with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that,
despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper. The
Certificate of Incorporation permits the Registrant to indemnify its directors, officers, employees and other agents to the maximum extent permitted by the DGCL, and the Registrant&#146;s bylaws provide that the Registrant will indemnify its
directors and officers and permit the Registrant to indemnify its employees and other agents, in each case to the extent not prohibited by the DGCL or any other applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Registrant has entered, and expects to continue to enter, into indemnification agreements with its directors and officers, that may be
broader than the specific indemnification provisions contained in the DGCL. These agreements, among other things, require the Registrant to indemnify its directors and officers against liabilities that may arise by reason of their status or service.
These indemnification agreements also require the Registrant to advance all expenses actually and reasonably incurred by the directors and executive officers in connection with any proceeding. The Registrant also maintains directors&#146; and
officers&#146; liability insurance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Item&nbsp;16. Exhibits </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit <BR>Number</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;1.1+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Underwriting Agreement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;1.2**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000119312523302123/d559675dex12.htm">Sales Agreement, dated December&nbsp;22, 2023, by and among Scilex Holding Company, B. Riley Securities Inc., Cantor Fitzgerald&nbsp;
&amp; Co. and H.C. Wainwright&nbsp;&amp; Co., LLC. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;2.1#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000121390022013697/ea157097ex2-1_vickers1.htm">Agreement and Plan of Merger, dated as of March<U></U>&nbsp;
17, 2022, by and among Vickers Vantage Corp. I, Vickers Merger Sub, Inc. and Scilex Holding Company (incorporated by reference to Exhibit 2.1 of Vickers&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (File No.<U></U><FONT
STYLE="white-space:nowrap">&nbsp;001-39852),</FONT> filed with the SEC on March<U></U>&nbsp;21, 2022).</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;2.2#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000110465922099785/tm2225830d1_ex2-1.htm">Amendment No.<U></U>&nbsp;1 to Agreement and Plan of Merger, dated as of September<U></U>&nbsp;
12, 2022, by and among Vickers Vantage Corp. I, Vickers Merger Sub, Inc. and Scilex Holding Company (incorporated by reference to Exhibit 2.1 of Vickers&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (File No.<U></U><FONT
STYLE="white-space:nowrap">&nbsp;001-39852),</FONT> filed with the SEC on September<U></U>&nbsp;14, 2022).</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000119312522287783/d374632dex31.htm">Restated Certificate of Incorporation of Scilex Holding Company (incorporated by reference to Exhibit 3.1 to the Registrant&#146;s Current Report
 on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (File No.<U></U><FONT STYLE="white-space:nowrap">&nbsp;001-39852),</FONT> filed with the SEC on November<U></U>&nbsp;17, 2022). </A></TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="89%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit <BR>Number</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000119312522287783/d374632dex33.htm">Bylaws of Scilex Holding Company (incorporated by reference to Exhibit 3.3 of our Current Report on Form<U></U><FONT
STYLE="white-space:nowrap">&nbsp;8-K</FONT><U></U>&nbsp;(File No.<U></U><FONT STYLE="white-space:nowrap">&nbsp;001-39852),</FONT><U></U>&nbsp;filed with the SEC on November<U></U>&nbsp;17, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000119312522287783/d374632dex32.htm">Certificate of Designations of Scilex Holding Company (incorporated by reference to Exhibit 3.2 of our Current Report on Form<U></U><FONT
STYLE="white-space:nowrap">&nbsp;8-K</FONT><U></U>&nbsp;(File No.<U></U><FONT STYLE="white-space:nowrap">&nbsp;001-39852),</FONT><U></U>&nbsp;filed with the SEC on November<U></U>&nbsp;17, 2022). </A><BR></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;4.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000121390021001411/ea133037ex4-1_vickers1.htm">Warrant Agreement, dated as of January&nbsp;6, 2021, by and between Vickers Vantage Corp. I and Continental Stock Transfer&nbsp;
&amp; Trust Company (incorporated by reference to Exhibit&nbsp;4.1 of Vickers&#146;s Current Report on Form&nbsp;8-K (File No.&nbsp;001-39852), filed with the SEC on January&nbsp;11, 2021). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;4.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000121390020042745/fs12020ex4-3_vickers1.htm">Specimen Warrant Certificate of Scilex Holding Company (f/k/a Vickers Vantage Corp.&nbsp;
I) (incorporated by reference to Exhibit&nbsp;4.3 of Vickers&#146;s <FONT STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-251352),</FONT> filed with the SEC on December&nbsp;15, 2020).</A></TD></TR>

<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;4.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000119312523242508/d537034dex41.htm">Senior Secured Promissory Note issued to Oramed Pharmaceuticals, Inc. on September&nbsp;21, 2023 (incorporated by reference to Exhibit&nbsp;
4.1 of our Current Report on Form&nbsp;8-K (File No.&nbsp;001-39852), filed with the SEC on September&nbsp;26, 2023). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;4.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000119312523242508/d537034dex42.htm">Form of Scilex Holding Company Warrant to Purchase Common Stock (incorporated by reference to Exhibit 4.2 of our Current Report on Form<U></U>
<FONT STYLE="white-space:nowrap">&nbsp;8-K</FONT><U></U>&nbsp;(File No.<U></U><FONT STYLE="white-space:nowrap">&nbsp;001-39852),</FONT><U></U>&nbsp;filed with the SEC on September<U></U>&nbsp;26, 2023).</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;4.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000119312522287783/d374632dex101.htm">Amended and Restated Registration Rights Agreement, dated as of November<U></U>&nbsp;
10, 2022, by and among Scilex Holding Company, Vickers Venture Fund VI Pte Ltd, Vickers Venture Fund VI (Plan) Pte Ltd, Sorrento Therapeutics, Inc. and certain security holders set forth on the signature pages thereto (incorporated by reference to Exhibit
 10.1 of our Current Report on Form<U></U><FONT STYLE="white-space:nowrap">&nbsp;8-K</FONT><U></U>&nbsp;(File No.<U></U><FONT STYLE="white-space:nowrap">&nbsp;001-39852),</FONT><U></U>&nbsp;filed with the SEC on November<U></U>&nbsp;17,
2022).</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;4.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000119312523004041/d371589dex101.htm">Standby Equity Purchase Agreement, dated as of January<U></U>&nbsp;
8, 2023, by and between Scilex Holding Company and B. Riley Principal Capital II, LLC (incorporated by reference to Exhibit<U></U>&nbsp;10.1 of our Current Report on Form<U></U><FONT STYLE="white-space:nowrap">&nbsp;8-K</FONT><U></U>&nbsp;
(File No.<U></U><FONT STYLE="white-space:nowrap">&nbsp;001-39852),</FONT><U></U>&nbsp;filed with the SEC on January<U></U>&nbsp;9, 2023).</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;4.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000119312523030002/d802493dex101.htm">Amended and Restated Standby Equity Purchase Agreement, dated as of February<U></U>&nbsp;
8, 2023, by and between Scilex Holding Company and YA II PN, LTD. (incorporated by reference to Exhibit 10.1 of our Current Report on Form<U></U><FONT STYLE="white-space:nowrap">&nbsp;8-K</FONT><U></U>&nbsp;(File No.<U></U><FONT
STYLE="white-space:nowrap">&nbsp;001-39852),</FONT><U></U>&nbsp;filed with the SEC on February<U></U>&nbsp;9, 2023).</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;4.9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000119312523075731/d280460dex102.htm">Registration Rights Agreement, dated as of March<U></U>&nbsp;
21, 2023, by and between Scilex Holding Company and YA II PN, LTD. (incorporated by reference to Exhibit 10.2 of our Current Report on Form<U></U><FONT STYLE="white-space:nowrap">&nbsp;8-K</FONT><U></U>&nbsp;(File No.<U></U><FONT
STYLE="white-space:nowrap">&nbsp;001-39852),</FONT><U></U>&nbsp;filed with the SEC on March<U></U>&nbsp;21, 2023).</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;4.10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000119312523239551/d554572dex101.htm">Settlement Agreement, dated September<U></U>&nbsp;
15, 2023, by and among Scilex Holding Company, Cove Lane Onshore Fund, LLC, HBC Investments LLC and Hudson Bay Capital Management LP (incorporated by reference to Exhibit 10.1 of our Current Report on Form<U></U><FONT STYLE="white-space:nowrap">&nbsp;
8-K</FONT><U></U>&nbsp;(File No.<U></U><FONT STYLE="white-space:nowrap">&nbsp;001-39852),</FONT><U></U>&nbsp;filed with the SEC on September<U></U>&nbsp;21, 2023).</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;4.11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000119312523242508/d537034dex102.htm">Registration Rights Agreement, dated September<U></U>&nbsp;
21, 2023, by and between Scilex Holding Company and Oramed Pharmaceuticals Inc. (incorporated by reference to Exhibit<U></U>&nbsp;10.2 of our Current Report on Form<U></U><FONT STYLE="white-space:nowrap">&nbsp;8-K</FONT><U></U>&nbsp;(File No.<U></U><FONT
STYLE="white-space:nowrap">&nbsp;001-39852),</FONT><U></U>&nbsp;filed with the SEC on September<U></U>&nbsp;26, 2023).</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;4.12+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Specimen Preferred Stock Certificate and Form of Certificate of Designation of Preferred Stock.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;4.13**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000119312523302123/d559675dex411.htm">Form of Indenture. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;4.14+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Debt Securities.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;4.15+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Common Stock Warrant Agreement and Warrant Certificate.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;4.16+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Preferred Stock Warrant Agreement and Warrant Certificate.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="88%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit <BR>Number</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;4.17+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Debt Securities Warrant Agreement and Warrant Certificate.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;4.18+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Rights Agreement and Right Certificate.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;4.19+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Unit Agreement and Unit Certificate.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;5.1**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000119312523302123/d559675dex51.htm">Opinion of Paul Hastings LLP. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.1++</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000119312522287783/d374632dex102.htm">Form of Indemnification Agreement of Scilex Holding Company (incorporated by reference to Exhibit 10.2 of our Current Report on Form <FONT
STYLE="white-space:nowrap">8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-39852),</FONT> filed with the SEC on November&nbsp;17, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.2++</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d7.htm">Scilex Pharmaceuticals, Inc. Amended and Restated 2017 Equity Incentive Plan (incorporated by reference to Exhibit 10.7 of Amendment No.&nbsp;1
 of Vickers&#146;s Form <FONT STYLE="white-space:nowrap">S-4</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-264941),</FONT> filed with the SEC on June&nbsp;27, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.3++</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d8.htm">Form of Option Agreement and Stock Option Grant Notice under the Scilex Pharmaceuticals Inc. 2017 Equity Incentive Plan (incorporated
 by reference to Exhibit 10.8 of Amendment No.&nbsp;1 of Vickers&#146;s Form <FONT STYLE="white-space:nowrap">S-4</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-264941),</FONT> filed with the SEC on June&nbsp;27, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.4++</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d9.htm">Scilex Holding Company 2019 Stock Option Plan, as amended (incorporated by reference to Exhibit 10.9 of Amendment No.&nbsp;
1 of Vickers&#146;s Form <FONT STYLE="white-space:nowrap">S-4</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-264941),</FONT> filed with the SEC on June&nbsp;27, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.5++</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d10.htm">Form of Option Agreement and Stock Option Grant Notice under the Scilex Holding Company 2019 Stock Option Plan, as amended (incorporated
 by reference to Exhibit 10.10 of Amendment No.&nbsp;1 of Vickers&#146;s Form <FONT STYLE="white-space:nowrap">S-4</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-264941),</FONT> filed with the SEC on June&nbsp;27, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.6++</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000119312522287783/d374632dex105.htm">Scilex Holding Company 2022 Equity Incentive Plan, as amended (incorporated by reference to Exhibit 10.5 of our Current Report on Form <FONT
STYLE="white-space:nowrap">8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-39852),</FONT> filed with the SEC on May&nbsp;5, 2023).</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.7++</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000119312522287783/d374632dex106.htm">Form of Stock Option Grant Notice and Stock Option Agreement under the Scilex Holding Company 2022 Equity Incentive Plan (incorporated by reference
 to Exhibit 10.6 of our Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-39852),</FONT> filed with the SEC on November&nbsp;17, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.8++</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000119312522287783/d374632dex107.htm">Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the Scilex Holding Company 2022 Equity Incentive
 Plan (incorporated by reference to Exhibit 10.7 of our Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-39852),</FONT> filed with the SEC on November&nbsp;17, 2022).
</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.9++</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000119312522287783/d374632dex108.htm">Scilex Holding Company 2022 Employee Stock Purchase Plan (incorporated by reference to Exhibit&nbsp;10.8 of our Current Report on Form <FONT
STYLE="white-space:nowrap">8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-39852),</FONT> filed with the SEC on November&nbsp;17, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.10++</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000119312523009256/d426852dex101.htm">Scilex Holding Company 2023 Inducement Plan (incorporated by reference to Exhibit 10.1 of our Current Report on <FONT
STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-39852),</FONT> filed with the SEC on January&nbsp;17, 2023). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.11++</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000119312523009256/d426852dex102.htm">Form of Stock Option Grant Notice and Stock Option Agreement under the Scilex Holding Company 2023 Inducement Plan (incorporated by reference
 to Exhbit 10.2 of our Current Report on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-39852),</FONT> filed with the SEC on January&nbsp;17, 2023). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.12++</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000119312523009256/d426852dex103.htm">Form of Restricted Stock Unit Award Grant Notice and Award Agreement under the Scilex Holding Company 2023 Inducement Plan (incorporated by reference
 to Exhibit 10.3 of our Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-39852),</FONT> filed with the SEC on January&nbsp;17, 2023).
</A></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="88%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit <BR>Number</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000121390022013697/ea157097ex10-1_vickers1.htm">Sponsor Support Agreement, dated as of March&nbsp;
17, 2022, by and among Vickers Vantage Corp. I and certain stockholders (incorporated by reference to Exhibit 10.1 of Vickers&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;
001-39852),</FONT> filed with the SEC on March&nbsp;21, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.14</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000110465922099785/tm2225830d1_ex10-2.htm">Amendment No.&nbsp;1 to Sponsor Support Agreement, dated as of September&nbsp;
12, 2022, by and among Vickers Vantage Corp. I and certain stockholders (incorporated by reference to Exhibit 10.2 of Vickers&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;
001-39852),</FONT> filed with the SEC on September&nbsp;14, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000121390022013697/ea157097ex10-2_vickers1.htm">Company Stockholder Support Agreement, dated as of March&nbsp;
17, 2022, by and among Vickers Vantage Corp. I, Scilex Holding Company and Sorrento Therapeutics, Inc. (incorporated by reference to Exhibit 10.2 of Vickers&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (File <FONT
STYLE="white-space:nowrap">No.&nbsp;001-39852),</FONT> filed with the SEC on March&nbsp;21, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.16++</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d17.htm">Offer Letter, dated as of April&nbsp;
19, 2019, between Scilex Pharmaceuticals Inc. and Jaisim Shah (incorporated by reference to Exhibit 10.17 of Amendment No.&nbsp;1 of Vickers&#146;s Form <FONT STYLE="white-space:nowrap">S-4</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;
333-264941),</FONT> filed with the SEC on June&nbsp;27, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.17++</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d21.htm">Offer Letter, dated as of April&nbsp;
27, 2022, by and between Scilex Holding Company and Elizabeth Czerepak (incorporated by reference to Exhibit 10.21 of Amendment No.&nbsp;
1 of Vickers&#146;s Form <FONT STYLE="white-space:nowrap">S-4</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-264941),</FONT> filed with the SEC on June&nbsp;27, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.18&#094;&#094;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-22.htm">Commercial Supply Agreement, dated as of February&nbsp;
16, 2017, by and among Scilex Pharmaceuticals Inc., Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.22 of Amendment No.&nbsp;
2 of Vickers&#146;s Form <FONT STYLE="white-space:nowrap">S-4</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-264941),</FONT> filed with the SEC on July&nbsp;21, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.19&#094;&#094;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-23.htm">First Addendum to Commercial Supply Agreement, dated as of August&nbsp;
31, 2017, by and among Scilex Pharmaceuticals Inc., Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.23 of Amendment No.&nbsp;
2 of Vickers&#146;s Form <FONT STYLE="white-space:nowrap">S-4</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-264941),</FONT> filed with the SEC on July&nbsp;21, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.20&#094;&#094;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-24.htm">Second Addendum to Commercial Supply Agreement, dated as of May&nbsp;
9, 2018, by and among Scilex Pharmaceuticals Inc., Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.24 of Amendment No.&nbsp;
2 of Vickers&#146;s Form <FONT STYLE="white-space:nowrap">S-4</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-264941),</FONT> filed with the SEC on July&nbsp;21, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.21</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-25.htm">Third Addendum to Commercial Supply Agreement, dated as of August&nbsp;
30, 2018, by and among Scilex Pharmaceuticals Inc., Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.25 of Amendment No.&nbsp;
2 of Vickers&#146;s Form <FONT STYLE="white-space:nowrap">S-4</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-264941),</FONT> filed with the SEC on July&nbsp;21, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.22#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000110465922099735/vcka-20220623xex10d26.htm">Exclusive Distribution Agreement, dated as of August&nbsp;
6, 2015, by and among Scilex Pharmaceuticals Inc. and Cardinal Health 105, Inc. (incorporated by reference to Exhibit 10.26 of Amendment No.&nbsp;4 of Vickers&#146;s Form <FONT STYLE="white-space:nowrap">S-4</FONT> (File <FONT
STYLE="white-space:nowrap">No.&nbsp;333-264941),</FONT> filed with the SEC on September&nbsp;13, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.23</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000110465922099735/vcka-20220623xex10d27.htm">Amendment to Exclusive Distribution Agreement, dated as of May&nbsp;
24, 2018, by and among Scilex Pharmaceuticals Inc. and Cardinal Health 105, Inc. (incorporated by reference to Exhibit&nbsp;10.27 of Amendment No.&nbsp;4 of Vickers&#146;s Form <FONT STYLE="white-space:nowrap">S-4</FONT> (File <FONT
STYLE="white-space:nowrap">No.&nbsp;333-264941),</FONT> filed with the SEC on September&nbsp;13, 2022).</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.24#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000110465922099735/vcka-20220623xex10d28.htm">Second Amendment to Exclusive Distribution Agreement, dated as of September&nbsp;
19, 2018, by and among Scilex Pharmaceuticals Inc. and Cardinal Health 105, Inc. (incorporated by reference to Exhibit 10.28 of Amendment No.&nbsp;4 of Vickers&#146;s Form <FONT STYLE="white-space:nowrap">S-4</FONT> (File <FONT
STYLE="white-space:nowrap">No.&nbsp;333-264941),</FONT> filed with the SEC on September&nbsp;13, 2022). </A></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit <BR>Number</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.25</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000110465922099735/vcka-20220623xex10d29.htm">Third Amendment to Exclusive Distribution Agreement, dated as of October&nbsp;
1, 2021, by and among Scilex Pharmaceuticals Inc. and Cardinal Health 105, LLC (f/k/a Cardinal Health 105, Inc.). (incorporated by reference to Exhibit 10.29 of Amendment No.&nbsp;
4 of Vickers&#146;s Form <FONT STYLE="white-space:nowrap">S-4</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-264941),</FONT> filed with the SEC on September&nbsp;13, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.26#&#094;&#094;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-33.htm">Supply Agreement, dated as of December&nbsp;
17, 2015, by and between Genzyme Corporation and Semnur Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.33 of Amendment No.&nbsp;
2 of Vickers&#146;s Form <FONT STYLE="white-space:nowrap">S-4</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-264941),</FONT> filed with the SEC on July&nbsp;21, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.27&#094;&#094;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-34.htm">Product Development Agreement, dated as of May&nbsp;
11, 2011, by and between Scilex Pharmaceuticals, Inc. (as successor to Stason Pharmaceuticals, Inc.), Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation. (incorporated by reference to Exhibit 10.34 of Amendment No.&nbsp;
2 of Vickers&#146;s Form <FONT STYLE="white-space:nowrap">S-4</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-264941),</FONT> filed with the SEC on July&nbsp;21, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.28</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-35.htm">First Amendment to Product Development Agreement, dated as of April&nbsp;
2, 2013, by and between Scilex Pharmaceuticals Inc., Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.35 of Amendment No.&nbsp;
2 of Vickers&#146;s Form <FONT STYLE="white-space:nowrap">S-4</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-264941),</FONT> filed with the SEC on July&nbsp;21, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.29&#094;&#094;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-36.htm">Second Amendment to Product Development Agreement, dated as of February&nbsp;
20, 2017, by and between Scilex Pharmaceuticals Inc., Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.36 of Amendment No.&nbsp;2 of Vickers&#146;s <FONT STYLE="white-space:nowrap">Form&nbsp;
S-4</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-264941),</FONT> filed with the SEC on July&nbsp;21, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.30&#094;&#094;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-37.htm">Third Amendment to Product Development Agreement, dated as of August&nbsp;
29, 2018, by and between Scilex Pharmaceuticals Inc., Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.37 of Amendment No.&nbsp;2 of Vickers&#146;s <FONT STYLE="white-space:nowrap">Form&nbsp;
S-4</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-264941),</FONT> filed with the SEC on July&nbsp;21, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.31</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-38.htm">Fourth Amendment to Product Development Agreement, dated as of December&nbsp;
13, 2019, by and between Scilex Pharmaceuticals Inc., Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.38 of Amendment No.&nbsp;2 of Vickers&#146;s <FONT STYLE="white-space:nowrap">Form&nbsp;
S-4</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-264941),</FONT> filed with the SEC on July&nbsp;21, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.32</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-39.htm">Fifth Amendment to Product Development Agreement, dated as of April&nbsp;
30, 2021, by and between Scilex Pharmaceuticals Inc., Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.39 of Amendment No.&nbsp;2 of Vickers&#146;s <FONT STYLE="white-space:nowrap">Form&nbsp;
S-4</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-264941),</FONT> filed with the SEC on July&nbsp;21, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.33#&#094;&#094;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d40.htm">Master Services Agreement - <FONT STYLE="white-space:nowrap">SP-102,</FONT> dated as of January&nbsp;
27, 2017, by and between Semnur Pharmaceuticals, Inc. and Lifecore Biomedical, LLC (incorporated by reference to Exhibit 10.40 of Amendment No.&nbsp;1 of Vickers&#146;s Form <FONT STYLE="white-space:nowrap">S-4</FONT> (File <FONT
STYLE="white-space:nowrap">No.&nbsp;333-264941),</FONT> filed with the SEC on June&nbsp;27, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.34</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d41.htm">Amendment No.&nbsp;1 to Master Services Agreement, dated as of April&nbsp;
26, 2018, by and between Semnur Pharmaceuticals, Inc. and Lifecore Biomedical, LLC (incorporated by reference to Exhibit 10.41 of Amendment No.&nbsp;1 of Vickers&#146;s Form <FONT STYLE="white-space:nowrap">S-4</FONT> (File <FONT
STYLE="white-space:nowrap">No.&nbsp;333-264941),</FONT> filed with the SEC on June&nbsp;27, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.35</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d42.htm">Novation Agreement re Master Services Agreement, dated as of June&nbsp;
15, 2022, by and among Scilex Holding Company, Tulex Pharmaceuticals Inc. and Aardvark Therapeutics Inc. (incorporated by reference to Exhibit 10.42 of Amendment No.&nbsp;1 of Vickers&#146;s Form <FONT STYLE="white-space:nowrap">S-4</FONT> (File <FONT
STYLE="white-space:nowrap">No.&nbsp;333-264941),</FONT> filed with the SEC on June&nbsp;27, 2022). </A></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit <BR>Number</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.36#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d43.htm">Master Services Agreement, dated as of November&nbsp;
23, 2020, by and between Aardvark Therapeutics Inc. and Tulex Pharmaceuticals Inc. as assumed by Scilex Holding Company on May&nbsp;
12, 2022, as novated to Scilex Holding Company, pursuant to the Novation Agreement re Master Services Agreement, dated as of June&nbsp;
15, 2022, by and among Scilex Holding Company, Tulex Pharmaceuticals Inc. and Aardvark Therapeutics Inc. (incorporated by reference to Exhibit&nbsp;10.43 of Amendment No.&nbsp;
1 of Vickers&#146;s Form <FONT STYLE="white-space:nowrap">S-4</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-264941),</FONT> filed with the SEC on June&nbsp;27, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.37#&#094;&#094;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d44.htm">License and Commercialization Agreement, dated as of June&nbsp;
14, 2022, by and between Scilex Holding Company and RxOmeg Therapeutics LLC, a/k/a Romeg Therapeutics, LLC (incorporated by reference to Exhibit 10.44 of Amendment No.&nbsp;1 of Vickers&#146;s Form <FONT STYLE="white-space:nowrap">S-4</FONT> (File <FONT
STYLE="white-space:nowrap">No.&nbsp;333-264941),</FONT> filed with the SEC on June&nbsp;27, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.38&#094;&#094;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d57.htm">Assignment Agreement, dated August&nbsp;
6, 2013, between Semnur Pharmaceuticals, Inc. and Shah Investor LP (incorporated by reference to Exhibit 10.57 of Amendment No.&nbsp;1 of Vickers&#146;s <FONT STYLE="white-space:nowrap">Form&nbsp;
S-4</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-264941),</FONT> filed with the SEC on June&nbsp;27, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.39&#094;&#094;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-59.htm">Office Lease, dated as of August&nbsp;8, 2019, by and between Scilex Pharmaceuticals Inc. and 960&nbsp;San&nbsp;
Antonio LLC (incorporated by reference to Exhibit 10.59 of Amendment No.&nbsp;2 of Vickers&#146;s <FONT STYLE="white-space:nowrap">Form&nbsp;S-4</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;
333-264941),</FONT> filed with the SEC on July&nbsp;21, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.40&#094;&#094;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-60.htm">First Amendment to Office Lease, dated as of September&nbsp;
15, 2019, by and between Scilex Pharmaceuticals Inc. and 960 San Antonio LLC (incorporated by reference to Exhibit 10.60 of Amendment No.&nbsp;
2 of Vickers&#146;s Form <FONT STYLE="white-space:nowrap">S-4</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-264941),</FONT> filed with the SEC on July&nbsp;21, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.41&#094;&#094;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000119312523177931/d378841dex1039.htm">Amended and Restated Industrial Lease, dated as of April&nbsp;
12, 2023, by and between Scilex Pharmaceuticals, Inc. and 960 San Antonio LLC (incorporated by reference to Exhibit 10.39 of Amendment No.&nbsp;
4 of Scilex&#146;s Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-271401),</FONT> filed with the SEC on June&nbsp;29, 2023). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.42&#094;&#094;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-61.htm">Sublease Agreement, dated as of May&nbsp;
18, 2022, by and between Scilex Holding Company and Live Action, Inc. (incorporated by reference to Exhibit 10.61 of Amendment No.&nbsp;2 of Vickers&#146;s <FONT STYLE="white-space:nowrap">Form&nbsp;
S-4</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-264941),</FONT> filed with the SEC on July&nbsp;21, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.43</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000110465922099735/vcka-20220623xex10d59.htm">Stockholder Agreement, dated as of September&nbsp;
12, 2022, between Vickers Vantage Corp. I and Sorrento Therapeutics, Inc. (incorporated by reference to Exhibit 10.59 of Amendment No.&nbsp;
4 of Vickers&#146;s Form <FONT STYLE="white-space:nowrap">S-4</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-264941),</FONT> filed with the SEC on September&nbsp;13, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.44#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000110465922099735/vcka-20220623xex10d60.htm">Contribution and Satisfaction of Indebtedness Agreement, dated as of September&nbsp;
12, 2022, by and among Sorrento Therapeutics, Inc., Scilex Holding Company and Scilex Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.60 of Amendment No.&nbsp;4 of Vickers&#146;s Form <FONT STYLE="white-space:nowrap">S-4</FONT> (File <FONT
STYLE="white-space:nowrap">No.&nbsp;333-264941),</FONT> filed with the SEC on September&nbsp;13, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.45</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000110465922109540/tm2214659d18_ex10-61.htm">Letter Agreement, dated October&nbsp;
17, 2022, between Scilex Holding Company and Sorrento Therapeutics, Inc. (incorporated by reference to Exhibit 10.61 of Amendment No.&nbsp;
5 of Vickers&#146;s Form <FONT STYLE="white-space:nowrap">S-4</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-264941),</FONT> filed with the SEC on October&nbsp;18, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.46#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000110465922109540/tm2214659d18_ex10-62.htm">Warrant Transfer Agreement, dated October&nbsp;
17, 2022, by and among Sorrento Therapeutics, Inc., Vickers Venture Fund VI Pte Ltd, Vickers Venture Fund VI (Plan) Pte Ltd and for the limited purposes set forth therein, Vickers Vantage Corp. I and Maxim Group LLC. (incorporated by reference to Exhibit
 10.62 of Amendment No.&nbsp;5 of Vickers&#146;s Form <FONT STYLE="white-space:nowrap">S-4</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-264941),</FONT> filed with the SEC on October&nbsp;18, 2022).
</A></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="89%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit <BR>Number</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.47#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000110465922109540/tm2214659d18_ex10-63.htm">Debt Contribution Agreement, dated October&nbsp;
17, 2022, by and among Vickers Vantage Corp. I, Vickers Venture Fund VI Pte Ltd and Vickers Venture Fund VI (Plan) Pte Ltd (incorporated by reference to Exhibit 10.63 of Amendment No.&nbsp;
5 of Vickers&#146;s Form <FONT STYLE="white-space:nowrap">S-4</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-264941),</FONT> filed with the SEC on October&nbsp;18, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.48</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000110465922109540/tm2214659d18_ex10-64.htm">Letter Agreement, dated October&nbsp;
17, 2022, by and among Sorrento Therapeutics, Inc., Vickers Venture Fund VI Pte Ltd, Vickers Venture Fund VI (Plan) Pte Ltd, Vickers Vantage Corp. I and Maxim Group LLC. (incorporated by reference to Exhibit 10.64 of Amendment No.&nbsp;
5 of Vickers&#146;s Form <FONT STYLE="white-space:nowrap">S-4</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-264941),</FONT> filed with the SEC on October&nbsp;18, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.49#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000119312523075731/d280460dex101.htm">Securities Purchase Agreement, dated as of March&nbsp;
21, 2023, by and between Scilex Holding Company and YA II PN, LTD. (incorporated by reference to Exhibit 10.1 of our Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;
001-39852),</FONT> filed with the SEC on March&nbsp;21, 2023). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.50</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000119312523075731/d280460dex41.htm">Convertible Debenture, dated as of March&nbsp;
21, 2023, executed by Scilex Holding Company (incorporated by reference to Exhibit 4.1 of our Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;
001-39852),</FONT> filed with the SEC on March&nbsp;21, 2023). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.51</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000119312523097796/d429390dex101.htm">Convertible Debenture, dated as of April&nbsp;
11, 2023, executed by Scilex Holding Company (incorporated by reference to Exhibit 10.1 of our Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;
001-39852),</FONT> filed with the SEC on April&nbsp;11, 2023). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.52</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000119312523108354/d498999dex101.htm">Convertible Debenture, dated as of April&nbsp;
20, 2023, executed by Scilex Holding Company (incorporated by reference to Exhibit 10.1 of our Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;
001-39852),</FONT> filed with the SEC on April&nbsp;20, 2023). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.53</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000119312523254137/d439599dex101.htm">Amendment to Convertible Debenture, dated as of October&nbsp;
11, 2023, by and between Scilex Holding Company and YA II PN, Ltd. (incorporated by reference to Exhibit 10.1 of our Current Report on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;
001-39852),</FONT> filed with the SEC on October&nbsp;11, 2023). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.54&#094;&#094;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000119312523176273/d443585dex101.htm">Credit and Security Agreement, dated as of June&nbsp;
27, 2023, by and between Scilex Pharmaceuticals Inc. and eCapital Healthcare Corp. (incorporated by reference to Exhibit 10.1 of our Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;
001-39852),</FONT> filed with the SEC on June&nbsp;27, 2023). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.55&#094;&#094;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000119312523176273/d443585dex102.htm">Guaranty Agreement, dated as of June&nbsp;
27, 2023, executed by Scilex Holding Company (incorporated by reference to Exhibit 10.2 of our Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;
001-39852),</FONT> filed with the SEC on June&nbsp;27, 2023). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.56&#094;&#094;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000119312523183184/d507324dex101.htm"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Debtor-in-Possession</FONT></FONT> Term Loan Facility Summary of Terms and
 Conditions, dated as of July&nbsp;5, 2023, by and between Sorrento Therapeutics, Inc., Scintilla Pharmaceuticals, Inc. and Scilex Holding Company. (incorporated by reference to Exhibit 10.1 of our Current Report on Form <FONT
STYLE="white-space:nowrap">8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-39852),</FONT> filed with the SEC on July&nbsp;7, 2023).</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.57&#094;&#094;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000119312523183184/d507324dex102.htm">Intercreditor and Subordination Agreement, dated as of July&nbsp;
5, 2023, by and among JMB Capital Partners Lending, LLC and Scilex Holding Company. (incorporated by reference to Exhibit 10.2 of our Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;
001-39852),</FONT> filed with the SEC on July&nbsp;7, 2023). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.58</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000095017023041842/sclx-ex10_9.htm">Junior Secured, Super-Priority <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Debtor-in-Possession</FONT></FONT> Loan and Security
Agreement, dated as of July&nbsp;28, 2023, by and between Scilex Holding Company, Sorrento Therapeutics, Inc. and Scintilla Pharmaceuticals, Inc. (incorporated by reference to Exhibit&nbsp;10.9 of our Quarterly Report on <FONT
STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-39852),</FONT> filed with the SEC on August&nbsp;11, 2023). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.59</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000119312523240648/d440182dex101.htm">Consulting Agreement, dated as of September&nbsp;
20, 2023, by and between Scilex Holding Company and Elizabeth Czerepak (incorporated by reference to Exhibit&nbsp;10.1 of our Current Report on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;
001-39852),</FONT> filed with the SEC on September&nbsp;22, 2023). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.60#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000119312523242508/d537034dex101.htm">Securities Purchase Agreement, dated September&nbsp;
21, 2023, by and between Scilex Holding Company, Oramed Pharmaceuticals Inc. and Acquiom Agency Services LLC (incorporated by reference to Exhbit 10.1 of our Current Report on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> (File <FONT
STYLE="white-space:nowrap">No.&nbsp;001-39852),</FONT> filed with the SEC on September&nbsp;26, 2023). </A></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="88%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit <BR>Number</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.61#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000119312523242508/d537034dex103.htm">Subsidiary Guarantee, dated September&nbsp;
21, 2023, made by certain of the Company&#146;s subsidiaries in favor of the holders of that certain Senior Secured Promissory Note dated as of the date thereof due March&nbsp;
21, 2025 in the original aggregate principal amount of $101,875,000 (incorporated by reference to Exhibit&nbsp;10.3 of our Current Report on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;
001-39852),</FONT> filed with the SEC on September&nbsp;26, 2023). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.62</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000119312523242508/d537034dex104.htm">Security Agreement, dated September&nbsp;
21, 2023, by and among Scilex Holding Company, the Subsidiaries of the Company party thereto, Oramed Pharmaceuticals Inc. and Acquiom Agency Services LLC (incorporated by reference to Exhibit&nbsp;10.4 of our Current Report on <FONT
STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-39852),</FONT> filed with the SEC on September&nbsp;26, 2023). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.63</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000119312523242508/d537034dex105.htm">Subordination Agreement, dated September&nbsp;
21, 2023, by and among eCapital Health Corp., Scilex Pharmaceuticals Inc. and Acquiom Agency Services LLC (incorporated by reference to Exhibit&nbsp;10.5 of our Current Report on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> (File <FONT
STYLE="white-space:nowrap">No.&nbsp;001-39852),</FONT> filed with the SEC on September&nbsp;26, 2023). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.64#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000119312523242508/d537034dex106.htm">Stock Purchase Agreement, dated September&nbsp;
21, 2023, by and between Scilex Holding Company and Sorrento Therapeutics, Inc. (incorporated by reference to Exhibit&nbsp;10.6 of our Current Report on <FONT STYLE="white-space:nowrap">Form&nbsp;
8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-39852),</FONT> filed with the SEC on September&nbsp;26, 2023). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.65</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000119312523242508/d537034dex107.htm">Assignment, Assumption and Release Agreement, dated September&nbsp;
21, 2023, by and among Scilex Holding Company, Oramed Pharmaceuticals Inc., Sorrento Therapeutics, Inc. and Scintilla Pharmaceuticals, Inc. (incorporated by reference to Exhibit&nbsp;
10.7 of our Current Report on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-39852),</FONT> filed with the SEC on September&nbsp;26, 2023). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.66#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000119312523242508/d537034dex108.htm">Letter Agreement, dated September&nbsp;
21, 2023, by and among Scilex Holding Company, Sorrento Therapeutics, Inc. and Scintilla Pharmaceuticals, Inc. (incorporated by reference to Exhibit&nbsp;10.8 of our Current Report on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> (File <FONT
STYLE="white-space:nowrap">No.&nbsp;001-39852),</FONT> filed with the SEC on September&nbsp;26, 2023). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.67#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000119312523242508/d537034dex109.htm">Letter Agreement, dated September&nbsp;
21, 2023, by and between Scilex Holding Company and Sorrento Therapeutics, Inc. (incorporated by reference to Exhibit&nbsp;10.9 of our Current Report on <FONT STYLE="white-space:nowrap">Form&nbsp;
8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-39852),</FONT> filed with the SEC on September&nbsp;26, 2023). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.68++</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000095017023063810/sclx-ex10_12.htm">Severance and Change of Control Agreement, dated as of November&nbsp;
8, 2023, by and between Jaisim Shah and Scilex Holding Company (incorporated by reference to Exhibit&nbsp;10.12 of our Quarterly Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;
001-39852),</FONT> filed with the SEC on November&nbsp;14, 2023).</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.69++</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000095017023063810/sclx-ex10_13.htm">Severance and Change of Control Agreement, dated as of November&nbsp;
9, 2023, by and between Henry Ji and Scilex Holding Company (incorporated by reference to Exhibit&nbsp;10.13 of our Quarterly Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;
001-39852),</FONT> filed with the SEC on November&nbsp;14, 2023).</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.70++</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000095017023063810/sclx-ex10_14.htm">Severance and Change of Control Agreement, dated as of November&nbsp;
8, 2023, by and between Stephen Ma and Scilex Holding Company (incorporated by reference to Exhibit&nbsp;10.14 of our Quarterly Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;
001-39852),</FONT> filed with the SEC on November&nbsp;14, 2023).</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;23.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d559675dex231.htm">Consent of independent registered public accounting firm. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;23.2**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000119312523302123/d559675dex51.htm">Consent of Paul Hastings LLP (included in Exhibit&nbsp;5.1).<B><I> </I></B></A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;24.1**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000119312523302123/d559675ds3.htm#sig">Power of Attorney (included on the signature page to this Registration Statement). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;25.1&#094;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Statement of Eligibility of Trustee under the Indenture.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>107**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1820190/000119312523302123/d559675dexfilingfees.htm">Filing Fee Table. </A></TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Filed herewith. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Previously filed. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">+</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be filed by amendment or as an exhibit to a Current Report on Form
<FONT STYLE="white-space:nowrap">8-K</FONT> and incorporated herein by reference, if applicable. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">++</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Indicates management contract or compensatory plan or arrangement. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">#</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Certain of the exhibits and schedules to this Exhibit have been omitted in accordance with Regulation <FONT
STYLE="white-space:nowrap">S-K</FONT> Item&nbsp;601. The Registrant agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#094;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be filed separately under the electronic form type 305B2, if applicable. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#094;&#094;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Certain identified information has been omitted pursuant to Item&nbsp;601(b)(10) of <FONT
STYLE="white-space:nowrap">Regulation&nbsp;S-K</FONT> because such information is both (i)&nbsp;not material and (ii)&nbsp;information that the Registrant treats as private or confidential. The Registrant hereby undertakes to furnish supplemental
copies of the unredacted exhibit upon request by the SEC. </P></TD></TR></TABLE>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Item&nbsp;17. Undertakings </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned Registrant hereby undertakes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To file, during any period in which offers or sales are being made, a post-effective amendment to this
registration statement: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To include any prospectus required by Section&nbsp;10(a)(3) of the Securities Act of 1933;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect in the prospectus any facts or events arising after the effective date of the registration statement
(or the most recent post- effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in
volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus
filed with the Commission pursuant to Rule&nbsp;424(b) if, in the aggregate, the changes in volume and price represent no more than a&nbsp;20&nbsp;percent change in the maximum aggregate offering price set forth in the &#147;Calculation of
Registration Fee&#148; table in the effective registration statement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To include any material information with respect to the plan of distribution not previously disclosed in the
registration statement or any material change to such information in the registration statement; </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Provided</I>, <I>however</I>, that
paragraphs&nbsp;(1)(i), (1)(ii)&nbsp;and (1)(iii) of this section do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the
registrant pursuant to Section&nbsp;13 or Section&nbsp;15(d) of the Securities Exchange Act of&nbsp;1934 that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule&nbsp;424(b)
that is part of the registration statement. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective
amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To remove from registration by means of a post-effective amendment any of the securities being registered which
remain unsold at the termination of the offering. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the
registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration
statement in reliance on Rule 430B relating to an offering made pursuant to Rule&nbsp;415(a)(1)(i), (vii), or (x)&nbsp;for the purpose of providing the information required by Section&nbsp;10(a) of the Securities Act of 1933 shall be deemed to be
part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As
provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration
statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. <I>Provided</I>, <I>however</I>, that no statement made in a registration statement or
prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time
of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such
effective date. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any
purchaser in the initial distribution of the securities the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used
to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell
such securities to such purchaser: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be
filed pursuant to Rule 424; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or
used or referred to by the undersigned registrant; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The portion of any other free writing prospectus relating to the offering containing material information about
the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The undersigned registrant hereby undertakes that, for purposes of determining any liability under the
Securities Act of 1933, each filing of the registrant&#146;s annual report pursuant to Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan&#146;s annual report pursuant
to Section&nbsp;15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such
securities at that time shall be deemed to be the initial <I>bona fide </I>offering thereof. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To file an application for the purpose of determining the eligibility of the trustee to act under subsection
(a)&nbsp;of section 310 of the Trust Indenture Act (Act) in accordance with the rules and regulations prescribed by the Commission under section 305(b)(2) of the Act. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act of&nbsp;1933 may be permitted to directors, officers and
controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act of&nbsp;1933
and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection
with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is
against public policy as expressed in the Securities Act of&nbsp;1933 and will be governed by the final adjudication of such issue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="sig"></A>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of&nbsp;1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets
all of the requirements for filing on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Palo Alto, State of California,
on the 8th day of January, 2024. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SCILEX HOLDING COMPANY</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Jaisim Shah</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Jaisim Shah</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:<I> </I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer and President</TD></TR>
</TABLE></DIV>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of&nbsp;1933, this Registration Statement
has been signed by the following persons in the capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="21%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Jaisim Shah</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Jaisim Shah</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Chief Executive Officer and President<BR>(<I>Principal Executive Officer</I>)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">January&nbsp;8,&nbsp;2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Stephen Ma</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Stephen Ma</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Chief Financial Officer<BR>(<I>Principal Financial and Accounting&nbsp;Officer</I>)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">January&nbsp;8,&nbsp;2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Henry Ji, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Executive Chairperson and Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">January&nbsp;8,&nbsp;2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Dorman Followwill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">January&nbsp;8,&nbsp;2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yue Alexander Wu, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">January&nbsp;8,&nbsp;2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Jay Chun, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">January&nbsp;8,&nbsp;2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">David Lemus</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">January&nbsp;8,&nbsp;2024</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Jaisim Shah</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jaisim Shah</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attorney-in-fact</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>d559675dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consent of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the reference to our firm under the caption &#147;Experts&#148; in Amendment No.1 to the Registration Statement (Form <FONT
STYLE="white-space:nowrap">S-3</FONT> <FONT STYLE="white-space:nowrap">No.&nbsp;333-276245)</FONT> and related Prospectus of Scilex Holding Company for the registration of common stock, preferred stock, debt securities, warrants, rights and units
and to the incorporation by reference therein of our report dated March&nbsp;7, 2023, with respect to the consolidated financial statements of Scilex Holding Company included in its Annual Report (Form <FONT STYLE="white-space:nowrap">10-K)</FONT>
for the year ended December&nbsp;31, 2022, filed with the Securities and Exchange Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Ernst&nbsp;&amp; Young LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego, California </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">January&nbsp;8, 2024 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g559675g07a07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g559675g07a07.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1I@4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &D2^9R0X0DE-! 0      " < 5H  QLE1QP"   "   < E  #%-U;FEL
M($MU;6%R-#A"24T$)0      $$M$)#GZ[RR$/',=1P2B3B(X0DE-!#H
M .4    0     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $
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M;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L
M  !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG
M3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^            !"<F14
M56YT1B-2;'0               !";&0@56YT1B-2;'0               !2
M<VQT56YT1B-0>&Q 8LB40         IV96-T;W)$871A8F]O; $     4&=0
M<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M     %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M        $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O
M;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T
M4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0
M    $ .__C4  @ ! [_^-0 "  $X0DE-!"8       X             /X
M #A"24T$#0      !    '@X0DE-!!D       0    >.$))30/S       )
M           ! #A"24TG$       "@ !          $X0DE- _4      $@
M+V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@
M  8       $ -0    $ +0    8       $X0DE- _@      '   /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H     /______________
M______________\#Z   .$))300(       0     0   D    )      #A"
M24T$'@      !      X0DE-!!H      S4    &              %<   #
M P         !                          $              P,   %<
M                      $                         $     $
M  !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   %<
M     %)G:'1L;VYG   # P    9S;&EC97-6;$QS     4]B:F,    !
M   %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N
M9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E
M;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &
M8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M    3&5F=&QO;F<          $)T;VUL;VYG   !7     !29VAT;&]N9P
M P,    #=7)L5$585     $       !N=6QL5$585     $       !-<V=E
M5$585     $       9A;'1486=415A4     0      #F-E;&Q497AT27-(
M5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N
M=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N
M96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R
M5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/
M=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M
M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@
M      P    "/_         X0DE-!!$       $! #A"24T$%       !
M  <X0DE-! P     $ (    !    H    $@   '@  "'    #^8 &  !_]C_
M[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$  P(" @)" P)"0P1
M"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,# P,# P1
M# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( $@ H ,!(@ "$0$#
M$0'_W0 $  K_Q $_   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $%
M 0$! 0$!          $  @,$!08'" D*"Q   00! P($ @4'!@@% PPS 0 "
M$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:B
MLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9V
MAI:FML;6YO8W1U=G=X>7I[?'U^?W$0 " @$"! 0#! 4&!P<&!34!  (1 R$Q
M$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"
MTD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&
MUN;V)S='5V=WAY>GM\?_V@ , P$  A$#$0 _ )]8ZOUBOJV?75G93&,R+6UL
M;98&@!S@UK=OYJ<]8<>.K=6;QRW=&GN_[4,_.7J*2K?=C9]?X?\ H3L#XOC$
M8Q^[ <( L2AZO\;#)\KZ;UCK#^HX;'YV4YKLBIKVNLLVD%[0YKI_-0:NL]8W
ML]7/SO3W>\L?87;9]VS=[=W]9>LG@K%KM=M!=<3(^B2\0?[*:>7(K]9^'_H3
M+C^*XYF1'*Q&@&\?ZW^J>'LZKE"LFOJW4WV[9:QS7-;NGZ#[/7=_GL8]0Q^K
M]9)MW9V68HN(W66 ;@PEA7?.?8W4N($:2ZV/\Y NR;J U[,C7< 728$@_2]4
M;$#@(UX_P_\ 0E\?B$""/N\23L9&'_<87AQUK.^S$GJ74?M7YK0YWI?2_.?N
M]7^;_D?31!UCJ&S&.1U#.8QU5A+J7N<[?ZMK:R]KW,;MV#]Y=C^ULK_N4W_P
M/_R*7[6RO^Y3?_ __(IOM?US]G_H:X\X/_$T-[^?PX:']'>2P^K9KNH4,KZE
MG75DOW^L7,&E;RWV-LM_/_E(%/6<EU%9MZKU-ENW](ULO:3_ ,&\W,=]']YB
M[9O5,AT[LQK(XGTS/W-3NZG> 2,UCCX#9_Y%'VOZY^S_ -#6_?!?^YX[ ?,.
MG%_Y3<'Z;QU76.H^CANLS<AU;\C);8;+KJY8&X_I>M91ON:UF_=^C:BNZGEM
MR,04=0N=OR*F/:W,NN.W=#]['U8[6U6+J?VME?\ <IO_ ('_ .12_:V5_P!R
MF_\ @?\ Y%+V_P"N?L_]#0>:O_P/']+]/T^J4I?+[/\ 6>1R>L9C>H9S+^HY
M];6WVMI%#BYHBRQNUP>]FUC6[=FQ1HZOU(XN2ZSJ&8&-OH:+ P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #> >T# 1$  A$! Q$!_\0
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M=F;VY$@>;NMCITY:^& ^7]XG0YV@L-GP\PN"'C_AV.?W,]=!VRY^3;R9D_\
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M#_R.OJ/Z]J^1OZAI;D#KC]F?S-T@=DNVYUU[19P+7^IK9XZ'7PUTY=>>/"$
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MI:FKIJFO%)3/#/+65--'%&MC(R[,37D\+8/JXKMC27%C;%E1\/-4>6F5I5W
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ML&P@ P4-G'4! 0SD<@(<@R.NEV]_;?GW_73>_P#T,5OOCG?F>2C'BWS*!_\
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M^=+V-[@WO:P'J&(Y D<[V&H OK>]K CD3H!?QZ\0'<1P #G8<YY_*(<ASG&
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M[(44$FS>42-QRS4MR$JZN-?U60:)'.B+TT4 7YZWQC_W0R8<QC\Y$?S'AQW
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M5=X<2QMS%^73%MME.UEI(Y'V:[1&EBWA%(V3[2F2/B !Q&QIMY.(H ;=(WP
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MG6<NT;OFV9N\+%X7:OJF:)V1XF>-C*2C-'(\992"4=T)W6(/R]Q%%_8A2_W
MBOXIJGNE+_)J?^AC_NXK\OY[\-9M]D:S\-A[B:,^Q&F/N!%?Q33NE+_)J?\
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MF :3)*TJWNS ;B1V9K!TW;!;DW<68]7?4WO;%VGR7*DRVKI4G,JSPF&KS O
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MV4$JH(+HJ]GL*%,-15E1)"K!).,$8@A7-/-+33A3:S&&H@FAD U26*1&LR,
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M8X;KZ^B;G2P!N0/OW!UT]@U&'>D /RPOJ^B#&^.>_L_=Z;KCQUTN018VUZD
M&X/2VNO/$;KF]@VEN2DWO_[)M][0^. G(']67V]H,??QJ;K87(U%B+_'ZS<:
MVUQ-FM>S6\0IY_>]GLZ\Y Z?(3%WS_5!R#'K\?# XVW$0Q%P.5M/7H;@WUYG
M6W/G;I8G$68]#[2IZ]!]J_(?'I@)R8_)EQMMV@]GCSZ?+MZIN/$:@Z#0Z^.M
MOE(U\3:TV)%PK>-K&_KYV^3H/9AVR!_5E'(?VP?P]/7X^&!$2+C46!OSYFP
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M.8?V<'&WCEN(_+G..>=/-S(KW\DT/UO']\=>1\1]L>UOM,)OY\;2_96JU_\
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MQF9NYM'M%G4PJ*-@#!.V[F)"-(IWMQK$<BHMZ5!&Y%4 '.G?;[BJ,QRW$ "
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M(L8/_M;H'IS_ $P=-1YPY!\.9/\ 9.B_#X>Y7VG_ ,W&WO\ 4_:'_#L/A/\
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M[0_X=A\*#AIY_"'L9CQ]]N@?Y0:><&0?#F4?9*BZ\O\ +X>Y7VG_ ,W&WO\
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M5QX<R.GAK\@O[+X8YYSD/ ,!X!GP]>V_JU'A8D"UQR%^MK7'VK6\;'1;QO\
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M97;X(I*&G8">BRTN8XV2.KK>+5)%W:\&'E&+F-73&GY_@@XF'D^G1L!-2LM
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MU4O&Q,BH^3DWX-5")-09HG>I1R+DRL@V2=&6>KHN"$39M#JN3(@F=58$Q,F
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M$CS9HQ4(-_AAERU9.)-,6573=9E@5P<4N/>>+3WJ-[,)Z"- -UW*4=35T\A
MXA5JAJ<PF$@O&S7!D=3$;BI'CQM5-4I?*L*E(C2L;9 L_,/FJ,ZSGWU4T-"@
MDLC7--N&[9C3\Q"RC-]#.$5("?GD(UQ+MH><>1DVFO'$QS+N4<-5,CQR/4PT
M<M+8M-354_<DCAE71BS35J)')&C0SQ@2TTLV\R1U\/>K'I8F61!3-5Q5(91%
M/ C5XD>,@LH"+E\Q='=)XV5UGAA54>3#U3^5EX<8\LPQI1A5U3U'&KVL291S
M]DA2\/+)W5I!"X,6LC4;I6009^C*+4/(/47K%)=S*@A QZ;EXL<Z&QCHIWJ8
M*8A5,F;QY3(U]XQNV<MDDDZJ![\BU<<QC16#RQ1&4\.$\48[2HM)WPDB-\IK
M,U@T_5%I*&&N,$AO:G=EJ:>-I)/>XWD* R3*L+Y2JGCVM];^8KP]P(=.E:0H
M:[_O)J2#BHDUZZDZK5;4RZ83"%N3Q#5<E%R:4\Z<,*@1J%XNX8QJ3Y.*.A)H
MBCBTJFJ&6! 1-F]?+EU'%:^[/'FE;E8%6UP*82R435,>D@[I+%-(R L%O582
MD2N=Y RY?0P9A4E;6:GFR],PD-.0S<9Z=9H:65/0;O9EA4$Q R8M2\KKPEO9
MNX]*1CRM%ZMMNWE#R<([@6[0'B[*3AH9B";U"1?IL8^6D)UGW$M))MF;5BA)
MOWPMT8UV"=DNYRT9G%'OQ/34]0B,P1OGIZ-((Y6LRQ,3F-$S_3;BS7 9D9<7
M&BX=='0S-N/(U4.(JF1=RB\H=Y= "&?AG*JT*HL7*1D6656Q>MM_*3V2N51;
M>?AX>J7%5$=6C@Y>B(GT/(KQ]57BHR0K. B&\^_D82*?,F+6'FFDG*J^8*(J
MQQCC&%%P@B;(K(S2QS3H1-3Q9CG^6B8^]@R[-T;5^93.MY&6".E1I%:,322,
MCPQ1R3(8\6D%ZEZ5_1FCI<JJV52)-Z/.<P3+*!(F!"--+4R1!E=HXXTECE>5
M8F#XQ2KY7:R*516P@@H2OG3>N8:GWU0S31%N+"E):L:1I>IZ2A(])\FP>U2>
M45JJ.C7KHK:#/$D79RBK-PS=F\VNST_!ES! V^M"FT!5K*'GDV=J4@K(Q&'8
M1B11/)!(7=7,<:?2S<5)C1I#"FBRR3T$;@F\<45?3552DS2Z!N&*<*T:KO$M
M*%._#PY,EN?*:6+:T!&7*6AZQ1IP9^:IRHD%H](LU$R$)9\MXERQ3-%1PPJ)
M->$7:,6[LDK&QJSE5<Z+]4S<K=PEIGBJ9J8D.T:5G#9"I$D])M1D^RK1$.R<
M-'KLXBF64DGNRK+PS'(7C(IDC,BZ "FD8."H%/4Y7F>:I*& ;><097,AB4$B
M8M$SK+&4/6JCRD-#4]4M(&0H*<E+6U-82A;_ +NOD7K\9N&IZX58.:'I^'5H
MAA3$HDI**SQX=!55[5D4R(E(N5A6!.,.9S:>)HILSAFT\G5.34N]$#-WB7/(
M,QEHQ&"(]TEZ%(RI)<K4B0+[TZ&E[*E 4LTE:VT*E&*HM/YM394F8/)("^]&
M(LQFD1T4J7HQ%?YY22/J4=Y42R=0MJE),4?<2!EJ.7NT\JEFA&Q\C'0M(6DJ
M2%@9>KW$O(/Z?!9LZ2JFEGBL,U8KSL2K*N&[U@+..5E%H"'NL%4654DBRGC$
MFZPU.;+0"&!7_P O&LV80Q=[C7@$+*9##+#/#%7+&\<IC"L^^9VIP .+-!!'
MFDKR/%<F&41Y/6L:5V,_HPF-9$J('DJM.^5"X:JSFWM.40VN)6,Y&T6PN&_B
MX"G8A9ZVH]Y0KBXBLMYN\J1D=TK'TVU54=Q,?YY,&>F;,FC!TJ\:]\>-HUED
MEM'# M6]1.;M'!'13T---)($#2%>\9C3QJ8T<Z3LX5:>4K2H+U"TJ6>HDJ8*
M2*,,HXL\_?BBI(Q6(*$R^HD+O(B%#$59C*@._%)5-&5K2]/5A"^<C#51"QL_
M$&>("U<JQ<NT2?1ZZS8QC'0.NT716[E0053!0"*E(H!B%KJ()*:>6GF&[- [
M12I<'<D0[KH2-"48%6L2+@V)%B;4,J3Q1S1DF.50\;$$;R-JC@&Q =;, P#
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M7T!Y6'4^KKRY_E?'$YR)D,HH8B::9#'4.<P$(0A"B8YSF,(%*4I0$QC&$
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MO-^Y%V5NH=T=N18.P1<O>G11,HFDN()IF[X%DBB HG'5(IP0_O\ $2'" AK
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M4<MC%TTUS^;E]C>9'R8GX'/&GG\^EE/DI:>_E>'+GT]6GFA)\*$VOSHTZ_\
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MA]?H,-.H^GU!TN/M:8'LTR C6IS<BXT:LA.H((YTM@00""-01IK;$!Q%UR.
M",I(1$<  0SD!SG;E)" ].N1VR.GE&<FP2$DV LC7/@-'U]F'N;9"-359P+7
M-^^Q&P&O\E%O'E]W';=7ZN2Q$?/:>IYF("GD7-/2#<<J%4,G^7/R?EA$U13#
M;ME(<2Y HXDYA4*2&CB4\B#&P/CR+"QL0?'4'PQ9BV V8J+<#,\QG%F(X694
M\M@A4,?0ISHI90W\4LMQKC-7#1Q&.3WLHMO7<A0U+4ZZ+4A',L^[F!2253I2
M;6:I%D9*4!LF=9PBDF!#@)E .*9 R<!#,R[-52M@[U)2T\1XH,DC"$;W"D(
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M9)RV<I)KMW""A%D%T%B HDLBJF)DU4E4S%.FH0QB'(8#%$0$!UL 0P#*0RL
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M>X! !QD ' Y#(9P/B'@/KTPQ.F&&F&/SV\3#Q..XGKB2"J1ETF-:,WBB!!1
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M TDRP('6X?\ 5&"V N/IS8 G&?'M1D\L.43QYI&T6>U#4>5,&D^>JE(YY'@
MW=Z)XQ331RK,(^'.G >TQ5#9?<(" _240$<A^5D'&/5V=\8QL(!RYCK$('7I
M:]A8_+?K?[1UQN^(_P#'?7GZ37]G.UO'V>W $$!V%!/<!#9(@8$  !'8N>8C
MOTSRU-E]1MJ=!R))%R=+6^/3GR&)XDG\=O7Z1U]OC@#=#?Z0EN'/NB[[Y /R
M(A@,] P.,AMD >CRTM?Y.FMR#>U_9;EIJXC_ ,=]>?I'X^O7#S=OG'<)^WNT
M]_5^1#KMGGD0 1#J !L;#V6MUYZ<[CEJ1[<1OOIZ;:?^D?M:Z>O 4&V0^D)
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MB"Z1^RLW<)*MUR)K)*$+[)3U,%7!'4TTJ3P3+OQ2QL&1UN1<$>!!!!L58%6
M((Q\"YKE.99'F-7E.<4-3EV94,IAJZ*KB:&>"0 , Z. =UT99(W%TEC=)(V9
M'5C<&KV-?AIAAIAAIAAIAAIAAIAAIABESD;Z9A9B(!5-'TK%OXWOE4/.DDO/
MFBK;O5&W>H><$3[WMF0[Y'O2@).]3[7;#'K(#54E53!^&:BGF@$F[O<,RQM&
M'W;KO;A;>MO+>UMX<Q>IY>!403E=\0S12[F]N[W#=7W=ZS;N]:V]NM:]['EC
MRQMAY/6^EF;5PUKJ$XW*F@6C!K4!7$M%6QBX=W+SDG;ZWU%0$BNU/6$G'MDJ
M8<49+RS6.BFK 9@:E4=3[J4JMK*5=4.;+*9FA)%A TCHI)99-_.*C-764#=)
M22&H>BE6(Q(L44;P) #(C6SN-/43;@43R!V2/= 110FC"HS*Y]&58:E&D#OO
M\2-F9#3K3C< G$Y*U?2]?3W'Q5,E4=))7,C8M]&6T=0ZRD%7%,Q4'$Q+AP6Z
M3]HY"D9R+/5S0TC%RC-S,N 3/'(D;=XO;!X<=6(1N2U='EE.93Z5I,N>N=:E
MD-U=JA:Z1)5!0A&E$<B\1#%<:572&)D][AFJ)"-[5N\30RR)=0A7<6GAB0J1
MZ,$+.&M(LN7ZOX/+J5/<:(N3%\4M04E53&TE"6XF74%2;SSV5?4A3=WD%JA!
M5:OC(,HVH[@U[1=P9:F5F#YK)KVKC(&9D)EI+'<Q5YY(@<VX$ B3,)JV:F4M
MO]R>>'*H*,,Q7YX&7P4>9+ "(@),YFJ$$<\"R2VR0Z9:LJ[QHB-]]%:HC:J[
MQ5*-Q8UB-2(Z2&9E!O'2HFZ(VX:_"T?"IQ/T#=V.N!7/')5MT:3;2$@[=6JD
MJ /%1+J(7H^2@&4$E)^^%))IDBI]\SJ4DTK +R+U6.1:O1,LX4?EA9(TIY(C
M LDK9?'3";>W&%8DS2/7VW7W7GC6. PJP2,([(_OLBFW(I<4H1N#P:J::4B[
M]X@=(DCIF^ELL!$SAQ<R-,N\BB&.V+Z X,>,1Q'0M5U[QMU9 7%4IZ0B91I!
MTE'U&C%$?M'1 C25')SB"D]'M9L[:IT07BF)DY!,6;06<9V6A#.B4[0Q+>26
MAI89)3=1WJ),RD:<Q^GO21U-= D<A<,:>CFB)*UI,%YG1JB20Q*(5KZR6&.]
MV%+-4T 2,-8</?HJ*5&2S*DM8LH EI$:3G<[@)XG+C49.4D7CRJ.,"KX)I3]
M7NY&U;R?2E8M&,J>(<QS:/2NU!,F+5PRJ)(#N"(GEEGD2TDGLB[>&*="N">.
M',:"L,"R4]'6K7/1LQ45,T>79%2P[THN8EAS#*:G-XU1"BU&921;ICB=JFAF
M<TO 5BDNXL0J  Q$1S',*N="C [YJ*2LARQV=B13TBLFZ9%2+O7P\G ]NQ=N
MJKV4QQ!3MLKG/:GMU4-'S4'3LNX3HUI1E#I4L_9/(EE<2"8U6O4,S&Q%0M9"
M7022@DF+^&:,'1)N5?KT44O<YA*JB16SFJS*HC>V[/35&7QT(R\@A@BJ!-))
M.%+2K.T0BC4%GJE99X*>&6,$4^4466HRL4+3TN<5&:/6%E <B6.=:04Y<A#%
M'4-+(R11Q77%\)?%VUE*E=R?'U5$A'SE3Q\O'Q[2U+./"GX)O6<543ZFHQ=[
M7<VJ4'T,UE*=/*K'6,1%^S.@P;LV+R/F**0I3BBXZ&J--)$]0&?<6L5(<U1X
MWLK-&C2UN7S *S,PRM(Y'?O+O'8G1I4K5C<PM4HRP.JJQHSNT2AT#7$C%:>J
M4GWL*U=)(B[\4!CN^Z?"17U91?$46@^(!_9JL+[5-:NHX.IZ7IA^J-&R%KI5
MN].\.S:5O3TM/R%80,?'T[4@-ZCA69FD:DX;M2-558LM,!,--!3V#&/-<US*
M1KD*R9CEM+ER4T:7(1::6E7,ED<RAJZ:0F/=L6RQ,HK#5M&''D>ER@(VZ21!
M4UM2T[L4*,TG?YJ8*L2.M,L:<9G177&=;\"-\JG<1+")XQ)B'HTMPHJO:OIJ
M6MK(U.[K<T/&6S291DO43BZS!]WC:?M^[J-K*+(O'+=:>)&E2&/B@3D+]/.*
M>JCG$2M#3NSTE-<A8#Y?K\X1C)9C)(*2IILKDD*!IDII:J7?EJBD.*ZLU,L0
M=A.U.T%54FS&I+Y.F62-PR!PD:?BUR1*Y$1:.GB94BXC^DT065:0[ E1R$:^
MF$&:)9>2C6"T-%NGI2 #ARSCG<E++Q[513)DFR\H^41*($,Z5$.V-@E;Z @:
M"Q()OH#J O-N0M<7 N2+FH ZWU-V.@Y+<D#UE5L"V@)!:R@V%3,8I0[1C%*7
M(!VC" !DP@4H9$0#)C"  '41  W$-1B<<LAG&=^>.N/'3##3##3##3##3##3
M##3##3##3##3##3##3#'YWN*X/Z(BZPYYU*/R $>QST'F(]/W]><9M^R57_T
MO_\ "N/T?[(R/<WV2'.V6<NI/>J@^(O;KI;KBEQ]V8EE;]C0SFF7#]N!8T94
MB<HG&LWCJ%GY^;:.5TP8/C/2R!)M-C)HJ$:K"VBFI478BJ MJ36(8886AWQ&
M\,P4O[V)88JJ%1N6;>C<U/'E6Z[TP*_28R:C8ZLFVBJL_BS6.FD8U:TC-2-4
MS00YAEV64,\<;]XI^ U,<N::DD4RHKUDK/%[V1+D&/OS3# [N;C>'RDD697A
M5 ?(MHXJ<:Z%)JDW[B22I(#,U$EB*+-DTETE"J.A$3'4 BHY*YA%&1(F7QHO
M'1T<!1NF.%8P@<0CTBR&H)4J>(6L "U^:J>SO-JF./+ZKM)SF2=J<1FGDEJ6
M:HB$DSRF2FDS@B994=8I6>-EW(5%@N\F*5.7MA)EXN);(4PC/O)1Y+IO#M(]
MX\<.9:F'4,S4<QSJF%47PED)!M4Z912*W=R;=J<K<O>&6/C/4HV^L=)''(1/
M&-T*VXTPW0XB,>DB,$8= 054*" N?0;"UU%#&3M[FLF6PTL%(T(GJ(8(XJ/-
M8*Z=(JJ'-4> -34LN5.=]I8:6693*=T(/I2E_4F-,4U0,O;!C6J$#WJ#1H\?
MBJ:1?KN:B4+WL4K!R212MO="N1@V8HMUT%D2'4=+D!-!"]Y0$T45.:02\.GX
M$?I;S@[BJTJ@QL1(%0A2FZ0K/O;Q(*V\W[.FES7--H:/:NHR)\P99IY8:<1K
M34Z)EP*K5+7TS'B>3T:IDJ'DCD1K+#&P=Y._*7X9.:>AZ-=V9C$DZ.AI)L5!
MP#58T8N_2B4EI$T:^IE9%J7OVRQUCR";I<_IQX8CM!XJW=IS49BLX56HHUX,
M+PKJ+1AYUDM9HR$1#>)%&[(%*VF#;Y>Q1]GM1#F%;G,.W%6SYW74TS2QF5>]
MQT_?2E.M5!FJ22G<EB*"!XXP<O@#020*\1Z<I?JDG4*O#>\?3;2.=.7TA$$%
MTQ*VC5'WH1%^XCFWN7*@4[A:G&R:RJ/8[PH*MW N!+V@I:OAL5-#&4XM-+$K
M%2(TA,!>-+Q:1U1B<S@65S-(;:F]VE[.\XBKEK5V_P UEJHX(*2M<13F:I$"
MY@],M3+Y6,AX29K*\22!@A$<D>Y>QP=4U7A4)9!-")8PR$A4;Z?49QB+1FP;
MI';(,HB,;,V#-@T30AVQ72:2J;<AG!GBJJA 5,H937N^\J+8#=::1S8#>DF9
M2Q"JH5$58T5$46!WSHI55] RO)O)S0/)65%:]/EE-ERS54DTT\CK-+/65<D]
M1-43-)6RO&61I"(U@1%8J%"X<J?9_36P[/GX[AT]$NQ'U>( (XY_)K09X+T\
M7(GB\C?^*=?#G86UOZL=AE]^[9G_ -!3WMR_7D-M#KJ/ VO\N/ED Y;B(X'G
MVAVR/R[<@Y=<<M<O;G:]AJ+6M<W.AMRM[>9YZ8MXO"WU6^X:L8"L 8&DCP+S
MSY-D5Z$>*ZI4E2)@+H6KT40*HH!Q$&YS' @E 4Q,!PS:&J[C4K4!&D*I.@"R
M&,@S4\D._O%)/I1(6 "ZD 7&-)M'DWG!DF89,U0M*M?"(7G,/>>&O$1VM%Q8
M0Y8(5!,@ OO$,!NG-=)<1SNGH!6)D8.2FY%><;2YIIQ/M!5+Z/-%DCA!B]IV
M0:F=H,8T&#M0!2:2B IF?L552=X.VAV@,4,220-+(LKS/,94(=V6LC<B)Z>0
M*'2MD#H&X3;@8(CR2._$9QV:19EF*UE-7TU!3)0S4:T$>73;A%3WAZD&>#,J
M681/43FH@%VFI'N()U2RBR+D7:"XDI2LBO!+QB5+A)H%:$GG<@DY9O:HD:B2
M(B=\T649N4 D5&2S@YWA5P004(@@DD5OK$J,U%3F-'7F%D:EX'O7'9@_ J))
MT >57<%@ZJ[,)&=@79B6W5WNS6R!V;H\WI4KXZDYIW:0S&@BIVBFARFERR1I
M$IY8TFC=J45"1J(#'Q'0N[,93EF'XK'D5-OI8*6D3-GE8U76IHE&LED8\TC4
MTE 296SAMZ",S?-(\\*L@F5ZT7$R<FX61*U>I-WB>PAVD,30_.TKQ1+4@0BJ
M/#9JBO[[OR(8&0LB-)3J2F]NOOQF-QKR%;V215=!#1C-Z998<FRG(Q6ODJ25
M*TV5T.841DBE[^)H)J@5L<K&"6,*U)'&_&IWDA:CQG$DC%R OD*->+$<4V:G
M7,4I6#E.&8E U/-PDJ:9HQ!!I^4684XS4=/VZJKLTX8)AJJT(@DR&@;0*%E5
MJ61EGIDIBO?' A([OOO2#@MW;>[M&R!=XI(SW9XQ%''FU/9F]53=W;.X5,>:
M>4XJM<FA>LJ"1F;FES69ZPC,J5)\UGCCIY%CA% .YR)(TDE1BWK:7S1MS%34
M<E3+^7-*U$UFTW"]3B@= K*7IZ9:IN -".P5?INJ>1(M)L_1BCMN\=)NT%03
M9 TMY7GHRR*.,4S3.E6E7O&?A@E9:255*F%R&/=#&[1NBR+):2-C'&5V.U&P
M3[35E'5/FE/1K2Y;-0-%'E0<.:BAS3+YG1A71%8#%FKO'2S=Y$$D$312IOU'
M&NBHN)HM34X^AWM(/D7SNF9VF1E$:K$_I!*=48&%[4*"L"8TNXB BV:,-^&&
MOFK<[M 3F*LF9O%3G@J:)Z5J:56:DIZ9I15!Q)P10VGE1H;R3-W% 7WA=79;
MDJC8U66=EQRO-(*Z'.89*>+-J'-NZOE(7NST"UBK3Y<Z5^[1PU9KIY*WWN7B
MRK!(%!1Q+:<%Q 3M.ITJVBT9=G'T[0DO1BK!G4RK-M)NY%*J4VU1'\WBRBB\
MBU*K=JL6ZGG8)';HF2<HJ*+**4KGLR*8H>/&@RQJ!52I*[DIA,(JT*Q*!(BD
M[B$$J2P$@!:^WK>SO+\Q;-9:MZ*>IS+:*DSU*B;*TFDIH*=\I>7+!Q*IA)!5
MKE$"5$B\$N)) T3JJ*O3G;V.)Y6W*[F&<E&A7<9(N6I99+S*2D8MO%,P<QY0
MB <1:TJC#M5YM1VXFU';\3+H'9HD(W&B3.>)4Y=.*<JN7G>2$2JJEV2!6X)$
M0,4)-.CB,K(ZL\J\4KPUCNT&PL=!%M-#'6QGS@BJZ:.;NC\>FIJN6LGX53>L
M,=6*1ZZ6*B$,="D5. DBS2,\F*DI?I26@)" JNG%)@'\(]IU>78S:,5-N8Q:
M9I:69'DWBT'+)24I'(THRB22*C1)1Q&]T19,56J9]0V;B:$0U5,96,$<,LR3
M+!).8I8G$\Q,$H>>18HHI9!8N$+L#(S,V.O9\M'F-/F.4YFM$:>OAS**DJ*%
MZRBAJEH,WHYDI88Z^C:FHYWSBIK#3+*XCJ2YC81R,N.RUXB'3::?2BE(QB[:
M;\UBY^-.Z(=)_1\71Y:)BJ9;.W<:[>QIF\*9V#R62656?.79U3-T#)( E>.?
M,7JN+31M'7FJ-?&KA!,LM.M-2I&QBD>$44:*8#O2,TH:5COD$6INS>*2BI:1
M,YJHY,NWZK+:D0L'ILXJ<[;/ZW,IH8JJ&"J$]?PC%2/&D=-%"(UD</)O:ZJF
M1,JJ+<ATD3**&0355*LHFD)C&3346(DB151,@E*HJ5!(JA@[8)$ P$#G_B^\
M=;"]M-2>IM:UP>0QZ4F^%42,K.%7?95*(SVLS*A=RBD@D*7<J" 78ZGY8  #
M;;GGG@-O9SWVQOD?6 SXZ6YG0@7UYWY]!?ESQ5@ YSC?EOL 9\>@CS ,8Z!X
MZ'0<K#UZ<K :G2_4'U#VAB,Y$,Y$-L"8 V'(=D<!C(;^T!QCGJ +@6TY@6]F
MNNO6^HN.76Q#$@/CG. '<-P#/3&WM#(CRR \A'V?_>TN>ECSO\5[WT.N&'4,
M8#[^0 ?'<<XZ!GD'+4D6!Y];6)\.9Y>%S]\G5C;#AAX2:RXBY!*;=J/Z0M*S
M=F2E*Q! A)&I#H& '$109':*R#I0IA,B]J5=NYA8Q4%6S8DI*(.FC/IMGMEZ
MG/7$TN_39:K#?J;6DJ""-Z*D#*0?!ZA@T:'11(ZLD?DG:CVNY-V;T[T,2T^<
M;7SPAZ3)2[-398L@)BK,_:%TDB0@"2#*XY8JZJ0I+*:2EDBFG]^Z"H&D;84E
M#T/0L(TI^F()!1&/C6@'$I3+KJNWCMPLJ91P\?R#U=P^D'[I55V^>N%W3E51
M94YQ]JHZ.FR^FBHZ.)8*>%2L<:]+DLS,3<L[L6=W8EG=BS$DDX_/O/\ :#.-
MJ,WK<]SZNFS'-*^17J:J8BY$<:0PQ1H@6.&GIX(XX*>")4B@@CCBB1410+PU
ME8TV&F&&F&&F&&F&&F&&F&&F&*3/H*.8*:;(R@0BSB)D4$IDV<1"BS-9,DF/
M9<LQPP,8'6SMJ/TK9P@/TPMBJ4O35"+-W=GAE45%R. 61@)@0\9!C)W]'3E]
M,O,78&"SPL8^,%EC8P_Z4!P3'JKCTP-W5&Y_2MR/D6YX/']RJ7HFB)'RC4Y6
M\_&I1$K1%3,IQTYJI.J:;G*[FT*JIAO%7F,B[=(QU;P<:J\<-YN<19TO'(%J
M!*#E7<+K9"9>^4]3%3*CT=52UO#4D[]/'DOD6>EG7<W>ZUC0U=;(51.)4U>9
M+.:B-HEIL5$X<4B2R-+'.)('61B(S(,\ILZC*:[_ !H3PJ&S2/PZ1,O-,E--
M'+)69'C.!^O:4I*L =\>U[(QG)U15<W"5"PG'%-P]*M*J95!'HTPX8*5@[@'
M\;"UG,QLW'.4B0T\NZBC1#V6<'E73@,2[&GR^!+&2GI::D21P9%K(U.6]T+Q
MZ-O&&D--$:>6/>IJH(N\W$>>_'9:BME<-(E3+)4.EPKTC U[51IWW61 14F6
M0U$,XCGA,Q $5,E+3%.!F\+6*N[4MO.*ZH:DK>\R7#W3[6MI::K:%>4M05J;
MC/ZFJAG"UA3U95!/2:,S3M2U9#Q4(T<PB#TJC5E4%0N'#^9J%>L$"".D :.%
M\PJ:Z>I4JU3)'4T59#3LRE5BJ9:<340A:4K3M'21.\,@'#:I92H1G59Y*6CJ
M8((I=[@=ZE&6K(+AB]-3M+ETDDFXLM4DM9.!,52%8KAJK@1KAU!.4U>->]D'
M54NRE::-<-W4M9$J$P5%7]"U-%L895&YT2V@%2-*0]R(Q=*%A8Z<0J&064C"
MK&(U.D825$C0(L J:CO/=X]Y@SP0;5,B#>):2&FCSRFG2!P\,0R"GD"*LDIC
M4SK D7&050IUID+3&R\../(H)=X !$>MFRRH:>=0LTK9M+$TCB./?ZD/P'7T
MAY<):8XW+V5]#QK>57C:#4JRYEMT)61"$K!G3;:8KVG;FU#,MF49+U.QE'+D
MU.SA'1Z:@SNXB0.U4*YAW]XK42)./49<**FE+E%HZ@1PP]_1-R56J#'$^\71
MKO(9%*. V+$$>Y+2M+-))'#6+4U 95D-1'WD5+4[#?B(B)'#5 ZCA%HS=&*X
MNF]_#)<B=H>RR;_CAK^R;2VM-C 7#J@L[,,EKI5#/#%(.)*:JI.X%"C'N%'Z
M+M*$3(@HX;FD$F[ 6R*?F*JJ,4U76O&.%#6"BBI*=#PV@[G5/5N4"NRO)6Q+
M'%5HJA6A253OHR\*J%9!34Z-=IX.]232BSAQ4T@I(U?WM25HW<S0R/Z33\*4
M[LF^TG7H;@:K^FD+C2B_%M<JI:JN-3]EX1"XJC5ZC5<9'6EEYR=3(63&L9!M
M(1M3*U%(,W<<@V8-AC%#"_5F91V_EW5SB!& ,80#:"7.JA %03QR23 Y=,FX
M%X4=,\5'&VZ%BBI8.'"C1KNW6E$NZ0%X:T$M)3@,76!IXZ%340EBPN9*-JD[
MXD:6:KGXTDL!6#%A0G#;5<54Z[J3\I56<H>I;DM:GIV(/5@MGBS"/7J"+?T(
MS9+W1>P<BQ4D%2.3HQ%+QY&U21+U!6/4B!;T]%V*0&.&D@%ZF6.*!VE8L\E7
M$$HG$K EVW)PDOIQ.JM!F<R$R;E"]-;J5WY*N4;T".9H]PV"4LG$F.ZNZL05
MH$W$"."RO112$JTN8BMM"LO)EWFK7W#+-O*%WI+,6YK*1J6,GY)G452R\7(R
M-'R](2[>,>*W::/(Q[(,*CDU7:SUW)IM$S,F$7'1T>,DA*UTC=VDAEL)0N4M
ME;%M&F^>ZJ>6H,@!+2-.:43;_$9WRV$22$JHBR*B<315D*Q\$5-6]59&L(0T
MM#/3Q*@51N4T=-)% OHQ<&NG/!WBKXVMI_A>NC!USZ?6XC+J2;!ZWO&\F72]
M?5FNU7E+BG00HF-C[<3\I4M(Q,;:5LFHZI>0BI&.(Y=J';R%.+)'!RG3,!+3
MU\$6]2FIH334\R,)I(*J2MJIVKE:15>&6GI94HHXT=XJA2LK)3245.7LHVY)
M2R.J3<.II9:B,J84DIZ.AI:<TPW&;?2OK(Y:ZJ=@DL+ 0K+41552,:ZU5Y-J
M[M9TU4U+U'QU7GFHBK:<B:>F(*92JJ9IA9%C!LXIZ?T/*73>'*B_?)/*A,V0
M>MS+2SANE+N9B+:*1[R\LJK/!,L2[M/FM!F:1$[P H$E"4HD8-((VF:"H!9G
M EIDE>.6<F8512&*/=6YE[G54IF+;K.U55I4/.ZQA%WN LE&1%PB()G2!Z>(
M+$/E27D^N)!]'TPZN;QQ79%_&W#>UG-T5"3=35A0C^+:3]//Z=I@C^KIF-GG
M4?YK3+9_))O6X,XV8D%D:68Q+%N^-4%RGJ$@2,-&*F4T62I(\P4&&NH09:^6
MF= )'2MJ9'9IZAGJ9&BAE<QPE:&&S4CCM((PM/&),UCC$08<6FK)*@4;U$9;
M<6:EII(Z98(CW6. .BJ]2L%?'>M,\!=ZZ5<0DPWXY+QSU304G#R",O5R54U"
MVDF\1-)3IX*=C'UT%"R].S;H73>=BUG*9G#)9JUC7<2DP3*K1%,L0I1P4<01
MP1S!M15\*/.HB\I-SQ&&;0N)+LZRY=3.[27LER=A-WFPX8FDK9(51B!3&K.6
ME5C LN[3C+V2-2FYN54P18W/$/IF@58J*)7"B:K@J295U4DA0256 @ JHFB9
M58R*9S@8Q$C++"F40(*J@AVQLM8L2H(4D[H)WB!?0%@%#$#0D*MSK8<L4"X
M#$%K"Y W03;4@7:P)U N;<KGGCZZC$X:88:88:88:88:88:88:88:88:88_.
M]Q6Y^$3=<>@5*(>']CF./:(<_D]FO.,W_9*K_P"E_P#X5Q^D/9'KV;;(WO\
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ME!YY9]$A_C/5IYM9#S\DT5_'@KB/=?[3OJVS_P"O#_=Q/P1>&;[2E!_<@/\
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MYW)0R[/A<NSVLV6ERNH[WM)E%&QJ(\LV2RNM)A6H::'A5T.[/%&9!+$'B?\
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M&!#H/(0SG? X#M;VR/*JHOK"#KH.G/U6UU&EP2'S$_8!:YV?SOH--I\XUO\
M]XYZ:C3GI86O/QSW'IR]\&C\CL'XV]);B/J%AG81Y9WQSWSJ!VM[9\S4T6G/
MYP@]?6QY6MR)OK:W.G\Y/V ]-GL[TM_"?-S]R<<_9UT/AZ]<#_EEK>WD/#6W
MXD4XJUURW)DV,?6J*HM[<U<Z,<X(E=JN#&&BI-4G=IBG(NG$&[7*=1&3CU'#
M>++ZALAVJT&;&*@S[A9;F+65*D'=H:IB3:Y:YI)"+#=D9HG:Y61"RQCX][=?
MF+-H]BUK=I>S1JO:O9B(-/4Y&ZB3:;)X@JES"D8 SVD5M]MZEBCKX8RJO2U*
MQR59]Q4E4ETDUT%$UD5DR*HK)'*HDJDH4#IJ)J$$2'3.40,0Y1$IBB E$0$!
MUZ\"" 0000""#<$'4$$:$$:@CGCX5='C=D=61T9D='4JZ.I(964@%64@AE(!
M!!!%\?34XIPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPQ1ZBG&5,
M4_.5)(E='CZ?AY.;?D9-E7KP[.*9+/W)6C- IEG;HR*!P;MD2F575$B291.8
M U8JJA*2FJ*J0.8Z:"6>0(N\Y2%&D8(NF\Q5387%SS(&N+U/ ]3404T9425$
MT4"%V"('E=8U+L=%4,PWF.BBYZ8TI>>4)L71]OJ#N+=QV^MO$7.HL]Q*(9IM
MW]=R3^D$("G9]XZDVU$QDL,-+L25/%1[F$7[YPL_6[,8K(MBG<$SZBFDIZMZ
M!RLE9%4PT<D<),D9J:B1XH(X9K*DJRR0SA)+*@6)G<HKQE[ 97B$Z-> K*X=
MP8V587=9#)&PWD*J(G(]*W'2.YD654L)UY5_A$<M03I*IJFJJHU7%*I-J9&B
M:OIQRLG5;]NDU54E*@@F4.T41B!D9T6KIZDX6:1:S<A"NW+-)=!3O4=W=600
MU#Q*LY8;@CES&#+#*%^G=8ZBHCWE12QC.^ 1BIP8WJHW!66C-:DL=B2)Z&@E
MS"6'>%U!,4+('N8^)Z.\=UB*G,^51X/((5U9&KJQ0CA;4NM$RHVQN"9I4"M7
M/ZZCXDL0@G3JDFJP[= 2[AU/KL&]/HM'4<N644!5P#;'0/-!!- AE:J9DIH0
M=R20@9.J%]ZRP)-/GV54\33F,M)5(P7@VE-4JB R<9Q&L$DT=0UF*PFG2HEF
M-P-V81P45?,_ ,G#2BJ!)N.H0T>YGE**;MY:FRMV6=E+BUO$WCL35E_R0M,O
M8,TY25(48SHA[.!-)O5F[ XL$*Y8N'CPK]!!%K'20HE=OO,(][5*O!S"2AD-
MA%3Y;425-B88TS3B"GX@ +@&1$@7=5VDGJ((T6S.Z7UI69)V5@S0YM6Y2L0#
M"2>:AFJ(Y7B4@$@I2S3E7W"D,;,Y6QQ=[#RGW!F^>Q4:-SGS.0EJ<2JDC9Y1
M59H SBCP$S4JHR"YX,$&;MM%P,@<\>L<K]5<&S5JV<.'2*1IE0Q&L-]Y**F[
MY+(H)5J9H5J$DATO,TD+-(L,>],%BF9HPD,C+AQEG:FC9"D]3*:=(6(++.LX
MI7C<J61%2H(BXK,(6=D5)&:1 U[59QL6XI1HPJ56#J22H)]8"O\ B$]T39)N
MPGVM,6_&,.\CGENYU2)K-L]F4)%0T(Y7C4VCI>.D$E#(HME71:A#(*F>D==R
M6(Y.H-PZ&3.JE*6DBD,99H)-Z17995#(D=2L@CE@$<ERG"U*4DD3KN5536T^
M](LD>XM#$\L]0@*%JB!!'NL\ >_&I'B$L=2CBUIWRCO#13C>;E)>H)V.@(0\
MG&GF)*D:OC4G]10]>35MI.)C$'=/IF?M&-74]-1;B<:*+QP*1KM=$RS(B;M6
MS/OPPK+N&1IERPTD2D!ZDYO%F,M /2(X J%RZ0J\P555U:4QK8M$8#L0YX21
M+5/4NP8K E''ETM01N@\8QIF=.66$LQ8\- [W5>3+RB?#XC45E*0JV1F*2J>
M_EO[/5W0,.K!S\Z9<MYI%:'I^*DY."AGD'%F:2H-&#J0>2J+4RSPANRDB4%%
M,PT<IS"KRZ,K)44DM5&_[A66CITJ97#/N@$I(@C2Y9V8!>3;M)N*6*K(]ZF%
M1;=.\P[L7XIW1J56..24G2RH18L54VDAY4?AF0N96EM*C6K2F7M*1XNF$@YH
M^?F JMXVO15MB)&(A(RG(Z7D!DD*YIAN1@T72(YEHR=8O6J!0:2)&MJF@>JI
MDJ(M3+)3"*'7B-!59-E>=Q5'(* M+FD:SQW,D+Q/<%6C+7*Y.X,!,P,8#)),
MH.Y'4*]6G=[$!W9NY5&Y(JF)REE<[R%LGW%\H!PN6JJ%U2E:UQ,1M0M*R94$
MI%(4)6TB[&I9)E3CU@W!-A N.PP>#5M.LF\RN*4.I)2:;(KX5D'8-[$1,S1)
M$K.TTE?"@52??,MF2"K5C]*A$DD8A#$&J$L!IA**BGXM,HX"-)*0B)%13,=2
M>'F$<DU,X4 NR\*&9YV52M*L,YJC#W>?AV])>4LX.XA1-)_<J30,I+UK"F$:
M KXQ&[RWR,(M5(NSEIL2M$&/NBAD457 I@_</B(L0<'27!(&#(CJ0R2T8KXV
M!!5Z9J>2JC92-"\E/$TJ1B\A4K=020+BPR,67=*E:J*B8-Z)6HFE:!48'4!9
MD>-V(W4>-P3H">LV\I'PT,*%H&MZ[GIFA27&CKIS5/PSNG*@J"0"#M'*5@QJ
M>5>C3<5(ILTQ9T3-2C-JX!-ZNBCYJ1N=Z (FR$IY)9XZ:,!IWILDJ)$N%6%L
M_@FFH(GD8A"SFFJHV=240P,TC(CH6@Q-NRR+9XHYJN)7%@95HZJAI)I%C8B3
M=67,Z $;M_GE-W>"N5ZS+RG?"#-TM/572E;U+6#*GY"5BG3.GK=UPYD59"&H
MRKZ]D$DV[B":E0;-J;H.K':\B_59QR"D0JW6=)JKM"N+4:/*BR1J61H*JHWC
MZ*K#1C)C.[EK!0OG!E"J#Z3O5\- SPU"Q.&14]U<A)144=,PU?=EKJC,*: 6
MC#LP,F5UQ<H&"1P"1K)+$SY:M;QF6(O+6,-0- S53RU3S;.M'S9NK0-:L(M%
MK;QQ3T?62[BI'T&WITJ$)-53"0"BR<HJFZFG1V+$SD[9R*5U:>1TJI4 :*C,
M(GD)" =XGJJ>GW5?==^.]%5M%NJ04@D8V*,!C-,JF$,&5JAMV,;K&[<!*EP2
M 57AQ21F3>(W3)&#^J)O;4ZL8NX:88:88:88:88:88:88:88:88:88_$AQ56
M?J6]/E)N-RFZ8N%(4)(PSB:JQBTC&\HZ>UM+0D#3QHFCF:;*4AF:3^5<+F*Q
M=RL@DW27*"+9%X_<-FBW@>=9;59EM!M4*2HE26DO41TD0=FKI13W$" .BAN$
MLS<I)&52D<,K-NC]C>S/;'+-B_F>^Q?,,UV?I\ZI:X4F43U%2]+%!D=)65^8
M=ZSB=IZ:LF>GI5B0S1TT!8K[Y-)##$\JXY8<&EZ&R-)4Q/<2CFFK@5C0,'<"
MG+:DD:I?.GA*SKN=H&IX!&61FV\&WJ*,<,&C>3;OEV24S/SS2F"N 6%5^;%&
MSF9&=Z%<U>2NAIJ2=:2)Y7$T&9@SNM/,9E@;B52I$"[103S.DTLT4(69MS5=
ML6QKG,\TH^S2.OV?RK/<QR&NVC:FRN"*"3(\CH<[RS,)J1Z&6M-!/3SS3TLD
M"3RT.6T$N8\$V[L+)H#A?OG6CF3C:XNW7U&2C6HKT0BT/^+-7OD*BL)!0M1U
M"SFS,JQ8QC&0DG<O%0]+&0D9,DE-@)4'!$R-UU\;+\DKJZ#O,V9543E:^H,2
M1SU3\2BK#!4(2LR+WQI8ZV58=9)!2,ZDB56&]V@[3=B,C6GDR79+(,XI):+8
MFI2M)H<G@DH=OJNNH,LFI1-E%1434E-%1S5.:-+3TW=J.3TX6;B1I4+D\&-W
M*>KR)HV/O%.U.[8519YO3-0U"SGZ:B5&]]ZGDJ8I^IZ7=N:AFG::L;*QC!K5
M[4$(^2BY09&._#BD"LNNJ=GZV.O%.N822-#F=-E)JFWXUX>84&89P*JB;C.:
MBBDIZ.M>ZM')/,P5(F:5]W'V=[9=D\PV?K,[GV.H<M@J,EVQK<QR^@FH,PJQ
M)L%EU%69CE.:PQ4%'%O2PUDKY5(9*BFGIE@J+Q)6(B96H?@[X@)>D+A6VMUQ
M U2JFO:.@;S&A75,RK"WU60TU,"_AZ=A[ADJ&66BZIB_= N[J*)812#(\\=_
M#O'DB1BO(HY;9%FO<<SI:?,IG7+:;+\QE@:)H:6IA%!'F*]QK5EEX\=%3U<K
MQQA4B>==Z,7>*;'+YSVO=G])G>SFT&T&P&5I*VU6U&QHKHLRI:K/LJJZ"$4E
M=7UVSS9=2+4Y;7297#'E]745,DXH5@JXXH&F6E:W8CR=G'!6*<L,;<B"ER4Y
M+KTW-%/=2J3>BYF';,0/%'3=1J9E7#4TBU8I@V(JB0RG>$6!B(.36WV4VADC
MJG-5#,E-'6/.PKI6_8^26@J$567>D9):6>C46L5@OO+#+"TF?/\ -#=B>6/1
MI-L[74CYI1P9G0D;+Y6.\T=<9*B*J#1U!54E2-JAED99&(W>'QPZ+;-9<,%^
M+271M_8"Y=\%*7I:[L&2>;56",K4BE.4M;F/<UG&/7[-%P=_$04=+M1>FCZ:
MJ-84CQ:$O)Q@R$/',$J'RK,H\U;)*O-A3A$FKDK9.+PX^XTU6]&]3-<2T\+1
M;Q#I)/3TDD]SO/%+N;#*.TS83:K9/.>T/9W85<SS+9>L6@ERI6I: 9AF6U-5
M39+6P4\KQ+35U=/2R+ 9\SR^%YDG>CIJA*:NJ)GR"OY.SBP+5T-#+7N9'I&?
MEZ=\YJY"NYB57_%RH6=)!--J<AY634DD!F9F;;P\@I*,V<FV:N%GCZ%/,-$'
M%]=ELZ-6D#U[10/F?D]93.[RK/)63Y='(U/'(5C#]S=MXS[@A18C(91P<:#\
M\1V5#**VNCV(E.:Y=E^9S1Y4<DHJ>)DRW+FSDT;9E54M,(&6DBR^2J@6DEEI
M9:B,1052TLTB:#W.MS7-I;U5E;BX[YW)5?2;PL;)/W3A\Z4=I>9(.(]=-S("
M9=5NI'KM3MS$57:"D8/,G+IKW+A3S?/XYH!44]3<5-/.8*@-O,1-"PC=0SJK
M. 1Z#E1OQ[K+=""?IC8#/\EVHV8RC:#9V&.GR?-:=ZJEACC@B$9,LJ3H8J?T
M4?O EX@98Y0X/'BBF#QK20 !R&1'D(9 /WPY"&>6X8Z;ZY'U"U]1IT 'WB0-
M?7ICN.G(7 T(/K%^1YV.FOM!P#/+<-OO\L[" = Z9WQRU)]8O8^!.A'A;V7Z
M6O[!!MT(YV%Q\O,'^-]KJ<>D<&TX>:TI*P-N*@<T; R,W:E23N'4U/K64IEY
M'R4#4-U)3S>4K)Y3CRI8VX[^/96\:$85!+-8F;IUPZCGIV$NX)*(>GI%LQF0
MRG+:IZ6E8Y305-?5T39+2!9X8Y$F05:P-(U<6E$E53U$P21(N(-V>)0WS!7S
M]I>19KVB[39=#G>904.V;TFS.59E'MQFL-31YAENR5(DE)DL.9T^5S[,05,V
MTLHJ<MI):O+\S2&H@%11(:27[7OL1PG6VH.Z:MN+CMJ]J=!",-0JDG<^BY)^
M5K'5A&,)B481],1"47,-Y6,=F.Q;(RJTP9!.32<1$0I$N7*^KSO)]G<MRNJ?
M+ZR.KK%J,D>/BU]+)-P)8\[3,2L%/&(YX6J(<O"I#++*D<T,\KQ(LT;-@^T#
MM@VFVDV23:C9F39_*I.^C/UI-E<[IJ4U%3D\M3E]'/4YK6O544M'/'(M3+)2
M1T0E[L\-76K611)T(>1LE<&@[*0M?(6GIE&8I2]\K<1>@6]HK?5TPFZ3=+RU
MK8I>I5Z<EI2'5J$D>W@44I=NZ6G&<DL=;SE\*;HF?42;/9A1T(J8\JISYL5F
M9U*Y5Y*RRH;/J;,,R[IEYG%-.T8J**:EC:F*,[(D#VXD,A;(JZ;;S9S/]MZS
M9V3:_-&I,^V#H-G%VCEVQVCR*?*\XI(:3:VNCRQ,RHJ6M3+)IYZ^26DDB6AG
MIE1.'3EH6J5:<.'"G!Q!9RD[K)STHC3J,NZI)Q>VUBAX]09">1=2Q)\E%D1F
MV<4T]QSP:2]S\95%0)2TJ2/005CW#9M%5L[LS1B:>ES)*J2#<=()<URMD1P^
M;QK-(#2NE=3//294!3JD,SQ5I:<0+(>ZX>0]IW:[F-:M!G&Q[Y;1R9E)219R
MFPNU:"I3NN3RPT1R]L]:3+ZBLE?:&#RPV85.599+EU(:AI4J(Y:C"/&73EIX
MJY*$W:"?I.?@ZL8&F9,:-J&EG<'"3G?J-G=/1]*4W'-"TLQC2HI"T4.[E&$V
M@N$A'KLBBM%,>=VQILKI]H,Q.2SP5675-;F%93RT]13RP!*C,:J1((8(%0TD
M-/&5AIX9#)OP)#4(XCE6./ONQ',]KZO93N.VF79QEV8Y/+'04XSO+<VAS"OH
M1!')%F55FV:5,QS:IJF>0S 04E10RH::ICF9$JJC4''/8=PV*.^/#Z'UCZ]L
M=-\<O\A.GJ!O:QO[!J/M$6Q[+[#J#J>7/Q.O+QY:Z7YERY@ <@';EG F <CC
MUYZ[@(Y$--.A.H!'@.@-O#7K][$ZZ@7T]9OZC;3U>S0^(P#.=@QO@0$1VVSC
M<!$ #.P!\VAY$G7XCKK<>/,C4]=/5@>OI#[G4]!S.@OH=-0<! <;;YZX# YV
M#KZ\ ._7(;ZGXR.IUTTYZZ:7U^UR%L!S(Y6Y7)Z>NW+F>AORMB];>6YKBZ]7
M1%"6XI>8K"KIUR1O&04&T.[=N#B)0,J<0#NVS5 # HZ>N5$&C1(IEG"R21#G
M#*H<OK<TJH:++Z66JJICNQPPH6>]P"QL0$1>;.6"*OTQ L<:/:/:3(=DLGK,
M_P!I,UH\ER?+XVDJZ^OF6"&)==U!?TI9I""D4$2R33.PCB1W8+C]I'DV^&?B
M'X:;0FIN_5VG%8G?IL%J;MR1?TU%VN:%1 ZT2SJ9X47SQ50Y^[<1C!3W.1ZB
M0C&"Y,JJZ5^M=@\@SS(,K[OG69M6,X0P40)ECR] -8DJ'O(YZ-&IX"$>]@WN
M?Q+^:8[3^SGM.VQ&9[ ;(1Y*M.9X\SVD9.Y56U4Q?=2LFRN!A30HJKO154Z>
M4JE7'>C&$2)?1W7=8^;,-,,-,,-,,-,,-,,-,,-,,-,,-,,-,,-,,-,,-,,-
M,,4F?F8^G(*:J&6,J2+@HF1F9(Z+=5VL5A&,UGKPR35 BBSE4&Z"@IH(D.JL
M< 33*8Q@ ;%3/%2TT]3-?@T\,LTME+GAQ(SO91JQW5-AUY8NP0R5$\-/$ 99
MY8X8P2%!DE<(@+'10687)T',X\QB<<]AJEHJX]:4':.D)6W]KK0PMV?25?R-
M,6U;2LI7%P;B6U)1T8SD:=FF;.3DY*UTZT+,.'2;&:?O:<C&Q7#.06E&&?4T
MD]$"9U0-'F^6Y/#%%(DDLDE72Y?7AH1=8P88\QI1!&TJ++.LQ:6F@B6H>Q"Z
M5)BX3,W'HLTS"1G5U6-,O/!#3'5MR5>,\[[IDI85 ,4M0[TT>'*:XV>'^4?F
MNS3/#%1<57-4&N+;0K"K*\I2E:@FV%D:1+<Z!0@('T#+,9A!](U:6F7KF 8K
M3$+5DHQC0"I(]'SJ.QGE>FHEFCWGBJ,JBS]H(B341+'F$-%PI(& DAD$;/40
MA $EJ:66&01/$:E;L,8JZA(92(FBS)\JXTI7@ UM+))+-Q58I,DDE.BL+NQH
M9XJM#NS]W?U'H-A9N[MOJ3K:'HJA)6G:IB&4XR1/3D _1:+NTWJCMDL4\>!4
MI&,?2DTPD45$47#:07ED'"**ZSM,<NMI#0U<]&6604LCP12II')"EHXI82"1
MP9HDC:(JQ4Q;FZ2H4XQ*.K:LIH:HJ\3U$:331.V])'-(%DEBE86WI8Y1:0D7
M,B;W,#&2PI*E0:-6 4S3_F+&+7A&3+T-'>:,X9T5(CJ(:M_-NY;QCDB"!'#!
M(A&JQ44BJ)&!,@!BDDEB3<L$#$ZEA$0T88G4B-@&0&X0@%;$#&2"5MNDK9F<
M6TL[A@SBW)F#,&8:L&8$FYQ3$[<6\1<@]1H.C$GA4C( Z2I>$3<@B=,$3H@N
M1B"O='1 $C)]KL&3 "" E#&AU#*?I77<<='0J4*L.3+N$K8W&Z2O+3 $@JP)
M#*V\I!(*L&W@RGF&#$M<:[QOSUQW HFC .BJ%(TP"C:%4IQNIZ BN\0IY8,+
M0*)_-.TE#*ALI%D$K%0-CH#J222Y)),FYQ"229.&;Q[Y.K;AU3>ONG5;'$#T
M=P+Z(C+-&!IN,^CLEOI2XT8K8MUOCXNJ!H1ZV*S>T523MH45!*U=4Y#N&Q15
M<N'BHE059G2 57;MTZ4$"@)W+EPN;*JRAC0=;$ZD;EB=;<,.J6ORW%=U2WTH
M=P+!C<- 0- ;@@: AMS>!'7>X4=_'AI?Z1;?<]%4:HXCG2E)4PHZAV[-K$N3
MP,49Q%M8Y0JT>VCEC-!49-V"Q2JLT6QDDVJA2G0*0P (3O-O,^\=]K[SW.\U
MQNG>;F;J #<Z@6Y8= O[D;UEZ#>OO6'(;USO>-S?F<?!Q0%".UG+AU15).7#
MP3"[77IR'56="=\,F<7"JC,RBXGDA&0,*AC=I\(NQRN(J:*2H4*2H4JRA38*
MR;A1EM:Q4QQ[I%BNXEK;JVEB6OO$MO!E;>-]Y71XV4WO<-'(\; Z,CNINK$%
M*4!0DX)S35%TG,&5="]4-*4[$2 J/!0\V%V<7;-83.1;_2!7'*O<_2^UV-M4
M@ $$"Q5F92-"K,R.S CD6>.-V(U9D1C<JI#>:Q&\;,H5A<V955D52.14([H
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M=YCN@W^E+.Q(! WF)MJ;].L,*.Y2&-#(079(U7?9%4(7*J-XJ  I-RNZ +
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MR8W(/)I7#WQ_X:-=;Y'_ '#?+O\ NZCZ$^NSE1]F:H_=2_4_)?0X=Z^:+/\
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MGK.TS^2;*?8JO_Q?$_@;CR?GV3<2/7]46C.O_LP^;PT\Q<F_TM?_ $\7XO\
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&##3#'__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
